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ABSTRACT 
 
JENNIFER LYNN KONOPKA:  Characterization of the Innate Host Response to 
Venezuelan Equine Encephalitis Virus, from the First Infected Cells to System-Wide 
Modulation In Vivo. 
(Under the direction of Dr. Robert E. Johnston) 
 
 The specific host changes induced following viral infection are reflective of the 
complex interaction occurring between pathogen and host.  These changes are 
often evident in a cascade of altered transcription patterns.  However, the elucidation 
of such cascades in vivo has been limited by a general inability to distinguish 
changes occurring within the minority of infected cells from that in surrounding 
uninfected cells.  Therefore, an innovative mRNP-tagging system was employed to 
isolate host mRNA specifically from infected cells following Venezuelan equine 
encephalitis virus (VEE) infection.  To dissect the contributions of autocrine and 
paracrine signaling events, simultaneous total RNA analysis was utilized in 
conjunction with this novel approach to directly analyze the infected cell response.  
The result was a multifaceted profile of the early response to VEE in primary 
dendritic cells, as well as within the initially targeted tissue in vivo, the draining lymph 
node.  A two-phase innate response to infection was revealed, in which the 
activation of host genes within infected cells led to the activation of surrounding 
bystander cells.  To further determine the impact of this robust innate immune 
response on the entire animal, we utilized VEE replicon particles (VRP) to limit 
infection in vivo to the initially infected cells, and examined the host antiviral 
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response within tissues distal to the site of replication.  Although these remote 
tissues had not encountered VRP, they nevertheless were exposed to high levels of 
soluble immune modulators, including serum interferon.  In the liver and brain, the 
rapid activation of a panel of interferon-stimulated genes was detected by 3h 
following VRP footpad inoculation, reaching peak expression levels of greater than 
100-fold over mock.  Moreover, mice receiving a footpad VRP inoculation 6, 12, or 
24h prior to an otherwise lethal VEE challenge were completely protected from 
death.  The results presented here document the rapid modulation of the host innate 
response within hours of pathogen invasion, a response that is capable of 
transforming the entire infected animal, and largely determining the outcome of 
infection. 
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THE INNATE RESPONSE TO VIRAL INFECTION 
 
The first-line host defense 
The innate immune system is an evolutionarily ancient, universal form of host 
defense against infection, with some form of innate immunity likely existing in all 
multicellular organisms (1, 2).  The innate host response provides the critical first line 
of defense against invading pathogens, inducing an antiviral state designed to 
impede the spread of infection in the body.  It is within this immediate response that 
pathogen invasion is initially sensed, and the rapid, non-specific host response is 
evoked.  It is termed “nonspecific” in the sense that it lacks immunological memory, 
and relies on inborn defense mechanisms encoded within the germline to defend the 
host from pathogen infection.  This also means that the innate immune system can 
recognize and respond to pathogens in an immediate manner, but unlike the 
adaptive immune response, cannot confer long-lasting protection.  However, the 
process of innate pathogen recognition triggers signaling cascades that induce the 
early expression of antiviral mediators, such as the type I interferon response, that 
are critical to the earliest stages of pathogen control.  Not only do these innate 
responses allow time and proper context for the antigen-specific response of the 
adaptive arm of immunity to be formed, increasing evidence suggests that the innate 
response is essential to shaping an effective adaptive response (3-6).    
Once the invading pathogen has been recognized (see below), the innate 
immune system encompasses a variety of cell-mediated defense mechanisms, as 
well as the antiviral activities of soluble defense molecules.  Cell-mediated 
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components of the innate immune response include the actions of phagocytic cells 
(e.g., dendritic cells, macrophages, and neutrophils), proinflammatory cells (e.g., 
mast cells, basophils), the non-T/non-B lymphocytes, and natural killer cells.  The 
process of pathogen recongition as well as the activation of innate immune cells 
induces the expression and release of soluble defense molecules, including 
components of the complement system, as well as the emmense repretoire of 
cytokines and chemokines.  An in-depth discussion of all arms of the innate 
response is beyond the scope of this review,  and as such, the primary focus will be 
on the process of innate virus recognition, and a key modulator of the innate antiviral 
response, the type I interferon (IFN) system.  
 
Innate recognition of pathogens 
The innate immune system may lack the specificity of the adaptive response, 
and it may not recognize every existing antigen, but it can nonetheless effectively 
detect the invasion of the “nonself.”  It does so by utilizing receptors that recognize 
highly conserved molecular structures, termed pathogen-associated molecular 
patterns (PAMPs), that are shared by a broad gamut of pathogens.  These receptors 
of the innate immune system, termed pattern-recognition receptors (PRRs), have 
evolved to recognize PAMPs such as lipopolysaccharide (LPS), peptidoglycan, 
mannans, and double-stranded RNA (dsRNA).  Additionally, these PAMPs are 
usually essential to the survival and spread of pathogens, and in this manner, the 
innate immune system has developed an effective way of alerting the host to the 
presence of infectious “nonself” (2).   
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Extracellular and endosomal sensors.  Thus far, there have been two major 
pathways elucidated for innate pathogen recognition and subsequent activation of 
the innate immune response.  The first utilizes extracellular or endosomal receptors, 
comprised predominately of members from the Toll-like receptor (TLR) family.  In 
recent years, the TLRs have become the prototype in modeling how the host senses 
pathogen stimuli and subsequently activates the innate immune response.  TLRs are 
primarily expressed on the surface of macrophages and dendritic cells; however, a 
subset of TLRs are found intracellularly, signaling from within endosomes.  It is 
estimated that most mammalian species have 10 to 15 different TLRs, each 
recognizing a unique set of PAMPs from viruses as well as other microorganisms 
(7).  TLRs 1, 2, 4, 5 and 6 seem to specialize mainly in the recognition of bacterial 
PAMPs, products that are unique to these pathogens and are not made by the host.  
TLRs 3, 7, 8 and 9 are primarily responsible for viral detection and recognize nucleic 
acids.  TLR7 and TLR8 recognize single-stranded RNA, and are activated in 
response to RNA viruses, while TLR9 recognizes DNA and is activated by DNA 
viruses.  TLR3, on the other hand, is activated upon recognition of dsRNA, and as 
such, can detect the dsRNA by-products of both RNA and DNA viruses (8).  As 
nucleic acids are obviously not unique to viruses, this subset of TLRs are localized 
to the intracellular compartment of late endosomes or lysosomes in order to prevent 
interaction with host nucleic acids (7).    
TLRs are defined by two domains:  the extracellular leucine-rich repeat 
domain responsible for ligand recognition, and the intracellular TIR (Toll-interleukin-1 
receptor) domain responsible for inducing downstream signaling events, including 
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the induction of type I interferon, through adapter molecules.  These adaptor 
molecules include myeloid differentiation primary response protein 88 (MyD88) in 
the case of TLR7/8/9, and TIR domain-containing adaptor-inducing IFN-β (TRIF) for 
TLR3-mediated signaling (8, 9).  By signaling through these adaptor molecules, 
TLRs activate the transcriptional pathways responsible for modulating the type I 
interferon response following innate pathogen recognition (reviewed in (10)). 
 
Cytoplasmic sensors.  A second class of recognition receptors exists that is 
ubiquitously expressed, and exclusively localized intracellularly.  These cytoplasmic 
sensors specialize in recognition of dsRNA, and are responsible for TLR-
independent mechanisms of virus recognition.  Until recently, the PKR (dsRNA-
dependent protein kinase) and the 2’-5’-oligoadenylate synthase (OAS)/RNaseL 
pathways were the predominant members of this class of sensors (1).  PKR, 
activated by dsRNA, phosphorylates and inactivates the translation initiation factor 
eIF2α, thereby blocking protein synthesis in infected cells.  Upon binding and 
processing of dsRNA by OAS, RNaseL is activated and degrades all RNAs within 
infected cells.   
The most recently emerging class of cytoplasmic PRRs with the ability to 
recognize dsRNA are the caspase recruitment domain (CARD)-containing RNA-
helicases, specifically retinoic acid-inducible gene-I (RIG-I) and melanoma 
differentiation antigen 5 (MDA-5) (11).  To activate the interferon-induced antiviral 
response, both of these helicases utilize the MAVS/IPS-1/CARDIF/VISA adapter 
molecule, which interestingly is associated with host mitochondria, (10, 12-15).  In 
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addition, recent evidence suggests that RIG-I and MDA5 can further distinguish viral 
pathogens based on recognition of different RNA structures induced during infection, 
and as such, can distinguish between different RNA viruses.  This included the 
finding that RIG-I was essential for the production of interferons in response to RNA 
viruses (e.g., influenza virus, paramyxoviruses, and flaviviruses), while MDA5 was 
critical for picornavirus recognition (16, 17).  Therefore, although some redundancy 
exists in the type of PAMP(s) recognized by the various PRRs, clearly multiple levels 
of regulation exist within these recognition processes.  Furthermore, a key element 
in the innate recognition of such a broad range of pathogens is the reliance on the 
multiplicity of PRRs available, presumably to increase the odds of innate pathogen 
recognition and activation of this critical first-line of defense. 
 
The interferon response to viral infection 
During viral infection, interferons are among the most prominent and potent 
cytokines induced.  Interferons were first discovered based on their ability to 
“interfere” with viral replication in cell culture (18, 19), and since then have been 
implicated as critical mediators of the global antiviral state, as well as important 
regulators of both the innate and adaptive immune response.  The interferon system 
affects many aspects of cell physiology (19); however, the focus here will be on the 
host defense response.  
 
Interferon classification and regulation.  Interferons are classified into two major 
categories, either type I (IFNα/β) or type II (IFNγ).  The type I superfamily is further 
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divided into 14 to 20 distinct IFNα members, a single IFNβ, and the lesser defined 
IFNω, κ, ε, δ (pig), τ (cattle and sheep) subtypes (20).  The type I interferons are 
secreted proteins made by both hematopoietic (IFNα and ω) and nonhematopoietic 
cells (mainly IFNβ), and their expression can be directly induced by PRR recognition 
of invading pathogens.   The IFN-mediated host antiviral response is initiated 
through the binding of type I IFNs to a common receptor, the type I IFNαβ receptor 
(IFNαβR or IFNAR), and the induction of antiviral genes can happen within minutes 
of this interaction (21).  The type I receptor is present in low abundance on all major 
cell types, at an estimated 2 - 5 x 103 binding sites per cell (19, 22).   
The type II interferon family consists of one member, IFNγ, a secreted 
glycoprotein made only by cells of the immune system, with natural killer cells being 
the main producers of IFNγ during the innate immune response.  IFNγ is primarily 
associated with the secondary wave of responses to infection, and not generally 
induced directly by invading pathogens.  An additional class of interferon-like 
cytokines has also been revealed, proposed by some as a type III interferon family 
consisting of IFNλs and ζ, which may function somewhat like type I IFNs.  However, 
this new class is still being characterized (20, 23, 24).  Being that the focus of this 
overview is on the earliest host response to viral infection, the emphasis will fall on 
the type I interferon response.   
The most immediate response to many viral infections is the induction of high 
levels of type I interferon (22).  Events such as the direct binding of viruses to the 
cell surface, as well as the recognition of any number of viral products by PRRs 
(discussed above), result in the triggering of complex signaling cascades that 
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ultimately lead to the production of type I interferon.  The transcriptional activation of 
the IFNαβ genes is complex and is often dependent on the specific mechanism of 
pathogen recognition.  However, these cascades converge onto the same regulatory 
elements within the type I genes.   
The IFNβ promoter has been extensively characterized in this regard.  At 
least three families of transcription factors are responsible for activating the IFNβ 
promoter through binding to positive regulatory domains (PRDs):  1)  IFN regulatory 
factors (IRFs; mainly IRF-3 and 7) bind to the IFN-stimulated response element 
(ISRE) sites (PRD-I and III); 2) nuclear factor (NF)-κB binds to the κB site (PRD-II); 
and 3) c-Jun/activated transcription factor-2 (ATF-2) heterodimer binds to the c-
AMP-responsive element (CRE)(PRD-IV) (25).  Upon viral infection, these 
transcription factors rely on phosphorylation for activation and/or translocation into 
the nucleus; activities that are controlled by the signaling cascades initiated by 
PAMP-PRR interactions.  While cJun/ATF-2 and NF- κB become activated by 
multiple stimuli, IRF-3 is more tightly regulated.  IRF-3 is expressed constitutively in 
all cells, existing in a latent state until viral infection and PAMP recognition leads to 
its phosphorylation (by TANK-binding kinase-1 or inducible IκB kinase), dimerization, 
and nuclear translocation (9).  The coordinated interaction of these activated 
transcription factors into an enhanceosome complex drives the transcription and 
early expression of IFNβ and IFNα4 in infected cells.   
 
Interferon-induced antiviral signaling.  Once induced and secreted into the 
extracellular environment, type I interferons bind to the IFNαβR on bystander 
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uninfected cells, and in a paracrine fashion, elicit an antiviral state in nearby cells to 
block the spread of infection.  Once interferon binds to the IFNαβR, dimerization of 
the receptor and tyrosine phosphorylation by members of the Janus kinase (Jaks) 
family ensues (Jak1 and Tyk2).  The receptor units, as well as specifically recruited 
members of the signal transducers and activators of transcription (STAT) family, are 
phosphorylated (19, 25).  The phosphorylated STATs (STAT1 and 2) form dimers 
(homo- or heterodimers), and translocate to the nucleus where they activate 
transcription of specific interferon-stimulated genes (ISGs, see below) by forming a 
transcription factor complex (ISGF3) with the DNA-binding protein IRF9 (also known 
as p48 or ISGF3γ).  An important ISG transcribed following engagement of the 
IFNαβR by early type I interferons is IRF-7, a component whose importance lies 
within the autocrine positive feedback loop (26).   
IFN secreted by infected cells may also bind to the type I receptor on the 
surface of other surrounding infected cells, or the very cell it was secreted from, and 
directly amplify the ensuing antiviral state (27, 28).  Interferon receptor signaling 
would again lead to newly synthesized IRF-7.  However, in cells where viral infection 
is still ongoing, IRF-7 becomes phosphorylated and thus active, leading to the 
induction of the remaining non-α4 members of the IFNα gene family.  Although 
some of the details of this positive feedback loop may still be controversial (25), it is 
likely responsible for the robust induction of type I interferon in infected cells, and 
explains why pretreatment with interferon in cell culture can prime its own 
expression (26, 29, 30).   
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A simplified overview of the regulation of interferon production would be as 
follows.  The initial sensing of viral infection by innate recognition mechanisms is 
required to induce the rapid production of IFNβ and IFNα4.  If these initial levels of 
IFN produced during infection can successfully block viral replication, then IFN 
production would decline due to latent IRF-7 (26).  However, if infection continues, 
then accumulating newly synthesized IRF-7 would be phosphorylated and lead to 
the robust induction of the full repertoire of type I interferons.   
Perhaps the most striking evidence of the critical nature of the interferon 
signaling pathways comes from studies in which either IFNα/β itself was blocked 
(e.g., through administration of blocking antibodies) or the activity of the receptor 
itself was inhibited (e.g., genetic deletion of the genes encoding the receptor).  For 
example, in mice naturally susceptible to infection, administration of anti-IFNαβ 
antibodies greatly aggravated infection with Semliki Forest virus (SFV) and herpes 
simplex virus-1 (31).  This administration also exacerbated the course of infection in 
naturally resistant mice following infection with viruses such as Sindbis virus, mouse 
hepatitis virus-3, and influenza virus (31).  In other examples, the targeted deletion 
of the IFNαβR greatly increased the susceptibility of mice to vesicular stomatitis 
virus, SFV, and vaccinia virus (32).  Numerous studies, including these few 
examples, clearly indicate the importance of early interferon production in 
determining the outcome of viral infection. 
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ISGs and the induction of the “antiviral state” 
By signaling through the type I receptor in both a paracrine and autocrine 
fashion, interferons induce the expression of hundreds of proteins that together 
establish what is termed the “antiviral state.”  These interferon-stimulated genes 
(ISGs) encode proteins that have antiviral, antiproliferative, and immunomodulatory 
activities, all aimed at preventing or limiting viral spread (19).  These activities can 
directly interfere with virus-specific processes, leading to the inhibition of any 
number of stages during the viral replication cycle.  This interference may also be 
directed at general cellular processes that are critical for the virus as well as the 
host, including inhibition of translation, cell cycle arrest, and the induction of 
apoptosis.    
 
Functional genomics and the antiviral state.  Advances in microarray technology, 
bioinformatics, and functional genomics over the past decade have led to an 
enormous burst of information regarding genes that are regulated by viral infection 
and/or stimulation by interferon.  Prior to these technologies, it was thought that only 
30-40 antiviral and interferon stimulated genes existed (33).  However, it has 
become increasingly apparent that there are hundreds of genes that are regulated 
by interferon and/or viral infection.   
The number of microarray studies designed to assess the modulation of host 
gene expression following infection with specific viruses is steadily increasing (e.g., 
influenza virus (34, 35), herpes simplex virus (36, 37), Sindbis virus (38, 39), and 
hepatitis C (40, 41)).  While these studies are undoubtedly invaluable to each 
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particular viral field, a handful of array studies have aimed more generally at 
characterizing the effects of interferon or particular PAMPs on host cells, greatly 
contributing to our understanding of the overall host response to infection (34, 42, 
43).  In two such studies, human and murine cell lines were treated with IFNα, β, 
and γ, either individually or in combination, and the effect on host gene expression 
was assessed (42, 43).  The result was the identification of over 300 ISGs, and a 
pivotal breakthrough not only in the sense that they provided target genes for further 
study, but also in the manner in which virologists viewed the host response to 
infection.  An additional study focused on the PAMP-mediated activation of the 
antiviral host response, using cell lines that lacked all type I IFN genes such that the 
effects of the autocrine actions of interferon were eliminated (34).  This study 
specifically examined the modulation of host antiviral gene expression by dsRNA-
mediated signaling pathways.  Nearly 300 dsRNA-stimulated genes (DSGs) were 
identified, being either induced or repressed by dsRNA treatment in the rapid, 
robust, and transient manner characteristic of the innate response to viral infection.        
The ISGs and DSGs identified in these studies have a broad range of cellular 
functions, belonging to a wide range of biological pathways (e.g., cytokine, 
chemokine, and growth factors; apoptosis; cell cycle regulation; metabolism; cell 
adhesion).  A few of what seem to be emerging as key antiviral genes from the 
expansive list are discussed below in more detail.  Additionally, as gene expression 
studies are translated into investigations of protein function, the specific 
contributions of these individual genes are being elucidated within the context of viral 
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infection.  As such, reference to specific studies in which a particular ISG/DSG was 
found to have an impact during viral infection will be mentioned.   
 
PKR.  In addition to mediating transcriptional signaling in response to viral infection 
and interferon, PKR (serine-threonine protein kinase) is itself an interferon-
stimulated gene, activated by dsRNA.  The most well-known antiviral activity of PKR 
is the inhibition of mRNA translation following PKR-mediated phosphorylation of the 
translation initiation factor, eIF2α.  PKR may also be activated in response to cellular 
stress (44), and can induce apoptosis through a Fas-dependent pathway (45).  It 
appears however, that like many ISGs, the role of PKR in the infected host can be 
virus-specific.  For instance, mice with targeted deletion of the PKR gene are more 
susceptible to vesicular stomatitis virus infection, but are still able to successfully 
clear influenza virus infection (46, 47).  A large number of viruses have evolved 
various strategies to block the activation and/or activities of PKR, demonstrating its 
critical role in the host response to infection, and rendering it one of the most 
extensively studies ISGs (19). 
 
OAS and RNaseL.  The coordinated activity of these two ISGs results in the global 
degradation of RNA in the infected cell.  Induced by interferon, the OAS gene family 
encodes a class of enzymes that are activated by dsRNA.  Even small or partial 
dsRNA structures, which are present during a wide variety of viral infections, activate 
the OAS enzymes to polymerize ATP into 2’-5’ linked oligoadenylates (48).  These 
molecules then go on to activate the RNase L ribonuclease, which in turn degrades 
 14 
both host and viral RNA within infected cells.  The expression of the OAS and 
RNaseL genes is induced following infection with numerous viruses, with the 
antiviral actions of their products documented to play pivotal role in the host 
response to viral infections, including West Nile virus (49, 50).  
 
Mx and GBP.  A growing class of antiviral genes exists having GTPase and/or 
guanylate binding activity.  The most well known may be the Mx proteins, which 
were originally identified as host antiviral molecules that could limit influenza virus 
infection (19).  The principal activity of Mx is the sequestering of viral nucleocapsids 
into specific intracellular compartments, including that of several bunyaviruses (e.g., 
Crimean-Congo hemorrhagic fever virus and La Crosse virus (51, 52)) (53). 
An additional class of GTPases, the guanylate-binding proteins (GBPs), is 
also induced following viral infection.  Their antiviral activity is speculated to be at the 
level of RNA synthesis, although the specific mechanism is unknown.  They are 
induced by a wide variety of viruses, and in particular, GBP-1 plays a role in the 
antiviral response to vesicular stomatitis virus and encephalomyocarditis virus (51).       
 
Antiviral chemokines.  There are increasing numbers of reports documenting the 
induction of interferon-stimulated proinflammatory molecules during the early 
immune response to viral infection (4).  The chemokine IP-10/Cxcl10 falls into this 
category, possessing interferon-stimulated response elements within its promoter.  
The best-described function of chemokines is leukocyte recruitment, an activity 
pivotal to the innate inflammatory response as well as the adaptive immune 
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response.  The key antiviral activity of chemokines, like IP-10, that are induced 
during the innate response to viral infection is likely mediated by their roles in 
recruitment of activated natural killer cells to the site of infection (e.g., during 
infection with Dengue virus (54)).        
 
IFIT family.  A growing class of proteins containing tetratricopeptide repeat domains 
(IFITs) is emerging as interferon-induced antiviral mediators.  These genes are 
induced strongly but transiently following infection with a variety of viruses, or 
stimulation with interferon or double-stranded RNA (55, 56).  IFIT1, also known as 
ISG56 or p56, belongs to this family, and has been regarded as the most strongly 
induced ISG (19, 43).  The antiviral activity of IFIT1/p56 appears to involve the 
inhibition of mRNA translation by binding to subunits of the translation initiation 
factor eIF3, with human and murine p56 targeting different subunits (57-59).  A 
recent study characterizing the closely related IFIT4/p54 protein found that while the 
kinetics of ISG54 and ISG56 induction in response to dsRNA, IFN, and Sendai virus 
were quite distinct, they both targeted eIF3 to inhibit translation (56).  These results 
document the subtle differences in antiviral mediators, which may seem to overlap 
mechanistically, but potentially serve to ensure protection from a multitude of 
pathogens.  
 
A dynamic system 
The information generated from the studies mentioned here, as well as countless 
others, consistently demonstrate that the host response to infection, including the 
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interferon-induced antiviral state, is differentially regulated from system to system, 
dependent upon the viral and host systems examined.  It is intriguing to think about 
the particular manner in which these pathways converge, as well as diverge, in 
forming the host antiviral state that is appropriate for each virus, at a specific time 
during infection, within a particular host.  The level of fine-tuning of the innate host 
response, seeming to occur specifically to each invading pathogen, is particularly 
impressive considering the responsible genes are fixed within the germline.         
However, viruses have likewise evolved equally elegant ways of subverting 
the interferon-induced antiviral state.  In fact, viral evasion of the interferon system 
has been documented on several levels, and includes virus-mediated activities such 
as the blocking of IFN synthesis, interfering with interferon signaling, and disrupting 
the functions of interferon-induced proteins [reviewed in (19, 33, 60).  Fortunately, 
the interferon response often targets more than one critical component or step in 
each viral life cycle, such that even if a key antiviral protein is disabled or blocked by 
infection, other antiviral proteins can usually compensate to ensure that infection is 
limited.  Indeed there are a growing number of examples documenting this 
phenomenon, as systems become available in which individual or combinations of 
ISGs or recognition receptors have been abrogated.  For example, mice triply 
deficient for Mx, PKR, and RNaseL can still mount an effective antiviral state (61).  In 
fact, while IFNαβR-/- mice rapidly succumb to fatal Sindbis infection, mice triply 
deficient for Mx, PKR, and RNaseL develop only mild disease and survive (62).  As 
more of these model systems become available, and as novel ways to profile the 
host response evolve from the field of functional genomics, certainly new 
 17 
breakthroughs can be expected that will transcend the gaps remaining in our 
understanding of the host-pathogen interface.  
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VENEZUELAN EQUINE ENCEPHALITIS VIRUS 
 
Overview 
Venezuelan equine encephalitis virus (VEE) is an arbovirus belonging to the 
Togaviridae family of viruses, specifically within the alphavirus genus.  Alphaviruses 
are generally divided into two categories, the Old World and New World viruses, 
based on their geographic distribution and disease outcome (63).  New World 
alphaviruses have the potential to cause febrile illness and encephalitis, and include 
VEE as well as Eastern and Western equine encephalitis viruses.  Old World 
alphaviruses, causing disease characterized by rash and arthritis, include Sindbis 
(SIN), Semliki Forest virus (SFV), Ross River virus (RRV), Chikungunya, and 
O’nyong-nyong virus.  All alphaviruses are transmitted by arthropod vectors, cycling 
primarily between mosquitoes and small mammals or birds. Larger mammals, such 
as horses and humans, tend to develop more severe disease and are often dead-
end hosts (63).  Venezuelan equine encephalitis was first recognized in the 1930s 
as a disease of horses, donkeys and mules in South America, with VEE identified as 
the causative viral agent in 1938, isolated from the brain of a horse that had 
succumbed to lethal encephalitis (64).   
VEE is maintained in an enzootic cycle within subtropical North and South 
America, involving the Culex (Melanoconion) subgenus of mosquitoes and small 
rodents (64).  The enzootic serotypes of VEE (1D-1F and II-IV) are antigenically 
distinct from epizootic VEE serotypes (1AB and 1C), and cause little to no viremia in 
experimentally infected horses (64).  The first widely recognized outbreak of 
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epizootic VEE occurred in 1935, spreading across Columbia and Venezuela through 
the mid-1940s, causing a high incidence of disease and mortality among donkeys 
and horses.  Epizootic viruses isolated during the outbreak were primarily from 
Psorophora confinnis and Aedes sollicitans mosquitoes, suggesting that the 
epizootic and enzootic transmission cycles differed (63, 65).  Although it is likely that 
VEE-induced human disease occurred during this early epidemic, it wasn’t until the 
1950s that the connection between equine and human disease was established 
(66).  VEE was isolated from human cases during this epidemic outbreak; however, 
the ability of VEE to infect humans had been documented previously in laboratory 
personnel (67).  While infection with epizootic VEE results in a high mortality rate in 
horses (ranging from 19%-83%), mortality in humans is quite rare (less than 1%), 
with neurological disease appearing in 4%-14% of cases (66).       
A widespread and long-lasting VEE epidemic began in 1969, which spread 
over the next few years through Central America, Mexico, and into Texas in 1971, 
causing human disease and high mortality among horses.  During this time, the 
extensive use of the TC-83 vaccine strain of VEE was instituted (66).  This live-
attenuated vaccine was developed by passaging the virulent 1AB subtype strain, 
Trinidad donkey, 83 times in cultured guinea pig heart cells (68).  The high equine 
mortality observed in the 1969-1973 outbreak, the presence of high levels of 
neutralizing antibody titers in the survivors, and the wide use of the TC-83 vaccine 
likely contributed to a nearly 20 year hiatus in epidemic VEE outbreaks until the 
1990s (64).  Small outbreaks of VEE were followed in Venezuela and Mexico in the 
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early 1990s, however one of the largest VEE epidemics occurred in 1995, involving 
an estimated 75,000-100,000 human cases (69, 70).   
Seeming to disappear at times for years between outbreaks, the viral source 
of the epizootic VEE has not been fully revealed.  Outbreaks of epizootic VEE tend 
to correlate with periods of heavy rainfall, during which increased populations of the 
epizootic mosquito vectors results.  While enzootic strains of VEE usually cause 
asymptomatic or mild infection in equines, the availability of susceptible equines is a 
key factor to epidemic VEE potential (65).  The high titer serum viremia that ensues 
following infection with epizootic VEE strains renders equines as the principal 
amplifying species for transmission, especially to nearby humans.  Evidence 
suggests that naturally maintained, enzootic pools of VEE may be the source, with 
amplification-competent epizootic variants emerging by mutation (64, 66, 71).  As 
the mechanism(s) of host-range change remains poorly understood for several 
emerging/reemerging viruses, future studies addressing the emergence of epizootic 
VEE serotypes will likely contribute to our overall understanding of this phenomenon.    
 
VEE structure, genome and replication 
VEE is a spherical, enveloped virus, 70nm in diameter with a single-stranded, 
positive-sense RNA genome of approximately 11,400 nucleotides in length that is 5’ 
capped and 3’ polyadenylated (63).  The genome has extensive secondary 
structure, including within the 5’ and 3’ untranslated regions (UTRs) where important 
regulatory signals for RNA replication exist (72-74).  The 5’ two-thirds of the VEE 
genome encodes the four nonstructural proteins (nsP1-4) which participate in viral 
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replication and protein processing (72).  nsP1 possesses methyl- and 
guanyltransferase activities.  nsP2 has at least two functions, serving as a 
helicase/NTPase and as the protease that cleaves the nonstructural proteins during 
replication.  The role of the nsP3 phosphoprotein is not fully understood, but it is 
essential to viral replication.  nsP4 serves as the viral RNA-dependent RNA 
polymerase.  The final 3’ one-third encodes the viral structural proteins (capsid, and 
the E1 and E2 glycoproteins) under an internal subgenomic 26S promoter (72).  The 
RNA genome is encased by a T=4 icosahedral nucleocapsid, consisting of 240 
copies of the capsid protein, which in turn is enveloped by a lipid bilayer derived 
from the plasma membrane, imbedded with the viral glycoproteins also in a T=4 
symmetry (75-77).  Evidence from structural analysis of other alphaviruses has 
demonstrated that the E2 glycoprotein forms the spikes protruding from the surface 
of the virion, while the E1 glycoprotein lies tangential to the lipid envelope, creating 
the icosahedral scaffold (78, 79).   
A single, definitive receptor for VEE binding and entry has not been identified.  
Though candidates have been identified or proposed, including the laminin-binding 
protein, c-type lectins DC-SIGN and L-SIGN, and heparin sulfate.  Considering the 
wide cell tropism of VEE, it may be more likely that VEE uses multiple receptors or a 
highly conserved receptor (80-82).  E2 is regarded as the glycoprotein responsible 
for interaction with the host cell receptor(s), while the E1 glycoprotein is involved in 
fusion events during entry (63).  The concept of alphavirus entry has also been a 
topic of some debate, with one camp supporting endocytosis for entry and low pH-
mediated membrane fusion for release into the cytoplasm (72, 83), while the other 
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supports a novel mechanism featuring a “pore-like” structure that would mediate 
entry at the plasma membrane independent of membrane fusion and endocytic 
internalization (84).   
Following binding and entry into the host cell, the nucleocapsid disassembles, 
and the RNA genome is released into the cytoplasm.  The message-sense genomic 
RNA is immediately translated by host translation machinery into the polyprotein 
precursor P123, or if read-through of an opal stop codon occurs, a P1234 precursor 
is synthesized.  VEE RNA replication is regulated through specific polyprotein 
cleavage events, mediated by the protease domain of nsP2, resulting in the 
processing of the precursor into the four mature nonstructural proteins (72).  The 
P123 intermediate, together with the nsP4 RNA-dependent RNA polymerase, 
mediates negative-sense viral RNA synthesis early in infection.  The subsequent 
cleavage of P123, releasing nsP1 plus the P23 intermediate, mediates the switch 
from minus-strand to plus-strand synthesis.  Upon further processing, the four 
individual nonstructural proteins comprise the plus-strand replicase complex, which 
drives the synthesis of positive-sense, full-length genomic and subgenomic RNAs 
from minus-strand templates.   
Subgenomic RNA from the internal 26S promoter is synthesized in a 5- to 10-
fold excess to genomic RNA, leading to a large pool of glycoproteins and capsid 
available for packaging new virions (72).  Full-length genomic RNA is specifically 
encapsidated by the interaction of the capsid protein with a packaging signal within 
the 5’ nonstructural region of the genome.  Assembly and budding of infectious 
progeny virions occurs at the plasma membrane.  Preformed nucleocapsids interact 
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with the plasma membrane, specifically at sites where the viral glycoproteins are 
present.  The interaction of the nucleocapsid with the glycoproteins nucleates the 
budding process, resulting in the acquisition of a tightly-fitted lipid bilayer envelope, 
and release of progeny virions from the host cell (63).  The cytopathic effects of 
infection are readily apparent in cultured vertebrate cells (e.g., cell rounding, 
detachment from the monolayer, membrane blebbing), as infection eventually leads 
to host cell transcription and translation shutoff, culminating in apoptosis of infected 
cells (63, 85, 86).   
 
VEE pathogenesis 
Clinical disease.  In equines, infection with VEE induces a wide spectrum of disease 
ranging from asymptomatic to lethal encephalitis.  While enzootic strains cause little 
(e.g., low viremia, short duration fever) to no clinical illness, disease induced by 
epizootic strains can be quite severe, including high mortality (87, 88).  Clinical signs 
usually appear within 2-5 days after infection with epizootic VEE, characterized by 
fever, depression, and anorexia.  Progression to encephalitis and death correlates 
with the magnitude of the viremia, with clinical signs of encephalitis (e.g., circling, 
ataxia, hyperexcitability) developing within 5-10 days after infection (66).  Pathology 
in fatal cases shows a profound peripheral leukopenia that coincides with viremia, as 
well as pancreatic necrosis.  In the brains of animals presenting with signs of 
neurologic involvement, swollen cerebrovascular endothelial cells, edema, and 
leukocytic infiltration into the perivenular spaces has been documented (89, 90).  
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Approximately 7 days after infection, antibody appears in equines that have survived 
(89). 
 A similar incubation period of 2-5 days occurs during human VEE infection, 
presenting with clinical symptoms including fever, malaise, and severe headache 
frequently associated with intense retro-orbital pain.  Interestingly, the same 
lymphopenia observed in horses is also observed in infected humans.  Clinical 
disease manifestations seem to vary with age, as children younger than 15 years of 
age are most likely to develop fulminant disease, while young adults and individuals 
older than 50 mostly develop flu-like symptoms (63, 91, 92).  As a result, the 
incidence of encephalitis as well as mortality in humans is relatively rare (less than 
5% and 1%, respectively) (91). 
 Several animal models have been utilized over the years to investigate VEE-
induced pathogenesis, including macaques (93-95), rabbits (96), chickens (97, 98), 
hamsters (99-102), and guinea pigs (96, 103).  However, pathogenesis studies in 
the mouse model, combined with the development of the infectious clone of VEE, 
have yielded a great wealth of information.  Derived from the virulent, epizootic 
Trinidad donkey strain of VEE, the infectious cDNA clone (V3000) provided the 
means to study the progression of pathogenesis in the mouse model from an 
inoculum that was far more homogeneous than stocks of natural isolates (104).  
Additionally, it provided a system in which specific mutations could be inserted into 
the genome of the virus and the resulting effects on the progression of pathogenesis 
evaluated, greatly increasing our knowledge of the genetic determinants of VEE-
induced disease. 
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VEE pathogenesis in the murine model.  An early, comparative study of VEE 
pathogenesis in several animal models identified the mouse as an experimental host 
sharing many of the same elements of pathogenesis naturally observed in the 
equine host (90).  Following subcutaneous inoculation of VEE, two distinct disease 
phases occur:  An initial peripheral phase within 1 to 2 days post-inoculation, in 
which the virus mainly replicates in lymphoid and myeloid tissues (thus termed the 
“lymphotropic” phase), and is characterized by the development of a high titer serum 
viremia.  This is followed by clearance of the virus from the serum and periphery.  
CNS invasion occurs 2 to 3 days post-inoculation when the neurotropic phase of the 
disease is initiated, leading to the death of the animal by 6 to 7 days post-
inoculation.   
The progression of pathogenesis was further defined, years later, using the 
infectious cDNA clone (105).  Following subcutaneous footpad inoculation with 103 
plaque forming units (PFU) of V3000, a route chosen to mimic delivery by the bite of 
an infected mosquito, replication in the draining popliteal lymph node was detected 
by 4 h post-inoculation (pi).  By 12 hpi, virus was detected in the serum, spleen, 
heart, lung, kidney, and adrenal gland, and by 18 hpi had also reached the thymus, 
pancreas, salivary gland, and the contralateral popliteal lymph node.  At 24 hpi, a 
high titer serum viremia (2 x 107 PFU/ml) was underway, and the characteristic VEE-
induced lymphopenia was observed.  Replication in the indicated tissues continued 
until clearance from the periphery occurred at 72 to 96 hpi.  By 5 to 6 days pi, 
peripheral tissues were completely clear of detectable infectious virus, and 
characterized by a return to nearly normal histological appearance, including signs 
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of cell repopulation within lymphoid tissues.  However, by this time, virus had already 
invaded the central nervous system (CNS).  By 48 to 72 hpi, virus could be detected 
in the brain, and reached a peak of 1 x 107 PFU/gram by 96 hpi.  At the earliest 
times that VEE antigen could be detected in the brain, it was present within areas 
involving olfaction.  VEE invasion of the CNS occurs primarily through the olfactory 
neuroepithelium, with the trigeminal nerve seeming to serve as a secondary entry 
point if the neuroepithelium is disrupted (106-108).  VEE can be found in all areas of 
the brain by 4 to 5 days pi, with evidence of neuronal apoptosis (109).  Mice infected 
by footpad inoculation succumb to lethal encephalitis by 5 to 6 days pi, with a 100% 
rate of mortality. 
 A series of studies using site-directed mutagenesis of the infectious clone 
further defined critical elements in the progression of VEE-induced pathogenesis.  
The basis for these mutations had come from a panel of attenuated mutants of VEE 
that had been isolated during selection for rapid penetration of cultured cells (110).  
Several E2 glycoprotein mutants were characterized, with individual mutations 
affecting different aspects of the progression of VEE pathogenesis, and all leading to 
attenuation (82, 105, 111-114).  For instance, one mutant (V3010) was delayed in its 
movement from the site of inoculation to the draining lymph node, resulting in a 
lowered serum viremia, while another mutant (V3014) rarely progressed beyond the 
draining lymph node at all (105).  Additional mutants with intriguing phenotypes 
included one virus (V3032) that could spread from the site of inoculation and seed 
the periphery, but did so with little to no viremia.  The V3034 mutant (V3034) spread 
to the periphery with similar kinetics to wildtype VEE; however, it could only 
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sporadically invade the CNS and was attenuated even after direct intracranial 
inoculation (105).  Studies involving this panel of viruses also demonstrated that 
revertants, with compensating mutations, could arise during infection with an 
avirulent mutant,  and were capable of overcoming the block in viral spread to at 
least partially restore virulence (113).  This body of work defined parameters critical 
to successful viral spread, further delineated the process of VEE pathogenesis, and 
demonstrated the central role of viral genetics in the outcome of infection.      
 
VEE replicon particles.  A tool essential to the study of early events in VEE 
pathogenesis are VEE replicon particles (VRP).  VRP are propagation-defective 
particles which contain a VEE-derived genome, based on the infectious cDNA clone.  
However, the genome is modified such that the structural genes are deleted and 
replaced by a heterologous gene of interest (115).  To facilitate assembly of VRP, 
two helper RNAs encoding the capsid and glycoprotein genes, but lacking a 
packaging signal, are supplied in trans.  When VRP infect cells, they undergo only 
one round of infection, in which the VRP genome is expressed at high levels.  
However, no new progeny are packaged or released, as the VRP genome does not 
encode the VEE structural proteins.         
 VRP provide at least two advantages in their application to the study of VEE 
pathogenesis.  First, as replication is limited to the first round of infected cells, VRP 
provide a system in which the earliest events of VEE pathogenesis can be modeled 
and characterized accurately within the host, without the confounding effects of viral 
spread.  Although infection in the murine model has been well studied for some time, 
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surprisingly little is known concerning the earliest features of VEE-induced disease.  
The body of work presented in the following chapters demonstrates the utility of VRP 
to facilitate the characterization of early virus-host interactions in vitro as well as in 
vivo.  A second advantage that VRP offer is the ability to express a marker gene, 
such as green fluorescent protein (GFP), specifically within infected host cells.  The 
expression of GFP from the VRP genome yields a fluorescent marker designating 
which cells have been infected.   
In fact, the utilization of GFP-VRP facilitated the identification of the cell 
population initially targeted by VEE in vivo.  Although the draining lymph node had 
been identified as a critical site of early viral amplification (105), and spread from the 
skin to the DLN was shown to be a key initial step in pathogenesis (105, 113), the 
identity of the specific cell type infected at the site of inoculation was unknown.  
Inoculation of VRP expressing GFP into the footpad of mice, facilitated the 
identification of Dendritic cells, specifically the resident Langerhans cells within the 
epidermis, as the initial viral target in vivo (116).  GFP-positive Langerhans cells 
were tracked, by fluorescence microscopy and serial tissue sectioning, from the site 
of inoculation in the skin, to the paracortex of the DLN.  By just 30 minutes following 
GFP-VRP footpad inoculation, GFP-positive cells were already present in the DLN, 
while the number of GFP-positive cells present in the footpad declined.  The data 
from this study suggested a model in which VEE delivered subcutaneously (e.g., by 
the bite of an infected mosquito), initially infects Langerhans cells resident within the 
skin at the site of inoculation.  The infected Langerhans cells then rapidly migrate 
from the site of inoculation to the peripheral draining lymph node, where replication 
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ensues.  Studies are currently underway in the Johnston laboratory in which the E2 
glycoprotein mutations, which conferred blocks at various stages of infection, are 
introduced into the replicon system and the effects on cell targeting and migration 
examined.      
Aside from their use in VEE pathogenesis studies, VRP have also been 
extensively utilized as vaccine vectors for the expression of a number of 
heterologous antigens.  Expression of these heterologous proteins from VRP often 
induces strong, protective antibody and T-cell responses, including the induction of 
mucosal IgA (115, 117-123).  The high level of antigen expression from the 26S 
subgenomic promoter, combined with the ability of VRP to target DCs and lymphoid 
tissue, are at least two factors that contribute to the efficacy of VRP as vaccine 
vectors.      
 
Protection from disease 
Both the innate and adaptive arms of the immune system are essential to the 
control of VEE infection and protection from VEE-induced disease.  Protection 
against VEE infection has typically been associated with neutralizing antibody (91, 
124-127).  However, nonspecific protection against VEE has also been suggested, 
including the involvement of the innate immune response (128-133).  The known 
contributions of the adaptive response will be briefly touched upon here, while the 
innate host response to VEE will be covered in more detail within a separate section 
(see below). 
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It has been well documented that protection in equines is often mediated by a 
protective neutralizing antibody response, established either through previous 
exposure to an avirulent enzootic strain of VEE or through vaccination with the TC-
83 vaccine strain of VEE (64).  The production of VEE-specific IgM appears to be 
critical for clearance of virus from the serum and peripheral organs, with production 
being independent of T-cell help (131).  While neutralizing antibodies are most often 
directed against the E2 glycoprotein, non-neutralizing antibodies against both E1 
and E2 also appear to be important mediators of protection (72).  However, while 
antibody responses are effective in preventing infection (e.g., after vaccination) 
and/or limiting viral spread in the periphery, they are not sufficient to prevent 
neuroinvasion and death in a primary exposure to virulent VEE (63).   
Instead of protecting animals from disease, the immune response to 
alphaviruses can also exacerbate disease by mediating direct CNS 
immunopathology (72).  While this has been demonstrated for Sindbis and Semliki 
Forest virus infections, the role of host-induced immunopathology seems to play a 
lesser role in VEE pathogenesis.  This was demonstrated by the continued 
destruction of the CNS in VEE-infected SCID mice—a pathology that was induced in 
a lymphocyte-independent manner (131).  However, the disease induced in these 
mice was more along the lines of a spongiform encephalopathy rather than the 
characteristic VEE-induced encephalitis.  Therefore, unlike other neurovirulent 
alphaviruses, VEE has a direct cytopathic effect in the CNS, even in the absence of 
the host immune response.    
 
 31 
THE INNATE HOST RESPONSE TO VEE 
 
In vivo models 
Over thirty years ago, the sensitivity of VEE to the host interferon response 
was first proposed as a critical virulence determinant, with naturally virulent and 
avirulent strains displaying differences in their relative sensitivity to IFNαβ (99, 134).  
Therefore, in addition to the adaptive host response, nonspecific protection against 
VEE also has been documented.  Although the full mechanism of this nonspecific 
protection against VEE is not well understood, it is likely that the interferon response 
as well as other soluble mediators play a crucial role.  In fact, particular regimens of 
interferon administered therapeutically in small animal models have proven effective 
in limiting disease (135, 136).  Additionally, following infection of mice, high levels of 
serum IFNαβ rapidly appear (up to nearly 400,000 IU/ml by 6 h post-inoculation), 
limiting virus replication early, and allowing time for the specific immune response to 
be induced (63, 133)[J.L.K., Fig. 3.2].  This is further evident following VEE infection 
of IFNαβR-/- mice, in which the average survival time is greatly reduced in 
comparison to wildtype animals (24 to 48 h versus 6 to 7 days, respectively) (132, 
133).   
Experimental infection of equines has typically revealed that enzootic strains 
of VEE produce little or no viremia and disease, while epizootic IC strains generate 
high-titer viremia and encephalitis.  Observations such as these gave rise to a 
commonly shared hypothesis that the relative sensitivity of these strains to the 
innate equine immune response mediated their different phenotypes.  Specifically, 
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epizootic strains were generally thought of as inherently resistant to the host IFNαβ 
response, leading to more efficient replication and higher viremia.  However, a 
recent report investigating the 1992 emergence of epizootic strains of VEE cautions 
against using murine IFNαβ sensitivity as a marker for epizootic potential in equines 
(87) .   
Nevertheless, exploring the interferon sensitivity of VEE in the murine model 
has facilitated the identification of VEE virulence determinants.   Specifically, the 5’ 
UTR of the VEE genome segregated with the relative IFNαβ resistance of the 
virulent Trinidad donkey strain versus the TC-83 vaccine strain (137, 138).  Upon 
further characterization, a single noncoding nucleotide change in the 5’ UTR was 
identified as a major attenuating mutation (133).  The substitution of G-to-A in the 
third nucleotide of the 5’ UTR resulted in the complete attenuation of VEE, from the 
observed 100% mortality in mice infected with wildtype VEE to 0% mortality with the 
nt3A mutant.  A major role for the innate immune response in this loss of virulence 
was indicated by its heightened sensitivity to IFNαβ (133).  Furthermore, this 
sensitivity appeared to be driven by a pathway independent of Mx, PKR, and 
RNaseL, as infection of mice triply deficient (TD) for these three factors were still 
protected upon infection with the nt3A mutant (L.J. White and R.E. Johnston, 
unpublished data).  This suggested that an alternative innate pathway may be 
capable of mediating protection from VEE infection.     
A similar investigation of Sindbis virus pathogenesis yielded a comparable 
phenotype, with TD and wildtype mice equally protected from Sindbis virus infection 
(62).  A group of over 40 candidate effectors at play within this potential alternative 
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antiviral pathway were identified by microarray, including the interferon-stimulated 
genes IFIT1 (p56), IFIT2 (p54), GBP-2, and the ubiquitin homolog ISG15, among 
others (38).  A recent study supported the notion of ISG15 being a central innate 
mediator following alphavirus infection, as ISG15-/- mice were more susceptible to 
Sindbis virus infection (139).  Furthermore, the increased susceptibility of ISG15-/- 
mice to Sindbis virus infection could be rescued by expressing wild-type ISG15.   
Together, these results lend further evidence to the notion that several host innate 
antiviral factors play a role in protection from alphavirus infection. 
In addition to the interferon-mediated innate response, a rapid 
proinflammatory response to VEE has been described.  Highly elevated levels of 
proinflammatory cytokine gene expression have been documented in the DLN of 
mice infected with virulent VEE, including proinflammatory IL-6, IL-10, IL-12, and 
tumor necrosis factor alpha (TNFα) (130).  Interestingly a similar level of expression 
was observed following avirulent VEE infection; however, the kinetics of expression 
were delayed by 24 h in comparison to virulent VEE.  These results suggested that 
the kinetics of proinflammatory cytokine expression, in addition to relative sensitivity 
to IFNαβ, may influence the outcome of VEE infection.    
However, there is evidence that this proinflammatory response as well as the 
interferon response, may also contribute to alphavirus-induced disease.  For 
example, the production of large amounts of interferon and proinflammatory 
cytokines (e.g., TNFα, IL-1, and IL-6) during the acute-phase of alphavirus infection 
has been correlated with the rapid induction of fatal disease resembling toxic shock 
in newborn mice (140). iNOS and TNF receptor knockout mice exhibit extended 
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average survival times following infection with VEE, suggesting that the inflammatory 
response in the brain of infected animals mediated by these pathways may actually 
contribute to VEE-induced neurodegeneration (141, 142), consistent with the studies 
in SCID mice mentioned above (131).  Therefore, regulation of the host response 
following alphavirus infection is critical, such that a balance can be found 
somewhere between an insufficient innate response and the induction of 
immunopathology.     
 
In vitro models 
In vitro studies also have yielded information regarding the specific 
components of innate immunity that are critical in the response to alphavirus 
infection.  Treatment of cultured cells with IFNαβ establishes an antiviral state that 
inhibits alphavirus replication, although the specific mechanism(s) of this inhibition 
are still not fully understood (63).  However, it has been well established that the 
formation of dsRNA replication intermediates is a necessary step for interferon 
induction following alphavirus infection (143, 144).  A recent study, investigating the 
role of interferon signaling in alphavirus-induced host translation shutoff, specifically 
examined the contribution of the dsRNA-mediated PKR pathway in host translation 
inhibition (145).  Their findings revealed that PKR-dependent pathways were not the 
only means of inhibiting host translation during alphavirus infection, and suggested 
that a PKR-independent mechanism was more likely to be the major pathway 
mediating host translational shutoff.  Furthermore, while this PKR-independent 
mechanism strongly affected the translation of cellular templates, translation of 
 35 
Sindbis subgenomic RNA was resistant to inhibition, suggesting that 1) interferon 
signaling may inhibit alphavirus replication downstream of translation, and 2) 
alphaviruses may co-opt the interferon system to some extent in promoting their own 
replication (145).   
In fact, recent data suggests that efficiency in the processing of the alphavirus 
nonstructural polyprotein precursor by the nsP2 protease may be a key determinant 
of virulence.  Mutants with an accelerated rate of nonstructural protein processing 
are attenuated in vivo, while viruses with slower nonstructural protein processing 
demonstrate increased virulence potential (146).  Furthermore, a recent correlation 
has been made between this accelerated processing phenotype and a subsequent 
increase in the amount of interferon induced during infection, which likely contributes 
to the attenuated phenotype of these mutants [M. Suthar and M. Heise, submitted 
manuscript].  The nonstructural polyprotein, as well as processing intermediates, 
may potentially play a role in the alphavirus resistance to the type I interferon 
response, possibly through interaction with and/or cleavage of the RIG-I pattern 
recognition receptor.  Future studies along these lines will certainly yield valuable 
information regarding the innate recognition of, and innate immune response to, 
alphavirus infection.  
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ABSTRACT 
A concept fundamental to viral pathogenesis is that infection induces specific 
changes within the host cell, within specific tissues, or within the entire animal.  
These changes are reflected in a cascade of altered transcription patterns evident 
following infection.  However, elucidation of this cascade in vivo has been limited by 
a general inability to distinguish changes occurring in the minority of infected cells 
from those in surrounding uninfected cells.  To circumvent this inherent limitation of 
traditional gene expression profiling methods, an innovative mRNP-tagging 
technique was implemented to isolate host mRNA specifically from infected cells in 
vitro as well as in vivo following Venezuelan equine encephalitis virus (VEE) 
infection.  This technique facilitated a direct characterization of the host defense 
response specifically within the first cells infected with VEE, while simultaneous total 
RNA analysis assessed the collective response of both the infected and uninfected 
cells.  The result was a unique, multifaceted profile of the early response to VEE 
infection in primary dendritic cells, as well as in the draining lymph node, the initially 
targeted tissue in the mouse model.  A dynamic environment of complex interactions 
was revealed, and suggested a two step innate response in which activation of a 
subset of host genes in infected cells subsequently leads to activation of the 
surrounding uninfected cells.  In addition to wildtype infection, the host response to 
infection with a mutant containing a single noncoding change in the 5’UTR was 
explored.  Although this mutation confers a heightened sensitivity to the interferon-
induced antiviral state, the mRNP-tagging system demonstrated that the resulting 
attenuation was not a function of an increased induction of antiviral effectors at early 
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times within infected cells.  Our findings suggest that the application of viral mRNP-
tagging systems, as introduced here, will facilitate a much more detailed 
understanding of the highly coordinated host response to infectious agents. 
 
INTRODUCTION 
At the interface of pathogen infection and host response lies a complex 
network of regulated interactions.  As the host seeks to eradicate the pathogen and 
maintain survival, the pathogen itself seeks to continue its own proliferation at 
whatever cost is necessary to the host cell.  Therefore, the insult associated with 
viral infection often involves numerous changes in host gene expression.  
Fundamental to many viral pathogenesis studies is the investigation of these specific 
changes within the host cell, or on a more global scale, within a specific tissue, 
organ, or the entire animal.  Although it has been possible in several systems to 
singularly identify cellular genes that are altered in expression due to infection, these 
genes most likely represent a very small fraction of all the genes induced or 
repressed.  The advent of high-throughput genomic profiling technologies has 
greatly expanded the ability to monitor the cellular response to pathogen stimuli in a 
global manner.  In an attempt to more fully understand the interactions between 
pathogen and host, virologists have turned to cDNA array analysis within the past 
decade to evaluate the status of host gene expression post-infection.  Although 
widely informative, there remains an inherent limitation in applying microarray 
analysis to viral pathogenesis studies.  In the absence of an acutely susceptible 
system in which all cells can be uniformly infected, a heterogeneous environment of 
infected and uninfected cells naturally exists during viral infection.  This is 
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particularly true in vivo, where only a minority of cells in a given tissue or organ are 
infected, even when that tissue is a major target of infection.  In traditional 
microarray analysis utilizing total RNA isolation, there is an inability to discriminate 
the population of host mRNAs isolated from the infected cells versus the surrounding 
uninfected cells.  As the percentage of uninfected cells is high in vivo, mRNA from 
uninfected cells likely creates background signal that skews or masks the analysis 
from infected cells.  Discriminating the direct viral impact on infected cells from the 
subsequent effects on bystander uninfected cells is critical to fully understanding the 
pathogenesis of a given virus, yet most analyses lack this distinction. 
To circumvent this limitation, we have optimized and implemented an 
innovative mRNP-tagging technique to isolate host mRNA specifically from infected 
cells following viral infection in cultured cells as well as tissues in vivo.  The mRNP- 
tagging technology was originally developed from a functional genomics approach 
termed ribonomics, which examines mRNAs functionally clustered in 
ribonucleoprotein complexes (1, 2).  The mRNP-tagging system takes advantage of 
the natural interaction of RNA-binding proteins with cellular mRNA to effectively 
enrich and isolate messages from a specific minority cell type within a 
heterogeneous environment.  One such interaction that has been used in several 
systems is the well established strong binding of poly(A) binding protein I (PABP) to 
the poly(A) tail of cellular mRNAs prior to translation (3-8).  In the mRNP-tagging 
technique, a unique version of PABP engineered with an epitope tag, is expressed in 
a cell- or tissue-specific manner.  The cellular mRNA bound to the tagged-PABP is 
then co-immunoprecipitated using an anti-epitope antibody, enriching the mRNA 
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from the targeted cell population and separating it from the mRNA of the surrounding 
cells or tissues (1, 2, 9).  Gene profiling methods such as cDNA microarrays or 
quantitative real-time PCR can then be performed using the enriched mRNA 
population to assess the gene expression status within the cell or tissue population 
of interest.  This method has been successfully applied to identify tissue-specific 
mRNA populations in Caenohabditis elegans and Drosophila melanogaster (10-13), 
as well as to identify cell type-specific gene expression changes in mixed cell culture 
models in vitro (14).  
Here, we have adopted the mRNP-tagging technique to characterize host 
gene expression changes following infection with Venezuelan equine encephalitis 
virus (VEE).  VEE is an arthropod-borne, single stranded (+)sense RNA virus 
associated with periodic epidemics and equine epizootics in the Western 
Hemisphere, and serves as a leading model for the study of alphavirus pathogenesis 
(15).  Numerous studies have underscored the dramatic role of virus genetics and 
the subsequent host defense response in dictating the course and outcome of VEE 
infection (16-32).  Although infection in the murine model has been well studied for 
some time, little is known concerning the molecular markers of VEE-induced 
disease, including the direct effects on host cell gene expression.  VEE infection is 
characterized by two distinct disease phases following infection in humans, horses, 
and mice:  An initial lymphotropic phase characterized by a high serum viremia, 
followed by invasion of the central nervous system and initiation of a neurotropic 
phase leading to encephalitis.  In horses and mice, progression to the neurotropic 
phase occurs at very high frequency, whereas progression in humans occurs in 
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approximately 1% of cases.  Previous studies in our laboratory have carefully 
examined the progression of pathogenesis in the mouse model, utilizing molecularly 
cloned infectious VEE as well as an extensive panel of mutants blocked at various 
stages of infection (18, 21, 22, 25, 27, 29).  The draining lymph node (DLN), in 
particular the dendritic cells, was subsequently identified as the initial site of viral 
replication, with infected Langerhans cells migrating there from the site of inoculation 
in the footpad (20).  It has been hypothesized that the early events within the DLN 
set the stage for a specific pattern of virus replication and host response that 
contributes to the pathogenesis of the infecting virus.  However, many details of the 
earliest stages of VEE infection remain largely undefined, with the innate host 
response likely playing a major role.  
To define the molecular profile of the early virus-host interactions central to 
VEE pathogenesis, we took advantage of several tools. One tool paramount to 
studying the early events in infection are VEE replicon particles (VRP).  VRP are 
propagation-defective vector particles that undergo only one round of infection, as 
the structural genes which normally drive the assembly of progeny virions are 
deleted and replaced with a marker gene of interest (33).  As such, VRP replication 
is limited to the first infected cells, allowing us to model the earliest events of VEE 
infection.  In addition, the application of an mRNP-tagging technology offers an 
opportunity for a distinct view of the VEE-induced changes in host gene expression.  
By expressing an epitope tagged version of PABP from VRP, host messages 
induced specifically within the first round of infected cells can be fractionated from 
those of the surrounding uninfected cells.  Through co-immunoprecipitation with 
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antibody to the epitope tag, the infected cell host mRNA bound to the VRP-delivered 
tagged-PABP can be isolated and screened as a discrete mRNA population for 
changes in host gene expression.  This technology enables discrimination of 
uninfected cells from infected cells, and specifically profiles the changes induced in 
the infected cell population—a distinction that previously has been difficult to 
achieve, particularly in vivo where the infected cells may be only a small minority in a 
given tissue (e.g., in the DLN post-VRP infection).   
Using VRP to infect primary dendritic cells in vitro, and to limit infection to the 
initially infected cells in vivo, we have elucidated gene expression patterns that 
define the early stages of VEE pathogenesis, including members of the interferon, 
proinflammatory, and general defense pathways.  This analysis revealed 
multifactorial interactions that occur with the virus infected host, and indicated a two 
phase innate response with distinct host profiles specific for infected cells and 
uninfected cells during the course of infection.   
This setting also provides a novel means to examine the effects of viral 
genetic determinants during infection using VEE mutants in relation to wildtype 
infection.  Comparing the host gene response to two differential VEE infections, and 
determining both the common and unique changes induced by each infection will 
facilitate a greater understanding of how the host response develops.  Therefore, in 
addition to wildtype VRP, the host response to infection with VRP containing a 
mutation that attenuates virulent VEE also was explored.   This single non-coding 
substitution of G-to-A in the third nucleotide of the 5’ untranslated region (UTR), 
results in the complete attenuation of the 100% mortality observed in mice infected 
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with wildtype VEE, and was originally defined as a primary attenuating mutation 
within the TC-83 vaccine strain of VEE (18, 28).  A major role for the innate immune 
response in the loss of virulence of this nt3A mutant is indicated by its heightened 
sensitivity to IFNαβ, which appears to be driven by a PKR/RNaseL-independent 
mechanism (18)(L.J. White and R.E. Johnston, unpublished).  The data presented 
here demonstrate that, consistent with the dramatic phenotypic differences in vivo, 
this mutant displays dramatic differences in host gene expression post-infection in 
comparison to wildtype VRP infection.   
   
MATERIALS AND METHODS 
VEE replicon particles (VRP) 
The construction and packaging of VRP using a split helper system have 
previously been described (33).  The replicon plasmid constructs used in this study 
were (i) null replicons that lack any functional transgene sequence downstream of 
the 26S promoter (null VRP), (ii) replicons expressing green fluorescent protein 
(GFP-VRP) and (iii) replicons expressing an N-terminally FLAG-tagged version of 
poly(A) binding protein I (FLAG-PABP VRP).  The production of GFP-VRP and null 
VRP have been described previously (20, 34).  The FLAG-PABP replicon plasmid 
was generated by the directional cloning of the ORF of PABP I containing an N-
terminal FLAG epitope tag (GACTACAAGGACCACGATGACAAG, kindly provided 
by J.D. Keene (Duke University Medical Center, Durham, NC) (14)), immediately 
downstream of the 26S mRNA promoter of the pVR21 replicon plasmid.   
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In addition to the wildtype null- and FLAG-PABP replicon genomes, a mutant 
genome containing a change from the wildtype nucleotide G at position three to a 
mutant nucleotide A also was utilized (nt3A mutant).  Nt3A mutant null- and FLAG-
PABP replicon plasmids were constructed by substituting the 543bp XbaI-RsrII 
fragment from the previously cloned pV5505 replicon plasmid containing the nt3A 
mutation, for the equivalent fragment in the wildtype constructs (18).  The presence 
of the nt3A mutation was confirmed by sequencing.  
All replicon particles used in this study were packaged in the wildtype (V3000) 
VEE envelope (33).  Briefly, the replicon RNA genome containing the VEE 
nonstructural genes and expressing the heterologous gene from the viral 26S 
promoter, along with two defective helper RNAs providing the wildtype capsid and 
glycoprotein genes, but lacking the virus-specific packaging signal, were co-
electroporated into BHK-21 cells (ATCC).  Due to the lack of encoded viral structural 
genes in the replicon genome, infectious VRP undergo only one round of infection, 
and the absence of propagating recombinant virus was confirmed by passage in 
BHK-21 cells.  VRP were concentrated from supernatants by centrifugation through 
a 20% sucrose cushion and resuspended in PBS.  BHK-21 titers were determined 
either by immunofluorescence (GFP-VRP), or immunocytochemistry (null VRP, 
FLAG-PABP-VRP) using sera containing antibody to the VEE nonstructural proteins.   
 
Cells and in vitro infections 
(i) Infection of L929 cells.  L929 murine fibroblasts (ATCC) were maintained 
at 37°C under 5% CO2 in complete alpha minimal essential medium (αMEM, Gibco) 
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containing 10% donor calf serum, 10% tryptose phosphate broth, 2 mM L-glutamine, 
100U/ml penicillin and 0.5 mg/ml streptomycin.  For VRP infection, 106 cells were 
seeded in 60 mm dishes and incubated overnight.  The medium was removed from 
the monolayer and the cells were infected at a multiplicity of infection (MOI) of 5 
(unless otherwise indicated) in 0.2 ml endotoxin-free PBS supplemented with 110 
mM Ca2+, 50 mM Mg2+, and 1% vol./vol. donor calf serum.  After 1 h of adsorption at 
37°C, complete αMEM was added to the monolayer.   
(ii) Generation of primary murine BMDCs.  Breeding pairs of IFNα/βR+/+ 
129Sv/Ev and IFNα/βR-/- mice were kindly provided by Herbert Virgin (Washington 
University, St. Louis, MO.) and Barbara Sherry (North Carolina State University, 
Raleigh, N.C.), respectively.  Mice were bred under specific pathogen-free 
conditions in the Department of Laboratory Animal Medicine breeding colony 
facilities at the University of North Carolina, Chapel Hill.  To generate primary 
immature BMDCs (35, 36), bone marrow cells from femurs and tibia of 8- to 14-
week-old mice were aspirated with RPMI-10 medium [RPMI 1640 (Gibco), 10% 
FBS, 2 mM L-glutamine, 50 uM 2-ME, 100 U/ml penicillin, 100 ug/ml streptomycin 
sulfate].  Cells were filtered through a 40 um cell strainer, pelleted (1200 rpm, 5 min), 
and resuspended in ACK lysis buffer (0.15 M NH4Cl, 0.1 mM  Na2EDTA, 1 mM 
KHCO3, pH 7.2-7.4).  Following lysis of red blood cells at room temp, 10 ml of RPMI-
10 media/mouse was added, cells were again pelleted and resuspended in fresh 
RPMI-10 media for counting.  Cells were seeded in 6-well low cluster plates 
(Corning) in RPMI-10 media supplemented with 20 ng/ml GM-CSF (Peprotech), and 
incubated at 37°C under 5% CO2.  On day three, RPMI-10 media supplemented with 
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20 ng/ml GM-CSF and 20 ng/ml IL-4 (Peprotech) was added to each well.  On day 
five, additional RPMI-10 media supplemented with 10 ng/ml GM-CSF and 10 ng/ml 
IL-4 was added to each well.  On day seven, cells were harvested by gently 
transferring to 50 ml conical tubes, and washing each well with cold PBS.  Cells 
were pelleted (1200 rpm, 10 min at 4°C), and resuspended in RPMI-1H (RPMI 1640, 
1% FBS, 10 mM Hepes, 2 mM L-glutamine, 50 uM 2-ME, 100 U/ml penicillin, 100 
ug/ml streptomycin sulfate).  BMDCs were cryopreserved at 2-5 x 106/ml in 90% 
FBS/10% DMSO.   
(iii)  Infection of primary BMDCs.  Cryopreserved BMDCs were quickly 
thawed in a 37°C water bath, and gently transferred to a conical tube containing an 
equal volume of RPMI-10.  The volume of RPMI-10 was brought up to 10 ml, and 
the cells were pelleted.  An additional wash with RPMI-10 was completed, and the 
cells were resuspended in 3 ml RPMI-10 per 2x106 cells, supplemented with 5 ng/ml 
GM-CSF and IL-4.  BMDCs were seeded at 2.5 x 106 cells/well in hydrated six-well 
low cluster plates, and allowed to recover overnight at 37°C, 5% CO2.  BMDCs were 
harvested and pooled with a cold PBS wash of each well.  After pelleting, cells were 
resuspended in RPMI-1H at 106 cells/ml, and 106 cells/well were seeded in a 
hydrated six-well low cluster plate.  BMDC were infected with VRP at an MOI of 0.5 
in 100 ul PBS supplemented with 1% donor calf serum and Ca+/Mg+.  Following 2hs 
of absorption at 37°C, 5 ml of RPMI-10 supplemented with 5 ng/ml GM-CSF and IL-
4 was added to each well. 
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Animals and in vivo infections 
Seven- to eight-week-old female BALB/c mice were obtained commercially 
(Charles River Laboratories) and allowed to acclimate for 5-7 days.  Mice were 
inoculated in each rear footpad with 106 IU of VRP diluted in 10 ul endotoxin-free 
PBS containing 1% donor calf serum.  Mock-infected animals received diluent alone. 
 
Total RNA isolation 
(i)  L929 cells.  At indicated times post-infection, media was removed and 
L929 cell monolayers were washed with cold PBS.  The UltraSpec RNA Isolation 
System was used to isolate total RNA, with 1ml of UltraSpec RNA Reagent added to 
each 60mm dish of L929 cells per manufacturer’s protocol (Biotecx).  
(ii) Primary BMDCs.  At 6 or 12hpi, BMDCs were transferred to a 15 ml 
conical tube and pelleted (1200 rpm, 10 min at 4°C), during which time each well 
was washed with cold PBS.  The wash was used to resuspend the pelleted cells, 
followed by a second spin.  Total RNA was harvested from BMDC using the RNeasy 
Mini Kit, according to the manufacturer’s protocol (Qiagen).   
(iii) Lymph Nodes.  At indicated times post infection, mice were euthanized 
and both draining popliteal lymph nodes were harvested, washed with cold PBS, and 
pooled together into 200 ul RNAlater RNA Stabilization Reagent (Qiagen, Ambion).  
Total RNA was harvested from tissue homogenate prepared using a plastic pestle 
with a handheld motor and the RNeasy Protect Mini Kit (Qiagen).   
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mRNA-tag immunoprecipitation and RNA isolation 
(i)  Antibodies.  The mRNP-tagging method as applied to cells and animal 
tissues infected with VRP was developed from general ribonomics/mRNP-tagging 
protocols previously described by the Keene laboratory (1, 2, 9, 14).  Polyclonal anti-
PABP antibody was generously provided by J. Keene (Duke University Medical 
Center).  Additionally, polyclonal anti-PABP H-300 antibody was obtained from 
Santa Cruz Biotechnology.  Monoclonal anti-FLAG M2 antibody was acquired from 
Sigma-Aldrich.   
(ii) Preparation of mRNP lysate from cultured cells.  L929 monolayers (106 
cells total) were washed with cold PBS, followed by lysis of the monolayer with 1ml 
of polysome lysis buffer [100 mM KCl, 5 mM MgCl2, 10 mM Hepes, pH 7.0, and 
0.5% Nonidet P-40 with 1 mM DTT, 100 U/ml RNaseOUT(Invitrogen), 0.2% vanadyl 
ribonucleoside complex (New England Biolabs), and 1 tablet/10 ml Complete Mini 
Protease Inhibitor Cocktail Tablet (Roche) added fresh at time of use].  For BMDC 
lysis, cells were gently pelleted and the media removed.  The pellet was washed 
with PBS and spun again, followed by resuspension and lysis in 500 ul of polysome 
lysis buffer.  Cells were lysed for 10 min, followed by centrifugation at 14,000 x g in a 
tabletop microfuge for 10min at 4°C to remove cellular debris.  The ~1 ml total 
volume of L929 mRNP lysate (isolated from 106 L929 cells) was stored at -80°C in 
200 ul working aliquots, while the 500 ul total volume of BMDC mRNP lysate 
(isolated from 106 BMDC cells) was stored at -80°C in 250 ul working aliquots.       
(iii) Preparation of mRNP lysate from whole animal tissue (DLN).  Freshly 
dissected DLN were washed with ice-cold PBS.  Five DLN were pooled per sample, 
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and coarsely homogenized in 200 ul polysome lysis buffer (containing RNase and 
protease inhibitors as described above) using a plastic pestle and hand-held motor.  
Samples were frozen at -80°C until use.  Upon thawing (on ice), the homogenization 
and lysis was continued to completion (as monitored microscopically), and the lysate 
spun at 4°C to pellet any remaining tissue/debris.  The supernatant was transferred 
to a fresh tube on ice, and a second round of lysis/ homogenization was completed 
on the pellet using 100 ul polysome lysis buffer.  Upon centrifugation, this 
supernatant was pooled with the first (~300 ul total) and kept on ice until use. 
(iv) mRNP immunoprecipitation.  For each immunoprecipitation sample, 
two 60 ul aliquots of protein beads were prepared; the first aliquot to coat with the 
specified antibody, and the second to pre-absorb the lysate for removal of non-
specific binding.  For antibody coating, 60ul Protein-A Sepharose beads (pre-swollen 
with 12ml PBS/1.5g beads, Sigma) or fast flow Protein-G Sepharose beads 
(commercially pre-swollen, Sigma) were washed with PBS (10 volumes), followed by 
a second wash of 10 volumes NT2 buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM 
MgCl2, 0.05% Nonidet P-40) tumbled end-over-end for 15 min at room temperature.  
Beads were resuspended in 10 volumes fresh NT2 buffer supplemented with 5% 
BSA, and tumbled overnight at 4°C with excess immunoprecipitating antibody (200 
ul anti-PABP antibody; 25 ul anti-FLAG antibody).  Prior to the immunoprecipitation 
reaction, the antibody-coated beads were washed with 1 ml NT2 buffer. 
To pre-absorb the lysate, a second 60 ul aliquot of beads (per sample) was 
prepared as described above through the 15 min NT2 buffer wash.  These beads 
were resuspended in 5-10 volumes NT2 buffer supplemented with 100 U/ml 
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RNaseOUT, 0.2% vanadyl ribonucleoside complex, 2 mM DTT, and 25 mM EDTA.  
The mRNP lysate was added (200 ul L929 lysate, 250 ul BMDC lysate, or 300 ul 
DLN lysate), along with 1 ul normal animal serum corresponding to the 
immunoprecipitating antibody (normal mouse serum for anti-FLAG 
immunoprecipitation samples; normal rabbit serum for anti-PABP 
immunoprecipitation samples).  Samples were tumbled at room temperature for 1 h 
to remove any material that would non-specifically bind to the beads.  This pre-
absorbed lysate was recovered by pelleting the beads (2000 x g, 3 min) and 
applying the supernatant to the specific antibody-coated beads, along with 5-10 
volumes of NT2 buffer supplemented as described above.  This immunoprecipitation 
slurry was tumbled end-over-end at room temperature for 2h.   
(v) RNA extraction from immunoprecipitated mRNP complex.  
Immunoprecipitated samples were centrifuged (5 min at 2000 x g, 4°C) to pellet the 
beads, and washed four times with ice-cold NT2 buffer (10 bead volumes).  Washed 
beads were resuspended in 600 ul proteinase K digestion buffer (100 mM Tris pH 
7.5, 12.5 mM EDTA, 50 mM NaCl, 1% SDS), plus 25 ul of 20 mg/ml proteinase K, 
and incubated for 30 min in a rotating device at 50°C.  600 ul phenol-chloroform-
isoamyl alcohol (Fisher) was added to the beads, which were vortexed for 2 min and 
then centrifuged for 5 min at 14,000 x g, 4°C.  This was followed by extraction with 
one volume of RNA-grade chloroform (Fisher), and precipitation with 1 volume of 
isopropanol, 60 ul of 4M ammonium acetate, 3 ul of 1 M MgCl2 and 8 ul of glycogen.  
The samples were stored at -80oC until use for gene expression analysis.  Upon 
thawing on ice, the samples were spun for 30 min (14,000 x g, 4oC), and the RNA 
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pellet washed with 100 ul of 80% ethanol.  The RNA pellet was resuspended in 
RNase-free water (Ambion), or hybridization buffer as necessary.    
 
RNase protection assay (RPA) 
RNase protection assays were used to determine the relative abundance of 
specific cellular mRNAs in infected and mock infected L929 cells.  32P-labeled RNA 
probes were synthesized by use of the RiboQuant in vitro transcription kit and a 
RiboQuant multiprobe custom template set (BD Pharmingen).  This custom set 
included template for the synthesis of radiolabeled probes specific to murine 
interferon beta (IFNβ) and interferon regulatory gene-1 (IRF-1), as well as mRNAs 
encoding the murine housekeeping proteins GAPDH and L32.  RNA isolated from 
the mRNP complexes was used as input RNA for the mRNP-tagging samples, using 
100% of the isolated RNA by resuspending the RNA pellet directly in hybridization 
solution.  2 ug of total RNA to be used as input samples for total RNA analysis was 
isolated as described above.  The custom probe set was mixed with each RNA 
sample, placed in a pre-warmed heat block at 90°C which was immediately turned 
down to 56°C, and incubated overnight.  The RNA-probe mixtures were treated with 
RNase according to the RiboQuant RPA kit protocol (BD Pharmingen).  The 
protected dsRNA species were electrophoresed on a 4.5% polyacrylamide-8M urea 
sequencing-sized gel, the gels were dried, and analysis conducted on a Molecular 
Dynamics Storm phosphorimager with ImageQuant software.  Values represent the 
fold change over mock expression, as normalized to anti-PABP immunoprecipitated 
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GAPDH housekeeping mRNA levels for the mRNP-tagging samples, or total 
GAPDH housekeeping RNA levels for total RNA samples.    
 
Fluorescence activated cell sorting (FACS) analysis 
To compare the infected cell host message profile generated by the mRNP-
tagging approach versus FACS-facilitated sorting, 1.5 x 106 L929 cells were mock 
treated or infected at a low MOI of 0.2 with either FLAG-PABP VRP or GFP-VRP.  At 
12hpi, cultures were treated in one of 2 ways to generate a profile of host message 
levels specifically from the infected cells.  The cell monolayers that had been 
infected with FLAG-PABP VRP were lysed, and FLAG-tagged host messages were 
immunoprecipitated from the infected cells per the mRNP-tagging protocol described 
above using 100% of the monolayer lysate.  A separate anti-PABP 
immunoprecipitation was completed from both mock- and FLAG-PABP VRP-infected 
cell lysates to isolate all PABP-associated mRNA and served as the mock reference 
with normalization to GAPDH signal levels. 
To generate a comparative profile of the infected cell host response, cell 
monolayers that had been infected with GFP-PABP VRP were prepared for FACS-
based analysis.  The monolayers were trypsinized, washed with media (αMEM 
supplemented with 2% FBS, 100 U/ml penicillin, and 0.5 mg/ml streptomycin) and 
resuspended in 700 ul of fresh media.  The UNC-CH Flow Cytometry Core Facility 
provided cell sorting capability using the Cytomation Inc. Modular Flow (MoFlo) 
FACS system, gating on GFP-positive signal to sort and recover the infected cell 
population.  This GFP-positive cell population was gently pelleted and resuspended 
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in 0.5 ml polysome lysis buffer.  100% of the resulting lysate was 
immunoprecipitated with anti-PABP antibody to isolate all PABP-associated 
messages specifically from the (GFP+ sorted) infected cell population.  A separate 
anti-PABP immunoprecipitation was completed from mock cell lysate and served as 
the mock reference with normalization to GAPDH signal levels.  The host message 
populations isolated from each technique were analyzed using Taqman real-time 
PCR (see below).  
 
cDNA synthesis, real-time PCR, and analysis 
(i) cDNA synthesis.  A one-tube DNase treatment and reverse transcription 
protocol was used to generate cDNA, using SuperScript III Reverse Transcriptase 
First Strand cDNA kit (Invitrogen).  0.5-0.75 ug of either mRNA-tag isolated or total 
RNA served as input RNA for the reaction, using RNase-free water to bring the total 
volume to 10 ul.  This was combined with 1 ul 10 mM dNTP mix (Amersham 
Biosciences), 4 ul 5X SuperScript III reverse transcriptase buffer, 1 ul 0.1 mM dTT, 1 
ul 40 U/ul RNaseOUT (Invitrogen), and 1 ul RQ1 RNase-free DNase (Promega).  
The samples were DNase treated at 37°C for 30 min, followed by the addition of 1 ul 
RQ1 Stop Solution (Promega) and heat inactivation of the samples at 65°C for 10 
min.  Following the addition of random hexamer primers (150 ng, Invitrogen), 
reverse transcription of the samples was continued in the same tube, according to 
the SuperScript III protocol (Invitrogen).  cDNA samples were stored at -20°C.  
(ii) Real-time PCR.  Real-time PCR was performed to determine the relative 
abundance of specific cellular mRNAs in infected and mock treated samples.  
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Taqman Gene Expression Assays (Applied Biosystems) containing primers and 
probes for various target host messages were used, with each reaction performed in 
a 25 ul total volume [5ul cDNA, 12.5 ul TaqMan Universal PCR Master Mix without 
AmpErase UNG (Applied Biosystems), 1.25 ul probe/primer mix (Applied 
Biosystems), and 6.25 ul RNase-free water].  The default amplification profile was 
performed by the ABI Prism 7000 Real-Time PCR System, and the data converted 
into cycle threshold (CT) values by the 7000 Sequence Detection Software (v1.2.3, 
Applied Biosystems).  Duplicate samples were amplified from each experimental 
group with GAPDH serving as the housekeeping control along with each target gene 
of interest.  A negative template control also was performed, with all samples run in 
parallel on the same plate.   
(iii) Total RNA real-time PCR analysis.  Real-time PCR results are 
presented as fold gene expression in the infected sample over that in the mock 
sample, as normalized to the GAPDH housekeeping gene.  During each reaction, a 
cycle threshold (CT) value was generated for the target gene of interest (and 
GAPDH), corresponding to the cycle number at which the fluorescence of the PCR 
product reached significant levels above the background threshold level.  Raw CT 
values generated from total RNA samples were analyzed using the well established 
delta CT (∆CT) method to generate the fold expression results [User Bulletin, ABI 
Prism 7000 Sequence Detection System (Applied Biosystems)].  Briefly, for each 
cDNA sample, the GAPDH CT value was subtracted from the CT value of the target 
gene (e.g., cytokine) of interest, yielding a ∆CT value.  The ∆CT value generated for 
the VRP-infected sample was then subtracted from the ∆CT value of the mock 
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sample, yielding a ∆∆CT value.  This widely-used method assumes the target and 
housekeeping genes were amplified with the same efficiency, thus the increase in 
host mRNA levels in the infected samples compared to the mock treated samples 
was calculated as 2 –(∆∆CT ).  
(iv) Real-time PCR analysis of mRNA-tagged samples.  Prior to this 
standard ∆CT analysis, raw CT values generated from mRNA-tagged samples were 
normalized in a manner that was inherently required for this system.  The mock 
signal values were generated from an anti-PABP immunoprecipitation which isolates 
all PABP-bound messages in the entire cell culture or tissue analyzed.  However, 
the infected sample values were derived using an anti-FLAG immunoprecipitation to 
specifically isolate the infected-cell minority subset of the population.  Therefore, an 
mRNP-tagging normalization step was utilized to account for two parameters:  1) 
The disparity in the cell population size of the mock and infected samples assayed 
by the mRNP-tagging system, and 2) any difference in the immunoprecipitating 
antibody strength (the polyclonal anti-PABP antibody versus the monoclonal anti-
FLAG antibody).  To do so, raw GAPDH CT values were generated from mRNP-
tagging samples in the following manner.  From FLAG-PABP VRP infected samples, 
raw GAPDH CT values were generated from both anti-FLAG and anti-PABP 
immunoprecipitation-derived cDNA, representing GAPDH expression in the infected 
cell subset or the entire culture respectively.  However from mock samples, raw 
GAPDH CT values were solely generated from anti-PABP immunoprecipitation-
derived cDNA, thus representing the expression of GAPDH in the entire cell 
population.  Therefore, to normalize the mock control values for comparison to the 
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infected samples, a ratio of the anti-FLAG GAPDH signal to the anti-PABP GAPDH 
signal was applied to account for the difference in cell population size and antibody 
strength(r):   
i)  VRP anti-FLAG raw GAPDH CT value 
─────────────────────────  =  “r”  
 VRP anti-PABP raw GAPDH CT value 
 
This ratio was then applied to the mock anti-PABP raw GAPDH CT value to generate 
a normalized mock GAPDH value:   
ii)      (r) x (mock anti-PABP raw GAPDH CT value) = Normalized mock   
                                                                                       GAPDH CT 
 
This normalized CT value served as the input mock GAPDH value for the standard 
∆CT analysis, as described above for total RNA. 
 
Affymetrix gene expression arrays and analysis 
L929 cells were mock treated or infected at an MOI of 5 with either wildtype or 
nt3A mutant null-VRP, and total RNA was isolated at 5h p.i. using the UltraSpec 
reagent protocol as described above.  The UNC-CH Functional Genomics Core 
Facility provided Affymetrix sample preparation and hybridization services, 
hybridizing the samples to Affymetrix Mouse Expression 430A (MOE430A) 
GeneChip arrays, which include analysis of ~22,600 genes.  cDNA was synthesized 
using 7 ug of total RNA and a custom cDNA kit from Life Technologies using a T7-
(dT)24 primer for the reaction.  Biotinylated cRNA was then generated from the cDNA 
reaction using the BioArray High Yield RNA Transcript Kit, and the cRNA was 
fragmented in fragmentation buffer (40 mM Tris-acetate pH 8.1, 100 mM KOAc, 30 
mM MgOAc) at 94oC for 35 min.  15 ug of fragmented cRNA was then added to a 
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hybridization cocktail (0.05 ug/ul fragmented cRNA, 50 pM control oligonucleotide 
B2, BioB, BioC, BioD,  and cre hybridization controls, 0.1 mg/ml herring sperm DNA, 
0.5 mg/ml acetylated BSA, 100 mM MES, 1M  [Na+], 20 mM EDTA, 0.01% Tween 
20).  10 ug of cRNA was used for hybridization.  The arrays were hybridized for 16h 
at 45oC in the GeneChip Hybridization Oven 640, followed by washing and staining 
with R-phycoerythrin streptavidin in the GeneChip Fluidics Station 400.  The arrays 
were then scanned with the Hewlett Packard GeneArray Scanner.  Affymetrix 
GeneChip Microarray Suite 5.0 software was used for washing, scanning, and basic 
analysis, with sample quality assessed by examination of 3’ to 5’ intensity ratios of 
certain genes.  Expression analysis files created by Microarray Suite were imported 
into GeneSpring 6.2 (Silicon Genetics) for further gene expression analysis and 
filtering.  Two independent array studies were completed, and gene lists were 
compiled representing only those genes that were up- or downregulated by greater 
than 2-fold in replicate analyses.       
 
RESULTS 
Establishment of the VRP mRNP-tagging system 
An mRNP-tagging technique has been optimized and applied to the isolation 
of mRNA specifically from infected cells following VRP infection.  The fundamental 
basis of mRNP-tagging relies on the natural interaction of RNA-binding proteins with 
RNA.  Synthesis of a uniquely tagged RNA binding protein in target cells or specific 
tissues of interest enables the isolation of a specific mRNA population, employing 
tag-specific antibodies and co-immunoprecipitation to isolate the target mRNAs.  To 
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apply this technique to a virus infection model, a FLAG epitope-tagged version of 
PABP was delivered specifically to infected cells by engineering the virus itself to 
express the unique RNA-binding protein.  The PABP coding sequence, with the 
FLAG epitope fused in frame at the 5’ end, was cloned directly downstream of the 
26S promoter of the VEE replicon plasmid (Fig. 2.1A), and the replicon RNA was 
packaged into VEE replicon particles to generate FLAG-PABP VRP.  Upon infection 
of BHK and L929 cells, the FLAG-PABP VRP programmed the robust expression of 
the epitope-tagged version of PABP within 2 -3hpi, as determined by Western 
blotting and anti-FLAG immunoprecipitation from cell lysates (data not shown).  High 
levels of expression were expected based on the documented high level of 
transgene expression from the 26S mRNA promoter of VRP (33), a key element for 
this VRP mRNP-tagging system.   
An outline of the VRP mRNP-tagging procedure is shown in Fig. 2.2.  Briefly, 
following infection with FLAG-PABP VRP at low MOI, the FLAG-tagged PABP 
molecule is synthesized only in the infected cells as the replicon RNA is expressed.  
At various times post-infection the cells are lysed, releasing PABP-bound messages.  
After pre-clearing, the lysate is mixed with agarose beads coated with anti-FLAG 
antibody and blocked with BSA.  The mRNA from the infected cells is 
immunoprecipitated specifically via the FLAG epitope of the PABP bound to the 
message in the RNP complex, as this form of PABP is only present in VRP-infected 
cells.  The message is subsequently isolated from that complex by proteinase K 
digestion and phenol-chloroform based extraction.  Initial experiments utilized 
RNase protection assays to detect host messages following the anti-FLAG 
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immunoprecipitation from infected BHK and L929 cell extracts.  These studies 
verified that the VRP-supplied tagged-PABP was in fact bound to host messages, 
and that it could be co-immunoprecipitated to isolate mRNA for use in gene 
expression profiling (data not shown).  Additionally, we determined the concentration 
of immunoprecipitating antibodies that would ensure antibody excess, which was 
important due to the high level of expression from the VRP (data not shown).   
An issue that could complicate the precise nature of the profiling involved in 
mRNP-tagging systems is the potential for promiscuous exchange or reassortment 
of endogenous and tagged-PABP among mRNAs in cell extracts.  To alleviate 
concern in this matter, several groups have employed the use of formaldehyde 
crosslinking to increase the stability of the mRNA – PABP interaction during 
immunoprecipitation (10-13).  However, in studies where this treatment was 
assessed, it was found that formaldehyde treatment had little to no effect on the 
level of mRNA enrichment from the target populations (9, 13).  Additionally, the 
degree of crosslinking that is effective, without irreversibly linking the mRNA to the 
protein and thus dampening RNA recovery, may be difficult to determine.  
Furthermore, concerns of PABP reassortment were also alleviated by studies 
demonstrating that mRNA originally bound to PABP in cell lysates was not displaced 
by competing excess poly(A) RNA, nor by a free pool of PABP (9).   
We designed an experiment to address the degree, if any, of PABP 
reassortment in our system, including whether it may occur intracellularly prior to 
lysate preparation.  L929 cells were pre-treated with actinomycin D (AMD), thereby 
inhibiting DNA-dependent RNA transcription, and then infected with FLAG-PABP 
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VRP under continued AMD treatment.  The AMD treatment prior to infection 
prevented new host RNA synthesis, and as such, new host messages were not 
available for binding with the tagged PABP (as delivered by the VRP).  Importantly, 
AMD does not inhibit alphavirus RNA replication or expression.  When host mRNA 
was isolated from AMD treated cells and analyzed, either a decrease in signal during 
the length of AMD treatment or a complete absence of host mRNA signal in anti-
FLAG immunoprecipitated lysates was observed (data not shown).  Therefore, the 
VRP-supplied tagged-PABP did not reassort with or out-compete endogenous PABP 
bound to mRNA during infection.  These results, along with the data generated from 
other groups, indicated that PABP reassortment was not a major concern. 
  
Analysis of the message population isolated by VRP mRNP-tagging 
The fundamental purpose of applying an mRNP-tagging approach to the 
examination of the host response during viral infection is to be able to discern 
changes in host gene expression that occur directly within the infected cells.  This is 
a distinct advantage over traditional profiling techniques when infected cells are the 
minority in the overall cell population.  However, the mRNP-tagging technique does 
isolate a particular subset of mRNA in the cell, namely those that bind PABP.  
Therefore, we wanted to verify that this method would yield an mRNA population 
representative of host transcription following infection.  To do so, cells were infected 
at a high MOI such that the tagging technique would assess the message profile of 
the same cell population as the more traditional total RNA isolation techniques.   
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L929 cells, a murine fibroblast cell line, were infected with FLAG-PABP VRP 
at an MOI of 5.  At 6, 12, or 24hpi, RNA was harvested using each of the following 
three methods:   1) For traditional isolation of total cellular RNA, a commercially 
available solution of guanidine salts and urea in conjunction with phenol and 
detergent (UltraSpec reagent) was used.  2) To isolate all poly(A) RNA bound to 
PABP in the cell population, an anti-PABP immunoprecipitation assay was 
performed on a separate set of mock and VRP-infected cells.  3) Finally, to isolate 
poly(A) RNA bound to the FLAG-tagged PABP provided by the FLAG-PABP VRP 
infection, an anti-FLAG  immunoprecipitation assay was performed.  RNA isolated 
from all three techniques was used as input RNA in an RNase Protection Assay 
designed to analyze the expression profiles of host genes relevant to this study.  The 
infected cell profile of two such genes, IRF-1 and IFNβ, relative to that in mock 
infected cells is shown in Fig. 2.3, with a comparison of the levels as assayed by the 
three different RNA isolations.  The data shown are representative of two separate 
experiments, and the specific mRNA signal generated from each isolation technique 
was normalized to GAPDH signal.  During a timecourse of 6, 12, and 24h post 
infection at a high MOI, the message profiles of these two relevant host genes were 
similar among the various methods that were used to isolate RNA.  Therefore, the 
mRNP-tagging technique was not limiting in terms of the availability or abundance of 
RNA screened. 
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mRNP-tagging provides a sensitive measure of viral-induced host gene 
expression 
While the robust RNA populations examined using the VRP mRNP-tagging 
system in a high MOI situation are representative of those induced in infected cells, 
the truly advantageous use of the technique is in low MOI situations, where the 
number of infected cells are a small minority (i.e., tissues from VRP-infected 
animals).  Therefore it was important to assess the level of sensitivity that could be 
expected in these low MOI situations.  An in vitro experiment was designed to model 
the in vivo-like condition of a low frequency infected cell population.  At 6hpi, cell 
lysates were prepared from L929 cells that were either mock infected or infected at 
an MOI of 5 with FLAG-PABP VRP.  The cell lysates were mixed in decreasing 
ratios of infected cell lysate to uninfected cell lysate, and the mixed lysate was then 
immunoprecipitated with anti-FLAG antibody, isolating the FLAG-PABP bound 
mRNA.  This mRNA served as template RNA in an RNase Protection Assay, using 
probes specific for several host mRNAs.  The results (Fig. 2.4) for two host mRNAs, 
IRF-1 and GAPDH, demonstrate that the mRNP-tagging system provides a sensitive 
measure of VRP-induced host gene expression, as the signal from FLAG-tagged 
host mRNA immunoprecipitated from the infected cells was detected in samples that 
contained as little as 1% infected cell lysate.  In this particular experiment, the 1% 
value is approximately equal to 2000 infected cell equivalents.  It is worthy to note 
that RPAs do not include an amplification step, and as such the input RNA is directly 
assayed.  Therefore, a higher degree of sensitivity was to be expected in assessing 
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a similarly dilute infected cell population using mRNP-tagging combined with 
methods that include an amplification step, such as real-time PCR.   
An alternate strategy to assess host gene expression changes specifically in 
the infected cell compartment might rely on the sorting of the infected cell population 
from the uninfected cells (e.g., by FACS), followed by the independent analysis of 
the RNA isolated from each population.  To further assess the level of sensitivity, 
VRP-induced changes in host gene expression as assessed by the mRNP-tagging 
method were compared to the host profile derived by a FACS-based method (Fig. 
2.5).  L929 cells (2x106) were infected at a low MOI of 0.2 with VRP expressing 
either GFP (Fig. 2.1) or FLAG-PABP.  At 12hpi, GFP expression was used as the 
basis for FACS-facilitated sorting of the GFP-VRP infected and uninfected cells into 
the two respective populations.  The recovered GFP-positive (infected) cells were 
lysed, and all PABP-bound host messages were subsequently isolated by anti-PABP 
immunoprecipitation and RNA isolation.  In parallel, the mRNP-tagging assay was 
used to sort messages from FLAG-PABP VRP infected L929 cells by lysing the 
entire monolayer, and using anti-FLAG immunoprecipitation to isolate FLAG-tagged 
PABP-bound messages specifically from the infected cells in the monolayer.  To 
compare host mRNA levels in each of the infected cell populations, mock treated 
L929 monolayers also were lysed, and the PABP-bound mRNA isolated by 
immunoprecipitation.   
As shown by real-time PCR analysis (Fig. 2.5), a substantial induction of 
IFNβ, IP-10 and IRF-1 mRNA in the L929 infected cell population over mock treated 
cells was apparent following analysis of both the FACS-based or mRNP-tagging 
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techniques.  Importantly, in comparing the two methods, the degree of sensitivity in 
detecting mRNA from the minority population of infected cells using the tagging 
technique was at least equal to (IFNβ, IRF-1), if not enriched (>5x enrichment in IP-
10) in comparison to those generated by the FACS-based method.  These results 
further validate the mRNP-tagging system as a powerful tool for the analysis of 
changes in host gene expression following viral infection. 
 
Utilizing VRP mRNP-tagging in dendritic cells provides an in vitro system for 
studying early events in VEE pathogenesis.   
A major advantage in using VRP as opposed to VEE virus in the mRNP-
tagging system is the opportunity they provide to study the earliest events in the 
course of VEE pathogenesis, as VRP infect and replicate only within the first round 
of infected cells.  We have previously demonstrated that dendritic cells represent an 
important early target of infection in vivo, as VRP target DCs at the site of inoculation 
following footpad delivery in the mouse model (20), and have likewise been shown 
to efficiently transduce human DCs in vitro (37).  Furthermore, several groups have 
examined DC-tropic properties for other alphaviruses, such as Sindbis virus (38-41) 
and Ross River virus (35).  In light of these previous studies, primary murine bone 
marrow dendritic cells were chosen as an in vitro model system to study early VRP-
induced gene expression patterns.       
To compare the host response profile following traditional total RNA isolation 
of BMDCs versus that generated using the mRNP-tagging system, primary DCs 
isolated from 129sv/ev mice were infected at an MOI of 0.5 with FLAG-PABP VRP.  
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At this MOI, it is estimated that less than 5% of the cells are infected (T.P. Moran 
and R.E. Johnston, personal communication).  At 6hpi, RNA was isolated from mock 
treated and VRP-infected BMDC by either 1) preparing cell lysates for isolation of 
PABP and FLAG-PABP bound mRNAs by immunoprecipitation, or 2) adding 
UltraSpec reagent for isolation of total RNA.  The mRNP-tagging method specifically 
isolated mRNA from the infected cells using the bound FLAG-tagged PABP marker, 
and this population of mRNA was compared to endogenously PABP-bound 
messages in the mock BMDC culture.  In contrast, the traditional RNA isolation 
lacked this discrimination, and therefore total cellular RNA was isolated from the 
entire infected and mock treated BMDC cultures for comparison.   
As shown in Fig. 2.6 (black bars), the gene expression profiles (IFNβ, IP-10, 
IL-6) evaluated specifically from the infected cells of the BMDC culture using the 
mRNP-tagging technique were dramatically enhanced in comparison to profiles 
generated using total RNA isolated from the entire population of infected and 
uninfected DCs.  The fold induction over mock of IFNβ, IP-10 and IL-6 mRNA in the 
infected BMDC cultures were found to be approximately 20 to 200 fold higher than 
that measured by total RNA (comparing the black bars in Fig. 2.6).  It is likely that 
the high proportion of uninfected cells in the low MOI environment masked the signal 
from the minority of infected cells when assayed from the total RNA samples.  
Additionally, it is possible that fundamental differences existing between the infected 
and uninfected cell responses contributed to the observed difference in these gene 
profiles assayed by the two methods.  All three of the evaluated defense response 
genes were induced to high levels in the infected DCs at this early timepoint of 6h 
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post-infection, suggesting that the host innate response is rapidly initiated following 
VRP infection of BMDCs.  Although this rapid response could be detected in the DC 
culture as a whole using the total RNA analysis, the mRNP-tagging method was 
required to reveal the full extent of this early defense response within the infected 
cell population.  
  
In the absence of IFNAR signaling, the defense response in infected BMDCs is 
greatly diminished.   
The contribution of the IFNαβ system in determining the outcome and severity 
of VEE disease has been described for over 30 years (42, 43).  Therefore, in 
seeking to further characterize the initial stages of VEE pathogenesis, the interferon 
response was a primary target for study.  The host response to infection in primary 
BMDC isolated from IFNαβ  receptor knockout (IFNαβR-/-) animals also was 
analyzed in the previous experiment, with the same sample groups isolated and 
analyzed at 6h post-infection as described above.  We hypothesized that in a system 
lacking IFNαβ receptor signaling, the mRNP-tagging method of specifically profiling 
the infected cell response should detect a diminished induction in interferon-
stimulated genes (ISGs), as the positive autocrine feedback signaling within these 
cells should be crippled in the absence of the IFNαβ receptor.  In this manner, the 
IFNαβR-/- BMDC also provided another model system for substantiating the VRP 
mRNP-tagging technique.   
As demonstrated in Fig. 2.6, the ISG response in the infected IFNαβR-/- 
BMDC (stippled bars) as measured by the mRNP-tagging assay was much 
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diminished in comparison to the response in wildtype BMDC (black bars).  The 
induction of IFNβ and IP-10 in the receptor knockout BMDC was diminished by 200-
2000 fold respectively, in comparison to levels of induction in the wildtype BMDCs.  
The IL-6 response also was reduced specifically in the infected cells of the  
IFNαβR-/- BMDC culture as compared to the wildtype IFNαβR+/+ BMDC culture, 
with the induction of IL-6 message measured by the mRNP-tagging assay at only 
background levels in comparison to mock treated IFNαβR-/- BMDC culture.  
Therefore, the host response in the absence of IFNαβ receptor signaling did in fact 
demonstrate a diminished induction of interferon-stimulated genes specifically within 
VRP-infected cells.     
In contrast to the infected cell response, when the same cultures were 
globally assayed for changes in gene expression using total RNA analysis, the loss 
of the IFNαβ receptor in the culture overall appeared to have little effect on 
interferon-stimulated gene induction at this early time post-infection (Fig. 2.6).  As 
compared to mock treated cells, the induction of IP-10 and IL-6 mRNA was similar in 
wildtype and interferon receptor knockout BMDC when measured by total RNA at 
6hpi.  Additionally, IFNβ total RNA message levels were found to be approximately 
five fold higher in the IFNαβR-/- BMDC culture in comparison to the wildtype BMDC 
culture, following VRP infection.  This enhancement may be due in part to IFNαβ 
receptor-independent signaling induced in the uninfected cell majority by cytokines 
and/or dsRNA released into the BMDC culture media following VRP infection.  
However, it is clear from the total RNA profile of the IFNαβR-/- BMDCs, that in this 
low MOI infection, the high background of uninfected cells in the culture masked the 
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dramatic effect of the receptor knockout on host gene expression in the infected cell 
population.  This decreased host response of IFNαβ, IP-10 and IL-6 message in the 
infected IFNαβR-/- cells would have gone undetected had the mRNP-tagging system 
not been utilized. 
 
Comparison of the early host defense response to wildtype and IFN-sensitive 
VEE in vitro.   
As an initial approach, Affymetrix DNA microarray analysis was used to 
globally define changes in the host gene expression profile following VRP infection.  
Null-VRP were utilized for infection in the array analysis because they lack a 
transgene downstream of the 26S subgenomic promoter (Fig. 2.1C), thus eliminating 
any effect on host gene expression that an exogenous gene driven from a replicon 
might otherwise have imposed.  In addition, the host response to null-VRP 
containing a mutation at nucleotide position 3 in the 5’ UTR region was compared to 
wildtype null-VRP.   
Previous studies have described characteristics of the nt3A mutation (18, 28), 
the most prominent being avirulence of this mutant in vivo.  Infection of mice with 
VEE harboring the nt3A point mutation results in 0% mortality, which is in stark 
contrast to the 100% mortality experienced in the mouse model following wildtype 
VEE infection (18).  This attenuation was attributed largely to a heightened 
sensitivity of the mutant to the host interferon response, mediated by a pathway 
other than PKR, RNaseL, and Mx (L.J. White and R.E. Johnston, unpublished), and 
importantly not due to any defect in replication (18).  The array studies presented 
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here included differential analysis of the changes in host gene expression following 
wildtype and nt3A mutant null-VRP for two main purposes:  1) To elucidate potential 
host factors and pathways involved in the increased IFN sensitivity of the nt3A 
mutant, and 2) by analyzing genes similarly and differentially regulated by the two 
infections, to better understand the hallmark effects that virulent VEE induces in host 
cells during the early stages of infection.   
Total RNA was isolated at 5hpi from L929 cells that had been mock treated, 
or infected with either wildtype or nt3A mutant null-VRP (MOI=5).  The samples were 
subsequently analyzed for changes in host gene expression using the Affymetrix 
Mouse Expression 430A GeneChip technology.  Data from two independent array 
experiments were analyzed to determine genes induced or repressed during each 
infection, as compared to mock treated cells.  Only those genes that were modulated 
in both array experiments are reported (Fig. 2.7, Table 2.1, Supplemental Fig. 2.1, 
Supplemental Table 2.1).  At the early time of 5h post-infection, there was an 
abundant host response to infection with either wildtype or nt3A mutant VRP.  
Analysis of messages that were differentially modulated during each infection by >2-
fold over mock treated cells demonstrated a striking population of mRNAs that were 
uniquely affected by the two separate infections (Fig. 2.7).  Of the 125 genes 
reproducibly upregulated by >2-fold following wildtype infection, only 55 of these 
genes were also upregulated following nt3A mutant infection, during which an 
additional 10 distinct genes were induced.  Similarly, of the 332 genes reproducibly 
downregulated by >2-fold by wildtype VRP, only 20 of these genes were also 
downregulated following nt3A mutant infection.  Twelve genes were uniquely 
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repressed by >2-fold by nt3A mutant VRP infection.  When the analysis was 
restricted to the more rigorous parameter of modulation by >4-fold over mock 
expression, unique populations of messages up- or downregulated following each 
infection were again revealed (shown in parentheses, Fig. 2.7), suggesting that 
infection with the nt3A mutant may modulate pathways of the host response that 
differ from those affected by wildtype VRP infection.  It may be important to note 
however, that a large number of genes were modulated, just not in a reproducible 
manner.  This was particularly true of unique as well as shared sets of genes 
downregulated following infection by wildtype and nt3A mutant VRP, supportive of 
the global but perhaps nonspecific shutoff of host transcription that occurs following 
alphavirus infection (15, 44, 45).    
In light of the interferon sensitivity phenotype and in vivo attenuation of the 
nt3A mutant, genes belonging to interferon-related, proinflammatory, and host 
defense response pathways were examined specifically, under a general hypothesis 
that nt3A-containing VRP might induce a more robust response in these pathways.  
However, when the fold induction of messages belonging to these gene categories 
were examined, the levels of expression following nt3A mutant VRP infection were 
found to be at or below levels following wildtype infection (Table 2.1, Supplemental 
Table 2.1).  Two independent array studies were completed, and gene lists were 
compiled representing only those genes that were up- or downregulated by greater 
than 2-fold in both replicate analyses.  The fold induction (over mock) in message 
levels of IFNβ, Oasl1, Isgf3g/IRF-9, ifit1/p56, IP-10, IL-6, and a multitude of other 
ISGs were found to be lower at 5h following infection with nt3A mutant VRP than 
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with wildtype VRP.  The same was true for proinflammatory and host defense 
response mediators, including Rantes, GROα, MIP2α, Socs2, and TLR2.  Therefore, 
although VEE virus harboring the nt3A mutation is up to 100-fold more sensitive than 
wildtype virus to the interferon-induced antiviral state in cultured cells (18), it does 
not appear that this is due to the induction of a more robust interferon-stimulated 
gene response to the mutant early after infection in vitro. 
 
In vivo, the combination of mRNP-tagging and traditional profiling reveals 
dynamic multifactorial interactions in the DLN.   
Previous studies by our group and others have examined the succession of 
events characteristic of VEE pathogenesis in the mouse model.  Following 
inoculation in the footpad, Langerhans-like cells infected at the site of inoculation in 
the footpad subsequently migrate to the popliteal draining lymph node (DLN), which 
is the initial site of viral replication (20).  It has been hypothesized, based on these 
observations, that the early events within the DLN set the stage for the specific 
pattern of virus replication and host response that are hallmarks of VEE 
pathogenesis.  However, many details of the earliest lymphotropic stages of VEE 
infection in vivo remain largely unknown.  Seeking to focus on the early interactions 
of virus and host in the DLN, as well as returning to the system where the most 
compelling data on the nt3A mutation has been described, we extended our 
characterization of the host response to the mouse model.  VRP were again chosen 
as a tool to limit infection to the initially targeted cells, and the mRNP-tagging 
technology was employed to analyze the early host response.  As the infected cell 
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population within the DLN post-footpad inoculation is by far a minority, we 
hypothesized that combining total RNA profiling with the tagging system would 
generate a more comprehensive view of the host response post-infection in vivo.  
Additionally, the comparison of the nt3A mutant profile to that of wildtype VRP in vivo 
rather than in a fibroblast cell line was expected to more accurately elucidate 
mediators contributing to the attenuated nt3A mutant phenotype demonstrated in 
vivo.     
Adult BALB/c mice were inoculated in each rear footpad with 106 IU of either 
wildtype or nt3A mutant FLAG-PABP-VRP.  At 6h and 9hpi, the popliteal DLNs were 
removed, pooled, and either total RNA or RNA specifically from the infected cells 
was isolated by anti-FLAG immunoprecipitation.  cDNA was synthesized from each 
RNA sample, and Taqman real-time PCR was performed to analyze several target 
host genes.  Two independent DLN samples were analyzed from each group, with 
GAPDH serving as the internal housekeeping control gene, and the results were 
averaged.  The expression profiles of four host messages (IFNβ, IP-10, GM-CSF, 
and IL-6) characterized from the DLN post-infection are shown in Fig. 2.8.  Two 
distinct views of the response to infection in the DLN were revealed:  The profile 
generated from the traditional total RNA isolation grants a view of the overall 
response to infection in the DLN as a whole, including both the infected and 
uninfected cell response.  The mRNP-tagging profile of each gene reveals the host 
response to infection specifically within the infected cells of the DLN, granting a view 
of the impact of infection directly within the infected cells of the DLN.   
 87 
First, examining the response to infection over time within the infected cells, 
an early robust expression of IFNβ, IP-10 and GM-CSF was exhibited in the anti-
FLAG isolated RNA at 6hpi, which waned by 9hpi.  This suggests a very rapid 
response to VRP infection within infected cells of the DLN.  While the response was 
waning between 6 and 9hpi within the infected cells, the total RNA profile of the DLN 
demonstrated that the response in the organ as a whole was increasing during this 
time interval.  By 9hpi, the majority of the IFNβ, IP-10, and GM-CSF host response 
appears to have shifted to the surrounding uninfected cells of the DLN.  This is likely 
due to a robust activation of the innate immune response directly within the infected 
cells, initiated by  binding, entry, and replication of the VRP, which then induces 
mediators (e.g., cytokines) that are released into the surrounding environment of the 
DLN and activate a paracrine response in neighboring uninfected cells.  This 
detailed view of events occurring at early times post-infection has been difficult, if not 
impossible, to examine previously, and suggests a much more intricate induction of 
innate responses than that apparent from total RNA analysis.   
The IL-6 host response presents an interesting scenario, as there was a 
complete lack of signal detected at 6hpi in the infected cells of the DLN as measured 
by the mRNP-tagging system (Fig. 2.8, asterisk).  However there was a robust IL-6 
response measured at 6hpi from the total RNA isolated from the entire DLN.  This 
suggests that the infected cells of the DLN are not the main producers of IL-6 initially 
following VRP infection.  Instead, the uninfected bystander cells may be particularly 
poised to respond to paracrine signals from infected neighboring cells, resulting in 
IL-6 expression.  By 9hpi, IL-6 expression was detected in both the infected cell 
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population as well as in the DLN as a whole, indicating a continuation of the dynamic 
interplay between the infected and uninfected cells in this environment.  This two 
phase innate response would have otherwise gone undetected had the mRNP-
tagging technique not been integrated with the traditional profiling. 
Assessing the host defense response in vivo to wildtype versus nt3A mutant 
VRP infection (Fig. 2.8, black versus grey bars), this integrative approach continued 
to offer two distinct views of the innate response.  Looking globally within the DLN as 
a whole, the IFNβ, IP-10, GM-CSF and IL-6 responses were similar at 6h and 9h 
following wildtype and nt3A mutant VRP infection.  However, evaluation of the 
infected cells of the DLN by the mRNP-tagging method demonstrated a less robust 
host response following nt3A mutant VRP in comparison to wildtype infection.  The 
results generated in vivo, specifically from the infected cells of the DLN, mirrored the 
results from the in vitro Affymetrix GeneChip experiment, in which a high MOI was 
used to ensure infection of nearly 100% of cultured cells.  As was also described in 
vitro, it does not appear that the interferon sensitivity of the attenuated nt3A mutant 
can be attributed to a more robust induction of the innate host defense response in 
vivo, at least not within 6-9h in the DLN.  Here, the mRNP-tagging technique allowed 
the specific profiling of infected cells in the naturally low MOI environment in vivo.  
Altogether, this integrative approach allowed a uniquely multifaceted examination of 
the VRP-infected host.  The total RNA profiling and mRNP-tagging approaches are 
together far more informative than either alone. 
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DISCUSSION 
Here we have introduced an innovative approach for assessing gene 
expression changes following viral infection in vitro and in vivo, addressing a critical 
parameter that has been difficult, if not impossible, to address previously.  By 
distinguishing changes in the host transcriptional program of infected cells from that 
of uninfected bystander cells, the mRNP-tagging technology provides an important 
advancement in gene expression profiling, and promises to increase our 
understanding of the host response to virus infection, particularly in vivo.    
Characterization of the VRP mRNP-tagging approach has demonstrated 
several key aspects of the system.  First and foremost is the ability of the system to 
effectively target and isolate mRNA from the infected cell population.  In high MOI 
cell culture experiments, where all cells are infected, the gene expression profiles 
generated from total RNA and RNA isolated by mRNP-tagging were similar.  
Additionally, in low MOI cell culture experiments, where only a minority of cells are 
infected, the RNA profiles generated from the infected cell population isolated by 
FACS were similar to the gene expression profiles isolated by the mRNP-tagging 
technique without prior cell sorting.  These results demonstrate that mRNP-tagging 
yields profiles that are representative of infected cells, even when they are the 
minority cell population.    
An equally important aspect of the mRNP-tagging system is that the method 
is sensitive.     In mixing experiments, where the infected cell signal was diluted with 
mock lysate, the mRNP-tagging approach detected a unique transcriptional profile 
when as few as 1% of the cultured cells were infected.  Moreover, the sensitivity of 
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directly isolating infected cell mRNA via the mRNP-tagging approach proved to be 
as great, or even enhanced in comparison to analysis of message levels when 
isolated from infected cells following a commonly utilized FACS-based approach.  
This ability to effectively analyze a small minority of infected cells, such that the 
mRNA signal from infected cells is no longer masked by the background of 
uninfected cells, is a property well suited for application in vivo.  Additionally, the 
VRP mRNP-tagging technique allows this level of specificity without harsh treatment 
of the infected cell populations prior to RNA isolation.  This is in contrast to FACS 
analysis, which commonly requires physical manipulation of cultured cells or tissues 
(e.g., trypsinization, collagenase digestion), and may result in cellular damage to 
delicate cell types analyzed post-infection, such as the shearing of fragile dendrites 
from the cell body of DCs.  This physical manipulation may affect the host gene 
expression profile of cells, similar to the profound effects various isolation techniques 
can have on the maturation and function of DCs (46).  However, since the VRP 
mRNP-tagging system isolates mRNA from infected cells following lysis directly in 
the culture vessel or from intact tissue, the cells are not distressed prior to message 
isolation and may more accurately reflect the host transcriptional program at the time 
of isolation.  Furthermore, given the well-established roles for PABP in translation 
initiation and mRNA stability (5, 7, 8, 47), PABP-associated mRNA may actually be 
more representative of the cell’s actively translated message population or the 
proteome.  Therefore, the VRP mRNP-tagging system may provide a more accurate 
view of the biological state of the cell post-infection (1, 13).  
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Application of the mRNP-tagging method has revealed several important 
insights into the host innate response to virus infection.  First, the host response is 
dramatically different in infected and uninfected cells within the same in vitro cell 
culture or the same tissue in vivo, varying in quantitative, qualitative and temporal 
terms.  Quantitatively, the level of response in each population varied by gene, 
indicating that the transcriptional programs of infected and uninfected cells within the 
same culture or tissue are uniquely affected.  On a gene by gene basis, comparing 
the infected cell profile generated by the mRNP-tagging system to the total RNA 
profile generated from the entire culture or tissue allows the relative contribution of 
the infected versus uninfected cell populations to be teased apart.  In the case 
where a small percentage of primary BMDC were infected in vitro, the induction of 
IFNβ, IP-10 and IL-6 in infected cells as measured by the mRNP-tagging system 
was up to 200 times that indicated in the total RNA sample for the entire culture.  
Similarly, at 6h in the DLN following infection in vivo, induction of GM-CSF mRNA in 
the infected cell population was nearly 80 times that in the total RNA sample from 
the entire lymph node.  These results suggest that the infected cells are the primary 
source of the IL-6 and GM-CSF response to VRP infection at 6h in BMDC cultures 
and the DLN, respectively.   
In the above instance, had the mRNP-tagging system not been utilized, the 
induction of both of these genes would likely have been overlooked due to the low 
total RNA induction measured from the culture as a whole.  Therefore, at particular 
times the level of response in the infected and uninfected cell populations can differ 
so extensively that their analysis becomes qualitatively different.  In other words, a 
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response that is robust in one population may be completely absent in the other, and 
in this regard, the host response will appear to be quite different when evaluating 
infected cells alone rather than the entire culture or tissue.   
Temporally, the combination of the mRNP-tagging approach and total RNA 
analysis offered a unique vantage point into the kinetics of the infected and 
uninfected cell responses.  In the DLN, this analysis demonstrated two phases of the 
innate host response.  The first apparent phase was a rapid response in the infected 
cells of the DLN, including the robust activation of several host defense genes (IFNβ, 
IP-10, and GM-CSF) at 6h following footpad inoculation.  While this infected cell 
response was waning by 9h post-infection, an apparent second phase of response 
was mounting in the surrounding uninfected cells of the DLN, with induction of the 
same defense genes increasing from 6h to 9h post-infection.  In fact, a similar rapid 
onset of the host innate response has been described previously following virulent 
VEE infection, with cytokine RNA levels in the DLN of infected mice peaking at 6-
12h following footpad inoculation, and waning by 24-48h (48).  However, the use of 
VRP and the application of the mRNP-tagging system in our study provided the 
ability to distinguish the events specifically occurring within the first round of infected 
cells in vivo from the effects on the uninfected bystander cells of the DLN, revealing 
the unique kinetic response to infection occurring in each population.   
   Several signaling events are likely to contribute to the kinetics of this two 
phase activation, highlighting another important insight gained using this system.   In 
the heterologous environment that exists following infection in vivo, autocrine and 
paracrine mediators are induced in the first infected cells that drive the host 
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transcription profile of infected and uninfected cells, respectively.  Replicon particle 
binding, entry, and replication provide a multitude of signals to initiate the early host 
defense response directly within the infected cells.  It is likely that the rapid innate 
activation of the infected cell population leads to the secretion of cytokines and other 
soluble immune modulators.  A portion of these mediators then initiate the cell 
signaling events in uninfected bystander cells that are responsible for the strong 
response in the DLN at later times post-infection.  This would undoubtedly include 
the activation of cells which have homed to the DLN as an active site of viral 
infection.  In fact, a large influx of cells to the DLN has been observed following 
footpad VRP inoculation, resulting in a visible increase in node size, and includes 
cells of the proinflammatory response as well as antigen presenting cells (e.g., T-
cells, B-cells, and DCs) (J.M. Thompson, A.C. Whitmore, J.L. Konopka, T.P. Moran 
and R.E. Johnston, unpublished data).  These recruited cells would remain 
uninfected, but would be susceptible to the primed environment of the DLN, and 
likely contribute to the induction of the second phase of the host innate response in 
the uninfected cells of the DLN.   
Our results highlight the role of the innate immune response during VEE 
infection, particularly the interferon response.  Evidence for the interferon system as 
a major factor in controlling VEE replication and spread in vivo has been well 
established (18, 19, 23, 35, 42, 43, 49-51).  Infection with VEE results in tremendous 
levels of soluble, biologically active interferon in the serum, measured at up to 
80,000 IU/ml following virulent wildtype VEE infection (18).  In the absence of 
interferon signaling in vivo, a significantly shorter average survival time has been 
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documented following VEE infection in mice lacking the IFNαβ receptor (30h) in 
comparison to wildtype mice (7.7 days), with a 10,000-fold increase in virus titers 
(18).  When signaling through the IFNαβ receptor was specifically investigated in 
BMDC, the role of the interferon response in autocrine and paracrine signaling of 
infected and uninfected cells was further elucidated.  While ablating the IFNαβ 
receptor had no apparent effect on the total RNA induction of IFNβ, IP-10, and IL-6 
genes in the BMDC culture as a whole, a dramatically reduced induction of each of 
these host response genes was observed in the infected BMDC population by 
mRNP-tagging analysis.  This strongly suggests that autocrine signaling through the 
IFNαβ receptor plays a critical role in the high level of interferon stimulated gene 
induction seen in the infected cell population.  Conversely, the induction of these 
host response genes apparently was not reduced in the majority uninfected cell 
population.  This suggests that interferon-mediated signaling through the IFNαβ 
receptor is not the primary paracrine mediator leading to the induction of these 
particular host response genes in uninfected bystander cells.  This is consistent with 
previous findings that levels of serum IFNαβ are not reduced at early times after 
VRP infection of IFNαβR-/- mice compared to wildtype controls (18). 
Taken together, the data presented here highlight an important additional 
observation.   Namely, reductionist in vitro approaches do not always recapitulate 
what is occurring in vivo.  Often, high multiplicity infections of largely homogenous 
culture cells are utilized in vitro to draw conclusions about what occurs in naturally 
low multiplicity infections of complex heterogeneous tissues in vivo.  However, the 
data presented here strongly argue that the naturally heterogeneous environment of 
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infected and uninfected cells existing during infection in vivo must be appreciated in 
order to understand the dynamic interactions occurring between these populations.  
For example, in cultured BMDC, IL-6 was highly induced in VRP infected cells at 6h 
post-infection.  However, this did not appear to be the case in vivo where induction 
of IL-6 mRNA was first documented in the uninfected bystander population.  Using a 
combination of high and low multiplicities of infection, and contrasting how the 
infected cell responds with and without neighboring bystander cells will likely 
facilitate a better understanding of what cell-cell interactions or signaling events 
regulate the innate response to VEE pathogenesis.  
Finally, large differences in the host responses to wildtype and mutant VRP 
infection were revealed in this study.  A single non-coding substitution of G-to-A in 
the third nucleotide of the VEE 5’ UTR results in a mutant virus that is up to 100-fold 
more sensitive to the interferon-induced antiviral state, rendering this nt3A mutant 
virus completely avirulent in mice (18).  It has been hypothesized that these 
properties of the nt3A virus may increase the induction and/or activation of IFNαβ-
related antiviral effectors early in infection.  In fact, both wildtype and nt3A mutant 
VRP infection mounted a substantial early host response, and unique subsets of 
host genes were induced and repressed following each infection.  Surprisingly, the 
induction of interferon, proinflammatory, and host defense response genes were 
actually reduced following nt3A mutant VRP infection in comparison to infection with 
wildtype VRP.  This was demonstrated following high multiplicity infection of cultured 
cells, as well as in the DLN following infection in vivo.  Importantly, the mRNP-
 96 
tagging technique was required to detect this differential induction in vivo in the 
minority of infected cells.   
These results strongly suggest that the documented attenuation of the nt3A 
mutant is not a function of a more robust induction of antiviral effectors at this early 
time in infection.  However, it does not prove that other IFN-mediated host factors 
not yet included in our analyses are involved.  Other aspects of infection that have 
been explored (e.g., replication kinetics, host translation shutoff, induction of 
apoptosis) have not identified a clear attenuating mechanism for the nt3A mutant 
[J.L. Konopka and L.J. White, unpublished].  However, a recent study examining the 
response to Sindbis virus infection in systems triply deficient in PKR, RNaseL, and 
Mx identified several candidate interferon-stimulated genes as important antiviral 
mediators within this alternative pathway (41).  A more extensive kinetic examination 
of the induction of antiviral effectors following nt3A mutant VEE infection, including 
these new candidate gene families, may be required, as well as further studies into 
the subsequent activation of such molecules.  
The VRP mRNP-tagging system suggests a multitude of future studies that 
promise unique perspective on the highly coordinated host response to viral 
infection.  A critical future application of the VRP mRNP-tagging system is the 
analysis of the host response to infection within the brain, where the most extensive 
pathogenesis is observed following VEE virus infection.  Alphavirus CNS 
pathogenesis has been studied extensively in several model systems.  Much of the 
pathology associated with alphavirus induced disease in the CNS is a direct result of 
the host’s own immune response to the infection.  However, unique to VEE, 
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extensive pathology within the CNS is observed even in the absence of the adaptive 
immune response (52), suggesting that multiple parameters contribute to VEE-
induced disease in the brain.  In addition, although there is strong evidence of 
apoptosis occurring in the brain of VEE-infected animals (53, 54), the relative 
contribution of death induced directly in infected versus bystander neurons remains 
to be fully addressed—a distinction shown to be critical following infection with 
neuroadapted Sindbis virus (55, 56).  The use of the mRNP-tagging system in the 
context of such studies may facilitate a deeper understanding of VEE-induced 
neurodegeneration. 
Additional future studies may include the application of the mRNP-tagging 
system in the context of VEE virus infection.  Recombinant viral constructs encoding 
double 26S subgenomic promoters have been utilized previously, allowing the 
expression of the viral structural genes as well as a marker gene of interest (20).  
Therefore, it is feasible to utilize mRNP-tagging in the context of a propagating VEE 
infection, in which a double promoter virus expresses the FLAG-PABP marker from 
a second subgenomic promoter.  This would facilitate the characterization of the 
host response to VEE infection downstream of the DLN, including the impacts of 
virus budding as well as cell-to-cell spread during infection.      
This VRP mRNP-tagging system could also be developed using RNA-binding 
proteins other than PABP, and may identify subsets of functionally related mRNAs 
representing post-transcriptional RNA-operons in infected cells (1).  For instance, 
utilizing proteins like HuR that activate mRNAs encoding immediate early gene 
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transcripts, such as cytokines and chemokines, would be of particular interest in the 
development of future mRNP-tagging systems (57). 
The application of mRNP-tagging technology to the study of the host 
response to viral infection opens avenues of investigation that have previously been 
difficult to navigate.  A better understanding of virus-host interactions may 
subsequently facilitate the design of improved therapeutics and vaccines.  More 
specifically, gaining a clear profile of the host response to VEE infection promises to 
further our understanding of the specific virus-host interactions that define alphavirus 
pathogenesis in vivo.   
 
ACKNOWLEDGMENTS 
 
We thank Nancy Davis and Clayton Beard for critical reading of the manuscript, and 
the entire Carolina Vaccine Institute for stimulating discussions.  This work was 
supported by the National Institutes of Health (NIH) Public Health Service Grant 
R01-AI51990 (to R.E.J.), and the NIH Predoctoral Training Grant T32-AI07419.   
 
 
 
 
 
 
 
 
 99 
REFERENCES 
1. Tenenbaum, S. A., C. C. Carson, P. J. Lager, and J. D. Keene. 2000. 
Identifying mRNA subsets in messenger ribonucleoprotein complexes by 
using cDNA arrays. Proceedings of the National Academy of Sciences 
97:14085-14090. 
 
2. Tenenbaum, S. A., P. J. Lager, C. C. Carson, and J. D. Keene. 2002. 
Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies 
to RNA-binding proteins and genomic arrays. Methods 26:191-198. 
 
3. Deo, R. C., J. B. Bonanno, N. Sonenberg, and S. K. Burley. 1999. 
Recognition of Polyadenylate RNA by the Poly(A)-Binding Protein. Cell 
98:835-845. 
 
4. Bernstein, P., and J. Ross. 1989. Poly(A), poly(A) binding protein and the 
regulation of mRNA stability. Trends in Biochemical Sciences 14:373-377. 
 
5. Burd, C. G., and G. Dreyfuss. 1994. Conserved structures and diversity of 
functions of RNA-binding proteins. Science 265:615-621. 
 
6. Gorlach, M., C. G. Burd, and G. Dreyfuss. 1994. The mRNA Poly(A)-Binding 
Protein: Localization, Abundance, and RNA-Binding Specificity. Experimental 
Cell Research 211:400-407. 
 
7. Sonenberg, N., and T. E. Dever. 2003. Eukaryotic translation initiation factors 
and regulators. Current Opinion in Structural Biology 13:56-63. 
 
8. Imataka, H., A. Gradi, and N. Sonenberg. 1998. A newly identified N-terminal 
amino acid sequence of human eIF4G binds poly(A)-binding protein and 
functions in poly(A)-dependent translation. Embo J 17:7480-7489. 
 
9. Penalva, L. O., S. A. Tenenbaum, and J. D. Keene. 2004. Gene expression 
analysis of messenger RNP complexes. Methods Mol Biol 257:125-134. 
 
10. Roy, P. J., J. M. Stuart, J. Lund, and S. K. Kim. 2002. Chromosomal 
clustering of muscle-expressed genes in Caenorhabditis elegans. Nature 
418:975-979. 
 
11. Kunitomo, H., H. Uesugi, Y. Kohara, and Y. Iino. 2005. Identification of 
ciliated sensory neuron-expressed genes in Caenorhabditis elegans using 
targeted pull-down of poly(A) tails. Genome Biology 6:R17. 
 
12. Pauli, F., Y. Liu, Y. A. Kim, P.-J. Chen, and S. K. Kim. 2006. Chromosomal 
clustering and GATA transcriptional regulation of intestine-expressed genes 
in C. elegans. Development 133:287-295. 
 100 
13. Yang, Z., H. J. Edenberg, and R. L. Davis. 2005. Isolation of mRNA from 
specific tissues of Drosophila by mRNA tagging. Nucl. Acids Res. 33:e148-. 
 
14. Penalva, L., M. Burdick, S. Lin, H. Sutterluety, and J. Keene. 2004. RNA-
binding proteins to assess gene expression states of co-cultivated cells in 
response to tumor cells. Molecular Cancer 3:24. 
 
15. Griffin, D. E. 2001. Alphaviruses. In Fields virology, 4th ed. D. M. Knipe, B. N. 
Fields, and P. M. Howley, eds. Lippincott Williams & Wilkins, Philadelphia, 
Pa. . 917-962. 
 
16. Anishchenko, M., R. A. Bowen, S. Paessler, L. Austgen, I. P. Greene, and S. 
C. Weaver. 2006. Venezuelan encephalitis emergence mediated by a 
phylogenetically predicted viral mutation. PNAS 103:4994-4999. 
 
17. Greene, I. P., S. Paessler, L. Austgen, M. Anishchenko, A. C. Brault, R. A. 
Bowen, and S. C. Weaver. 2005. Envelope Glycoprotein Mutations Mediate 
Equine Amplification and Virulence of Epizootic Venezuelan Equine 
Encephalitis Virus. J. Virol. 79:9128-9133. 
 
18. White, L. J., J. g. Wang, N. L. Davis, and R. E. Johnston. 2001. Role of 
Alpha/Beta Interferon in Venezuelan Equine Encephalitis Virus Pathogenesis: 
Effect of an Attenuating Mutation in the 5' Untranslated Region. The Journal 
of Virology 75:3706. 
 
19. Powers, A. M., A. C. Brault, R. M. Kinney, and S. C. Weaver. 2000. The Use 
of Chimeric Venezuelan Equine Encephalitis Viruses as an Approach for the 
Molecular Identification of Natural Virulence Determinants. The Journal of 
Virology 74:4258-4263. 
 
20. MacDonald, G. H., and R. E. Johnston. 2000. Role of Dendritic Cell Targeting 
in Venezuelan Equine Encephalitis Virus Pathogenesis. The Journal of 
Virology 74:914-922. 
 
21. Bernard, K. A., W. B. Klimstra, and R. E. Johnston. 2000. Mutations in the E2 
Glycoprotein of Venezuelan Equine Encephalitis Virus Confer Heparan 
Sulfate Interaction, Low Morbidity, and Rapid Clearance from Blood of Mice. 
Virology 276:93-103. 
 
22. Aronson, J. F., F. B. Grieder, N. L. Davis, P. C. Charles, T. Knott, K. Brown, 
and R. E. Johnston. 2000. A Single-Site Mutant and Revertants Arising in 
Vivo Define Early Steps in the Pathogenesis of Venezuelan Equine 
Encephalitis Virus. Virology 270:111-123. 
 
23. Spotts, D. R., R. M. Reich, M. A. Kalkhan, R. M. Kinney, and J. T. Roehrig. 
1998. Resistance to Alpha/Beta Interferons Correlates with the Epizootic and 
 101 
Virulence Potential of Venezuelan Equine Encephalitis Viruses and Is 
Determined by the 5' Noncoding Region and Glycoproteins. The Journal of 
Virology 72:10286-10291. 
 
24. Grieder, F. B., and H. T. Nguyen. 1996. Virulent and attenuated mutant 
Venezuelan equine encephalitis virus show marked differences in replication 
in infection in murine macrophages. Microbial Pathogenesis 21:85-95. 
 
25. Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. 
Suzuki, and R. E. Johnston. 1995. Specific Restrictions in the Progression of 
Venezuelan Equine Encephalitis Virus-Induced Disease Resulting from Single 
Amino Acid Changes in the Glycoproteins. Virology 206:994-1006. 
 
26. Davis, N. L., K. W. Brown, G. F. Greenwald, A. J. Zajac, V. L. Zacny, J. F. 
Smith, and R. E. Johnston. 1995. Attenuated Mutants of Venezuelan Equine 
Encephalitis Virus Containing Lethal Mutations in the PE2 Cleavage Signal 
Combined with a Second-Site Suppressor Mutation in E1. Virology 212:102-
110. 
 
27. Davis, N. L., F. B. Grieder, J. F. Smith, G. F. Greenwald, M. L. Valenski, D. C. 
Sellon, P. C. Charles, and R. E. Johnston. 1994. A molecular genetic 
approach to the study of Venezuelan equine encephalitis virus pathogenesis. 
Arch Virol Suppl 9:99-109. 
 
28. Kinney, R. M., G. J. Chang, K. R. Tsuchiya, J. M. Sneider, J. T. Roehrig, T. 
M. Woodward, and D. W. Trent. 1993. Attenuation of Venezuelan equine 
encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the 
E2 envelope glycoprotein. The Journal of Virology 67:1269-1277. 
 
29. Davis, N. L., N. Powell, G. F. Greenwald, L. V. Willis, B. J. Johnson, J. F. 
Smith, and R. E. Johnston. 1991. Attenuating mutations in the E2 
glycoprotein gene of Venezuelan equine encephalitis virus: construction of 
single and multiple mutants in a full-length cDNA clone. Virology 183:20-31. 
 
30. Johnston, R. E., and J. F. Smith. 1988. Selection for accelerated penetration 
in cell culture coselects for attenuated mutants of Venezuelan equine 
encephalitis virus. Virology 162:437-443. 
 
31. Johnson, B. J., R. M. Kinney, C. L. Kost, and D. W. Trent. 1986. Molecular 
determinants of alphavirus neurovirulence: nucleotide and deduced protein 
sequence changes during attenuation of Venezuelan equine encephalitis 
virus. J Gen Virol 67 ( Pt 9):1951-1960. 
 
32. Wang, E., A. C. Brault, A. M. Powers, W. Kang, and S. C. Weaver. 2003. 
Glycosaminoglycan Binding Properties of Natural Venezuelan Equine 
Encephalitis Virus Isolates. J. Virol. 77:1204-1210. 
 102 
33. Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. 
Smith. 1997. Replicon-Helper Systems from Attenuated Venezuelan Equine 
Encephalitis Virus: Expression of Heterologous Genes in Vitro and 
Immunization against Heterologous Pathogens in Vivo. Virology 239:389-401. 
 
34. Thompson, J. M., A. C. Whitmore, J. L. Konopka, M. L. Collier, E. M. B. 
Richmond, N. L. Davis, H. F. Staats, and R. E. Johnston. 2006. Mucosal and 
systemic adjuvant activity of alphavirus replicon particles. PNAS 103:3722-
3727. 
 
35. Shabman, R. S., T. E. Morrison, C. Moore, L. White, M. S. Suthar, L. 
Hueston, N. Rulli, B. Lidbury, J. P. Y. Ting, S. Mahalingam, and M. T. Heise. 
2007. Differential Induction of Type I Interferon Responses in Myeloid 
Dendritic Cells by Mosquito and Mammalian-Cell-Derived Alphaviruses. J. 
Virol. 81:237-247. 
 
36. Serody, J. S., E. J. Collins, R. M. Tisch, J. J. Kuhns, and J. A. Frelinger. 2000. 
T Cell Activity After Dendritic Cell Vaccination Is Dependent on Both the Type 
of Antigen and the Mode of Delivery. J Immunol 164:4961-4967. 
 
37. Moran, T. P., M. Collier, K. P. McKinnon, N. L. Davis, R. E. Johnston, and J. 
S. Serody. 2005. A Novel Viral System for Generating Antigen-Specific T 
Cells. J Immunol 175:3431-3438. 
 
38. Gardner, J. P., I. Frolov, S. Perri, Y. Ji, M. L. MacKichan, J. zur Megede, M. 
Chen, B. A. Belli, D. A. Driver, S. Sherrill, C. E. Greer, G. R. Otten, S. W. 
Barnett, M. A. Liu, T. W. Dubensky, and J. M. Polo. 2000. Infection of Human 
Dendritic Cells by a Sindbis Virus Replicon Vector Is Determined by a Single 
Amino Acid Substitution in the E2 Glycoprotein. J. Virol. 74:11849-11857. 
 
39. Ryman, K. D., W. B. Klimstra, K. B. Nguyen, C. A. Biron, and R. E. Johnston. 
2000. Alpha/Beta Interferon Protects Adult Mice from Fatal Sindbis Virus 
Infection and Is an Important Determinant of Cell and Tissue Tropism. J. Virol. 
74:3366-3378. 
 
40. Klimstra, W. B., E. M. Nangle, M. S. Smith, A. D. Yurochko, and K. D. Ryman. 
2003. DC-SIGN and L-SIGN Can Act as Attachment Receptors for 
Alphaviruses and Distinguish between Mosquito Cell- and Mammalian Cell-
Derived Viruses. J. Virol. 77:12022-12032. 
 
41. Ryman, K. D., K. C. Meier, E. M. Nangle, S. L. Ragsdale, N. L. Korneeva, R. 
E. Rhoads, M. R. MacDonald, and W. B. Klimstra. 2005. Sindbis Virus 
Translation Is Inhibited by a PKR/RNase L-Independent Effector Induced by 
Alpha/Beta Interferon Priming of Dendritic Cells. The Journal of Virology 
79:1487-1499. 
 103 
42. Jordan, G. W. 1973. Interferon sensitivity of Venezuelan equine 
encephalomyelitis virus. Infect Immun 7:911-917. 
 
43. Jahrling, P. B., E. Navarro, and W. F. Scherer. 1976. Interferon induction and 
sensitivity as correlates to virulence of Venezuelan encephalitis viruses for 
hamsters. Arch Virol 51:23-35. 
 
44. Gorchakov, R., E. Frolova, and I. Frolov. 2005. Inhibition of Transcription and 
Translation in Sindbis Virus-Infected Cells. J. Virol. 79:9397-9409. 
 
45. Garmashova, N., R. Gorchakov, E. Volkova, S. Paessler, E. Frolova, and I. 
Frolov. 2007. The Old World and New World Alphaviruses Use Different 
Virus-Specific Proteins for Induction of Transcriptional Shutoff. J. Virol. 
81:2472-2484. 
 
46. Swanson, K. A., Y. Zheng, K. M. Heidler, Z.-D. Zhang, T. J. Webb, and D. S. 
Wilkes. 2004. Flt3-Ligand, IL-4, GM-CSF, and Adherence-Mediated Isolation 
of Murine Lung Dendritic Cells: Assessment of Isolation Technique on 
Phenotype and Function. J Immunol 173:4875-4881. 
 
47. Mangus, D., M. Evans, and A. Jacobson. 2003. Poly(A)-binding proteins: 
multifunctional scaffolds for the post-transcriptional control of gene 
expression. Genome Biology 4:223. 
 
48. Grieder, F. B., B. K. Davis, X. D. Zhou, S. J. Chen, F. D. Finkelman, and W. 
C. Gause. 1997. Kinetics of Cytokine Expression and Regulation of Host 
Protection Following Infection with Molecularly Cloned Venezuelan Equine 
Encephalitis Virus. Virology 233:302-312. 
 
49. Anishchenko, M., S. Paessler, I. P. Greene, P. V. Aguilar, A.-S. Carrara, and 
S. C. Weaver. 2004. Generation and Characterization of Closely Related 
Epizootic and Enzootic Infectious cDNA Clones for Studying Interferon 
Sensitivity and Emergence Mechanisms of Venezuelan Equine Encephalitis 
Virus. J. Virol. 78:1-8. 
 
50. Schoneboom, B. A., J. S. Lee, and F. B. Grieder. 2000. Early Expression of 
IFN-alpha/beta and iNOS in the Brains of Venezuelan Equine Encephalitis 
Virus-Infected Mice. Journal of Interferon & Cytokine Research 20:205-216. 
 
51. Grieder, F. B., and S. N. Vogel. 1999. Role of Interferon and Interferon 
Regulatory Factors in Early Protection against Venezuelan Equine 
Encephalitis Virus Infection. Virology 257:106-118. 
 
52. Charles, P. C., J. Trgovcich, N. L. Davis, and R. E. Johnston. 2001. 
Immunopathogenesis and Immune Modulation of Venezuelan Equine 
Encephalitis Virus-Induced Disease in the Mouse. Virology 284:190-202. 
 104 
53. Schoneboom, B. A., K. M. K. Catlin, A. M. Marty, and F. B. Grieder. 2000. 
Inflammation is a component of neurodegeneration in response to 
Venezuelan equine encephalitis virus infection in mice. Journal of 
Neuroimmunology 109:132-146. 
 
54. Jackson, A. C., and P. R. John. 1997. Apoptotic cell death is an important 
cause of neuronal injury in experimental Venezuelan equine encephalitis virus 
infection of mice. Acta Neuropathologica V93:349-353. 
 
55. Darman, J., S. Backovic, S. Dike, N. J. Maragakis, C. Krishnan, J. D. 
Rothstein, D. N. Irani, and D. A. Kerr. 2004. Viral-Induced Spinal Motor 
Neuron Death Is Non-Cell-Autonomous and Involves Glutamate 
Excitotoxicity. J. Neurosci. 24:7566-7575. 
 
56. Carmen, J., Genevieve Gowing Jean-Pierre Julien Douglas Kerr. 2006. 
Altered immune response to CNS viral infection in mice with a conditional 
knock-down of macrophage-lineage cells. Glia 54:71-80. 
 
57. Keene, J. D., and S. A. Tenenbaum. 2002. Eukaryotic mRNPs may represent 
posttranscriptional operons. Mol.Cell 9:1161-1167. 
 
 
 105 
 
 
 
Figure 2.1. VEE replicon constructs.  The VEE replicon genome encodes the viral 
nonstructural genes, the authentic 5’ and 3’ UTR, as well as a cloning cassette 
downstream of the 26S subgenomic promoter for transgene insertion. Schematic 
representation of the replicon constructs used in this study are shown above:  (A) 
FLAG-PABP VRP, expressing an N-terminally FLAG-tagged version of PABP (FLAG 
epitope denoted by checkered shading); (B) GFP-VRP, expressing green 
fluorescent protein; and (C) Null-VRP, encoding the replicon genome devoid of 
functional transgene sequence.  Additional FLAG-PABP VRP and null-VRP genome 
constructs containing a change from wildtype ntG at position three to ntA were also 
utilized (position within the 5’UTR denoted by the small arrow).  All replicon particles 
used in this study were packaged in the wildtype (V3000) envelope.  
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Figure 2.2. The VRP mRNP-tagging system.  Flowchart illustrating the VRP 
ribonomics mRNA-tagging method of isolating mRNA specifically from infected cells.  
(A)  Cells are infected with FLAG-PABP VRP, delivering the unique epitope-tagged 
version of PABP only to infected cells.  (B) At various times post-infection, 
cytoplasmic lysates are prepared, containing the cellular mRNP complexes.  (C) 
Anti-FLAG antibody-coated agarose beads are added in excess to the lysate, 
coimmunoprecipitating the mRNA bound by FLAG-PABP, and thus fractionating the 
mRNA in the infected cells from the mRNA in the surrounding uninfected cells.  (D) 
The immunoprecipitated mRNA-PABP complex is dissociated using proteinase K 
digestion, and the infected cell mRNA is isolated by standard RNA extraction and 
precipitation.  
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Figure 2.3. RNA profile comparison following high MOI infection.  Changes in 
host gene expression were assessed following VRP infection, using RNA isolated by 
three distinct methods.  106 L929 cells were mock treated or infected with FLAG-
PABP VRP (MOI=5).  At 6, 12, or 24h, cellular RNA was harvested by three 
separate methods:  (i) Total RNA from mock and VRP-infected cells was isolated 
using UltraSpec reagent.  (ii) All mRNA bound to PABP in lysates prepared from 
mock and VRP-infected cultures were isolated by anti-PABP immunoprecipitation.  
(iii) mRNA from infected cells was specifically isolated by anti-FLAG 
immunoprecipitation, recovering the mRNA bound to the FLAG-PABP in VRP-
infected lysates.  The isolated RNA populations served as input RNA in an RNase 
protection assay to analyze the expression profile of several host genes.  The fold 
induction of (A) IRF-1 and (B) IFNβ, relative to expression in mock treated cells, are 
shown above comparing the profiles generated from the distinct RNA isolations.  
The data are a representative of two separate experiments, with the signal 
generated from each sample internally normalized to GAPDH signal.   
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Figure 2.4. Sensitivity of the VRP mRNP-tagging system.  To assess the level of 
ribonomics sensitivity, an in vitro experiment was performed to model the in vivo-like 
condition of a diluted infected cell population.  At 6hpi, cell lysates (1 ml) were 
prepared from 106 L929 cells that had been infected with FLAG-PABP VRP 
(MOI=5).  The resulting lysates were mixed in decreasing ratios of infected lysate to 
mock lysate, to a total volume of 200 µl.  Anti-FLAG immunoprecipitation was 
performed to isolate RNA from the infected cell portion of this mixed lysate. To 
assess the mRNA signal recovered from the infected cells, an RNase protection 
assay was used to detect several host mRNAs, two of which are shown above (IRF-
1, GAPDH).  Signal from infected cell RNA within the mixed lysate was detected in 
samples comprised of as little as 1% infected cell lysate (highlighted by the small 
dots), a value approximately equal to 2x103 infected cells.  
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Figure 2.5. Infected cell gene expression profiles generated by mRNP-tagging 
versus FACS-based assays.  The ribonomics approach and a FACS-based 
method of sorting infected cells were compared.  1.5 x 106 L929 cells were infected 
with either GFP-VRP or FLAG-PABP VRP (MOI=0.2).  12h after GFP-VRP infection, 
infected cells were sorted and recovered based on GFP expression via FACS.  The 
recovered GFP-positive (infected) cells were lysed, and all PABP-bound host 
messages were isolated by anti-PABP immunoprecipitation.  In parallel, 12h after 
FLAG-PABP VRP infection, the ribonomics assay was used to directly sort the 
mRNA from infected cells by anti-FLAG immunoprecipitation.  To evaluate and 
compare  host gene expression in the infected cell populations, two independent 
samples were analyzed for IFNβ, IP-10, and IRF-1 expression by Taqman real time 
PCR.  The results were normalized to GAPDH signal, compared to PABP-bound 
mRNA from mock infected cells, and averaged.   
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Figure 2.6. Role of interferon signaling in VRP-induced host gene expression 
in infected versus bystander BMDC.  106 BMDC generated from wildtype 
129sv/ev mice (black bars) were infected with FLAG-PABP VRP at a low MOI (0.5).  
At 6h, RNA was isolated from mock and VRP-infected BMDC by either 1) preparing 
cell lysates for isolation of FLAG-PABP-bound mRNA via anti-FLAG 
immunoprecipitation, or 2) using UltraSpec reagent to isolate total cellular RNA. The 
ribonomics method specifically isolated mRNA from the minority of infected BMDC 
via the bound FLAG-PABP.  Conversely, total RNA extraction was used to isolate 
cellular RNA from the entire VRP-infected BMDC culture, with the majority of the 
population being DCs that had not been infected. To examine the contribution of 
signaling through the IFNab receptor, the same analysis was carried out in BMDC 
derived from IFNαβR-/- mice (hatched bars). cDNA was generated from each RNA 
isolation, and assessed for changes in host gene expression by Taqman real-time 
PCR.  Two independent samples were normalized to GAPDH signal, analyzed in 
comparison to mock infected BMDC, and averaged.   
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Figure 2.7. Differential regulation of the host response following wildtype and 
interferon-sensitive VRP infection.  Affymetrix DNA microarray analysis was used 
to define global changes in host gene expression following wildtype and nt3A mutant 
null-VRP infection.  Total RNA was isolated at 5hpi from L929 cells that had been 
mock or null-VRP infected (MOI=5).  Samples were analyzed for changes in host 
gene expression by the Affymetrix Mouse Expression 430A GeneChip technology.  
Data from two independent array experiments were analyzed and filtered to uncover 
genes induced or repressed during each infection in comparison to mock treated 
cells.  Venn diagram assessment of genes that were modulated during infection by 
>2-fold over mock treated cells revealed populations of mRNAs that were uniquely 
modulated by each infection.  A similar analysis of genes modulated >4-fold (in 
parentheses) over mock continued to reveal uniquely regulated genes.  
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Table 2.1.  Modulation of host interferon, inflammatory, and defense response gene   
                  expression profiles following VRP infection of L929 cells*  
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Figure 2.8. In vivo, the combination of traditional and ribonomics profiling 
uncovers dynamic changes in host gene expression within the DLN. Adult 
female Balb/c mice were inoculated in both rear footpads with 106 IU of wildtype or 
nt3A mutant FLAG-PABP VRP.  Mock treated animals were inoculated with diluent 
alone.  At 6 and 9h, the popliteal DLNs were removed and washed with PBS.  To 
isolate RNA from the entire cellular population of the DLN, both DLNs were pooled, 
homogenized, and total RNA extracted.  For isolation of mRNA specifically from the 
infected cells of the DLN, the ribonomics mRNA tagging technique was used:  Five 
DLNs were pooled per sample and homogenized in lysis buffer, followed by anti-
FLAG immunoprecipitation.  cDNA was synthesized from each RNA sample, and 
Taqman real-time PCR was performed against several target host genes.  Two 
independent pools were analyzed from each group, with GAPDH serving as the 
internal housekeeping control gene, and the results were averaged.  Asterisks 
indicate samples from infected DLN that had no detectable signal following anti-
FLAG immunoprecipitation.  Ribonomics profiling in conjunction with traditional 
profiling reveals two distinct, comprehensive views of the response to infection within 
this target tissue in vivo.  
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Supplemental Fig. 2.1.  Differential regulation of the host response following 
wildtype and interferon-sensitive VRP infection.  Affymetrix DNA microarray 
analysis was used to define global changes in host gene expression following 
wildtype and nt3A mutant null-VRP infection.  Total RNA was isolated at 5hpi from 
L929 cells that had been mock or null-VRP infected (MOI=5).  Samples were 
analyzed for changes in host gene expression by the Affymetrix Mouse Expression 
430A GeneChip technology.  Data from two independent array experiments were 
analyzed and filtered to uncover genes induced or repressed during each infection in 
comparison to mock treated cells.  Venn diagram assessment of genes that were 
modulated during infection by >2-fold over mock treated cells revealed populations 
of mRNAs that were uniquely modulated by each infection.  A similar analysis of 
genes modulated >4-fold (in parentheses) over mock continued to reveal uniquely 
regulated genes.  This data corresponds to the same data in Fig. 2.7, except here 
groups (A-F) were assigned in order to designate the unique or common gene sets 
modulated during infection.  The individual genes belonging to each of these groups 
is listed in Supplemental Table 2.1. 
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 Supplemental Table 2.1.  Affymetrix Gene Expression Profiling of VRP Infected L929 Cells    
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  (Highlighted genes represent those modulated by greater than four-fold in each group.) 
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ABSTRACT 
 
The host innate immune response, in particular the interferon response, 
provides a critical first line of defense against invading pathogens, inducing an 
antiviral state designed to impede the spread of infection in the body.  While 
numerous studies have documented the profound changes imposed by the antiviral 
response within actively infected tissues, few have described on a molecular level 
how the infected animal is systemically affected.  Here, utilizing Venezuelan equine 
encephalitis virus replicon particles (VRP) to limit infection to the initially infected 
cells in vivo, a rapid, systemic activation of the antiviral response was demonstrated 
both in distal tissues as well as within the draining lymph node, where VRP infection 
is confined following footpad inoculation.  In the liver and brain, the expression of a 
panel of interferon-stimulated genes was detected by 1 to 3 hours (h) following VRP 
footpad inoculation, and reached peak expression levels of greater than 100-fold 
over mock.  Although these distal tissues had not encountered VRP, they were 
nevertheless subject to high levels of soluble immune modulators, including serum 
interferon.  Moreover, we found that mice receiving a footpad VRP inoculation 6, 12, 
or 24h prior to an otherwise lethal Venezuelan equine encephalitis virus (VEE) 
footpad challenge were completely protected from death.  This VRP pretreatment 
dramatically reduced challenge virus titers in the serum and brain, and also provided 
protection from intranasal VEE challenge.  Interferon signaling was necessary for 
both the induction of the antiviral response, as well as for protection from VEE 
challenge.  However, interferon itself was likely not the sole responsible immune 
mediator, as VRP-pretreated mice challenged with a heterologous, interferon-
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sensitive virus were not protected.  The results presented here document the rapid 
modulation of the host innate response within hours of pathogen invasion, a 
response capable of transforming the entire infected animal.  Furthermore, this 
system provides a promising model to investigate the components of innate 
immunity required for a protective response to VEE infection. 
 
INTRODUCTION 
 
Venezuelan equine encephalitis virus (VEE) is an arthropod-borne, single-
stranded, message-sense RNA virus, belonging to the Alphavirus genus in the 
Togaviridae family.  Associated with periodic epidemics and equine epizootics in the 
Western Hemisphere, VEE also serves as a leading model for the study of 
alphavirus pathogenesis in vivo.  In the murine model, which closely mimics infection 
of horses in nature, VEE causes a two-phase disease:  an initial, acute lymphotropic 
phase characterized by a high serum viremia, followed by invasion of the central 
nervous system during a neurotropic phase that leads to fatal encephalitis (1, 2).  
Utilizing the infectious molecular clone of VEE, as well as an extensive panel of 
mutants blocked in various stages of infection, the course of pathogenesis in the 
mouse model has been well described (2-6). 
Studies examining the molecular aspects of VEE-induced pathogenesis have 
underscored the critical role of virus genetics, and the subsequent host response in 
dictating the course and outcome of infection (2, 7-13).  However, many details of 
the earliest host-pathogen interactions during VEE infection remain largely unknown.  
A tool paramount to studying the early events in infection are VEE replicon particles 
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(VRP).  VRP are propagation-defective particles that can undergo only one round of 
infection, as the structural genes which normally drive the assembly of progeny 
virions are deleted from the replicon genome.  VRP are assembled using packaging-
defective helper RNAs, supplied in trans (14).  As such, VRP infection is limited to 
the first infected cells in vivo, allowing examination of the earliest interactions 
between virus and host. 
The utilization of VRP facilitated the identification of the draining lymph node 
(DLN) as the initial site of viral replication in vivo, documenting the migration of 
infected dendritic cells to this tissue from the site of inoculation in the skin (15).  It 
has been hypothesized that the earliest host-pathogen interactions occurring within 
the DLN set the stage for the specific course of events that define VEE-induced 
pathogenesis.  In fact, utilizing a VRP-based mRNP-tagging system in vivo, we 
recently reported the robust activation of the host innate antiviral response directly 
within the infected cells of the DLN, as well as in the surrounding uninfected 
bystander cells, at early times post infection (J.L.K., submitted manuscript). 
It has been well documented that the innate immune response plays a critical 
role in controlling viral infection and spread, with the interferon (IFN) system at the 
forefront of this first-line defense to a spreading infection (16-18).  It is likely, 
therefore, that one the effects of an early, robust innate immune response in the 
tissue(s) where replication first occurs is the contemporaneous induction of an 
antiviral state in tissues distal to the initial infection. 
We postulated that if early replication in the DLN induces the production of 
soluble immune mediators, such as IFNαβ, the induction of an innate immune 
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response may be rapidly transmitted downstream from the primary site of replication 
to distal tissues.  Therefore, utilizing VRP to limit viral spread, we examined the host 
antiviral response within the DLN at early times following infection, as well as in 
tissues remote from the site of replication.  Although such distal tissues had not 
encountered VRP, they were subject to signaling by the early systemic innate 
response induced by infection.  This included high levels of serum interferon 
detected by 3 to 6h following VRP footpad inoculation.  In the liver and brain, the 
robust expression of a panel of interferon-stimulated genes, a hallmark of the 
antiviral state elicited by IFNαβ, was detected by 1 to 3h following VRP footpad 
inoculation, and peaked at 6 - 12h with a subset of genes reaching levels of over 
100-fold of that measured in mock infected animals.  These results clearly suggest 
that the early innate response to VRP infection is capable of inducing a systemically 
active, antiviral state within the entire infected animal.  Moreover, we found that mice 
pretreated by footpad inoculation with VRP for 6, 12, or 24h prior to an otherwise 
lethal VEE footpad challenge were completely protected from death.  The same VRP 
pretreatment also provided protection from VEE challenge by intranasal inoculation, 
and significantly extended the average survival time of mice challenged with VEE 
intracranially. 
While protection from VEE infection has typically been associated with the 
presence of neutralizing antibody (19-23), nonspecific protection against VEE also 
has been suggested, including the involvement of the innate immune response (13, 
24-28).  In one instance, mice “vaccinated” with an attenuated clone of VEE were 
protected against lethal VEE challenge administered just 24h after vaccination (27).  
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In another study, the complete attenuation of a VEE mutant differing from wildtype 
VEE by a single noncoding nucleotide change in the 5’ untranslated region was 
attributed to the heightened sensitivity of the mutant to the host antiviral state (13).  
Additionally, mice with severe combined immunodeficiency infected with virulent 
VEE survive longer than immunocompetent mice (9 as opposed to 6 days) (10), 
whereas mice lacking the type I interferon receptor die within 48h.  These findings 
strongly indicate that the nonspecific response to infection is a critical component of 
controlling early VEE infection. 
While interferon and the interferon-induced antiviral state are undoubtedly key 
immune mediators of the initial response to VRP infection in vivo, they may not 
however be solely responsible for the rapid protection observed in the model 
presented here.  While therapeutic regimens of IFNα or IFNγ, administered after 
virulent VEE infection, improve the outcome of infection in mice (29, 30), studies in 
which interferons or IFN-inducing agents (dsRNA/poly I:C, LPS) were administered 
for a short interval prior to VEE challenge provided no protection from death (26, 31).  
This was further supported here, by the failure of VRP pretreatment to protect 
against a heterologous challenge with another interferon-sensitive virus, vesicular 
stomatitis virus (VSV).   
The data presented here provide new insight into the rapid mobilization of the 
host innate response which transforms the entire VRP infected animal, and offers a 
promising model system in which the components of innate protection from VEE-
induced disease can be further investigated. 
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MATERIALS AND METHODS 
Virus and replicon particles   
The construction of the full-length VEE cDNA clone pV3000, derived from the 
Trinidad donkey isolate of VEE, has been described previously (2, 3, 5).  Virus 
stocks of wildtype virulent VEE (V3000) were produced by electroporating infectious 
RNA into BHK-21 cells (2, 10).  Virus particles were harvested from the supernatant 
at 24 h post-infection when significant CPE was evident, and were clarified by 
centrifugation (10,000 x g, 30 min, 4°C).  Virus stocks were further concentrated by 
pelleting through 20% (wt/vol) sucrose in low endotoxin phosphate-buffered saline 
(PBS) at 72,000 x g for 5 h at 4°C.  Virus titers were determined by standard plaque 
assay on BHK-21 cells, and stocks were stored in single-use aliquots at -70°C. 
The construction and packaging of VEE replicon particles (VRP) using a split 
helper system have been described previously (14).  Replicon plasmid constructs 
that do not encode any functional transgene sequence downstream of the 26S 
promoter were utilized throughout this study.  The resulting particles, termed null 
VRP, contain the VEE nonstructural genes, 14 nucleotides (nt) of VEE sequence 
downstream of the 26S mRNA transcription start site and the 43 nt multiple cloning 
site (32).  The null VRP genome also includes the authentic viral 5’ and 3’ 
untranslated regions.  All replicon particles used in this study were packaged in the 
wildtype (V3000) VEE envelope, as described previously (14).  Briefly, the replicon 
RNA genome along with two helper RNAs providing the wildtype capsid and 
glycoprotein genes were co-electroporated into BHK-21 cells.  As the helper RNAs 
lack the cis-acting virus-specific packaging signal, and the replicon genome does not 
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encode the viral structural genes, infectious but non-propagating VRP undergo only 
one round of infection.  The absence of propagating recombinant virus was 
confirmed by blind passage in BHK-21 cells.  VRP were concentrated from 
supernatants by centrifugation through a 20% sucrose cushion and resuspended in 
endotoxin-free PBS.  BHK-21 titers were determined by immunocytochemistry using 
mouse sera containing antibody to the VEE nonstructural proteins. 
Vesicular stomatitis virus (VSV) was utilized as a heterologous challenge 
virus.    Stocks of VSV (Indiana-1 serotype, Orsay strain) were the generous gift of 
Douglas Lyles and John Connor (Wake Forest University, Winston-Salem, NC). 
 
Cells 
BHK-21 cells (ATCC CCL-10) and  murine L929 fibroblasts (ATCC CCL-1) 
were maintained in alpha-minimum essential media (Gibco) supplemented with 10% 
donor calf serum, 10% tryptose phosphate broth, 0.29 mg of L-glutamine/ml, 100 U 
of penicillin/ml, and 0.05 mg of streptomycin/ml (37°C, 5% CO2). 
 
Mice 
Specific-pathogen-free BALB/c mice were obtained commercially (Charles 
River Laboratories).  Unless otherwise noted, 10-12 week old female BALB/c mice 
were utilized.  Breeding pairs of IFNαβR-/- 129Sv/Ev mice were kindly provided by 
Barbara Sherry (North Carolina State University, Raleigh, N.C.).  Mice were bred 
under specific-pathogen-free conditions in the Department of Laboratory Animal 
Medicine breeding colony facilities at the University of North Carolina, Chapel Hill.  
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Age- and sex-matched wildtype 129Sv/Ev (129S6/SvEvTac) mice were obtained 
commercially from Taconic (Germantown, N.Y.).  Animal housing and care were in 
accordance with all UNC-CH Institutional Animal Care and Use Committee 
guidelines.  All mouse studies were performed in an environmentally controlled room 
in a biosafety level 3 facility, allowing mice to acclimate for 3 to 5 days in the facility 
before experimental manipulation. 
Mice pretreated with VRP were inoculated in the right rear footpad (RRFP) 
with 2x106 IU of null VRP (unless otherwise stated) in 10 ul of endotoxin-free PBS 
diluent containing 1% donor calf serum.  Mock-pretreated animals received diluent 
alone.  When footpad was the route of challenge, mice received 10 PFU of wildtype 
virulent VEE (V3000) inoculated in the opposing left rear footpad (LRFP) (10 ul total 
volume).  Mice challenged intracranially were anesthetized with isoflurane and 
inoculated with 103 PFU of wildtype virulent VEE (V3000) in 10 ul diluent.   Mice 
challenged intranasally with VEE received a dose of 103 PFU of wildtype VEE 
(V3000) in a 10ul volume, with 5 ul administered into each nare.  Mice challenged 
intranasally with VSV received a dose of 2 x 106 PFU of VSV diluted in 20 ul RPMI 
media (Gibco), with 10 ul administered into each nare. 
For morbidity and mortality studies, mice were monitored for clinical signs of 
disease and weighed every 24h for 14-18 days.  Morbidity was defined as greater 
than 10% weight loss and/or signs of clinical disease for two or more consecutive 
days.  Clinical signs of disease included ruffled fur, hunching, ataxia, paresis 
(dragging of hind limb), paralysis (complete loss of hind limb function) and/or a 
moribund state.  In the interest of animal welfare and in accordance with UNC-CH 
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Institutional Animal Care and Use Committee guidelines, mice experiencing a loss in 
weight of more than 20% of starting weight while showing clinical signs of disease 
were euthanized.  To determine viral titers in the serum and brain, mice were 
euthanized by anesthesia overdose, followed by cardiac puncture and 
exsanguination to collect blood samples.  The serum was separated in microtainer 
tubes, aliquoted and stored at -70°C.  Each animal was perfused with 1× PBS, and 
the brain removed by dissection, weighed, and stored at -80°C in a 20% (wt/vol) 
suspension of 1x PBS supplemented with 1% donor calf serum, 110 mM Ca2+, and 
50 mM Mg2+.  After one freeze-thaw cycle, the samples were homogenized and 
clarified by centrifugation at 10,000 x g, and viral titers were assessed by standard 
BHK-21 plaque assay. 
 
RNA isolation and cDNA synthesis 
At the indicated times post-infection, mice were euthanized and perfused with 
PBS.  The draining popliteal lymph node, liver, and brain were dissected and stored 
at -80°C in RNAlater (RNA stabilization reagent, Ambion).  According to the 
manufacturer’s protocol, tissue homogenates were prepared using a plastic pestle 
and handheld motor, as well as passage through an 18 gauge needle.  Total cellular 
RNA was isolated using the RNeasy Protect kit (Qiagen). 
A one-tube DNase treatment and reverse transcription protocol was used to 
generate cDNA, using the SuperScript III Reverse Transcriptase First Strand cDNA 
kit (Invitrogen).  0.75 - 1.0 ug of total RNA was brought to a final volume of 10 ul with 
RNase-free water.  This was combined with 1 ul 10 mM dNTP mix (Amersham 
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Biosciences), 4 ul 5X SuperScript III reverse transcriptase buffer, 1 ul 0.1 mM dTT, 1 
ul 40 U/ul RNaseOUT (Invitrogen), and 1 ul RQ1 RNase-free DNase (Promega) per 
sample.  The samples were DNase treated at 37°C for 30 min, followed by the 
addition of 1 ul RQ1 Stop Solution (Promega) and heat inactivation of the samples at 
65°C for 10 min.  Following the addition of random hexamer primers (150 ng, 
Invitrogen), reverse transcription of the samples was continued in the same tube, 
according to the SuperScript III protocol (Invitrogen).  cDNA samples were stored at 
-20°C. 
 
Real-time PCR and analysis 
Real-time PCR was performed to determine the relative abundance of 
specific cellular mRNAs in tissues isolated from mock and VRP-infected animals (3 
mice per group).  Taqman Gene Expression primer probe sets (Applied Biosystems) 
for various target host messages were used, with each reaction performed in a 25 ul 
total volume [5ul cDNA, 12.5 ul TaqMan Universal PCR Master Mix without 
AmpErase UNG (Applied Biosystems), 1.25 ul probe/primer mix (Applied 
Biosystems), and 6.25 ul RNase-free water].  For all samples, an equivalent amount 
of RNA was reverse transcribed and an internal reference control of 18s rRNA was 
included.  The default amplification profile was performed in the ABI Prism 7000 
Real-Time PCR System.  Using the 7000 Sequence Detection Software (v1.2.3, 
Applied Biosystems), the results were converted into cycle threshold (CT) values 
corresponding to the cycle number at which the fluorescence of the PCR product 
reached significant levels above the background level.   Results are presented as 
 132 
the fold gene expression in the infected samples over that in the mock samples, 
analyzed using the well established delta CT (∆CT) method [User Bulletin, ABI Prism 
7000 Sequence Detection System (Applied Biosystems)].  Briefly, for each cDNA 
sample, the 18s CT value was subtracted from the CT value of the target gene of 
interest, yielding a ∆CT value.  The ∆CT value generated for the VRP-infected 
sample was then subtracted from the ∆CT value of the corresponding mock sample, 
yielding a ∆∆CT value.  This widely-used method assumes the target and reference 
genes were amplified with the same efficiency, thus the increase in host mRNA 
levels in the infected samples compared to the mock treated samples was calculated 
as 2 –(∆∆CT). 
 
Interferon bioassay 
The levels of type I interferon present in the serum of infected mice were 
measured by a standard biological assay on L929 cells, as described previously (13, 
33).  Briefly, L929 murine fibroblasts were seeded in 96-well plates.  Serum samples 
were diluted 1:10 in alpha-minimum essential media (Gibco), and acidified to a pH of 
2.0 for 24 h.  Following neutralization to pH 7.4, the samples were added to the cells 
by titration of twofold dilutions down the plate.  Twenty-four hours after the addition 
of the serum dilutions, interferon-sensitive encephalomyocarditis virus (EMCV; 2 x 
105 PFU) was added to each well and incubated at 37°C.  At 18 to 24 h post-
infection, 3-[4,5-dimethylthylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT; 
Sigma), an indicator of viable cells, was added to each well.  The MTT product was 
then dissolved in isopropanol-0.4% HCl, and absorbance was read on a microplate 
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reader at 570 nm.  Each plate contained twofold dilutions of an IFN standard 
(Chemicon or R&D Systems), ranging from 500 to 0.49 international units (IU) per 
ml.  The concentration of type I IFN in each serum sample was based on the 
standard curves generated with the interferon standard.  The end-point titers were 
based on the dilution at which an optical density reading of 0.5 was reached, 
corresponding to ~50% protection of the cell monolayer from EMCV-induced cell 
death, and adjusted for the original titration of the serum samples.   
 
RESULTS 
VRP infection induces a robust antiviral state in vivo at the site of replication, 
as well as in remote downstream tissues.   
Several studies have previously highlighted the importance of the DLN during 
VEE infection (2, 13, 15, 27, 32, 34)(J.L.K., submitted manuscript).  In vivo, the DLN 
serves as the earliest known site for viral replication, with infected dendritic cells 
migrating there from the site of inoculation in the skin (15).  Consequently, the DLN 
is the site where the early host response to VEE infection is established, 
demonstrated by a robust induction of the host antiviral gene response (27).  In 
addition, a recent study utilizing VRP to limit infection to the initially infected cells in 
vivo, revealed a robust activation of the host defense response directly within the 
infected cells of the DLN at early times post infection (J.L.K., submitted manuscript).  
Accordingly, it has been hypothesized that early events within the DLN, such as 
those described above, set the stage for a specific pattern of virus replication and 
host response that define VEE-induced pathogenesis. 
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Utilizing VRP which do not propagate beyond the initially infected cells, we 
examined the early impact of infection not only within the DLN, but also at sites 
downstream from this primary site of replication.  To determine whether the strong 
antiviral state established early in the DLN leads to a systemic response throughout 
the animal, mice were inoculated in the right rear footpad (RRFP) with 2 x 106 IU of 
null VRP.  At 1, 3, 6, 12, and 24h post inoculation, mice were euthanized, serum 
collected by cardiac puncture, and each animal perfused with PBS.  The popliteal 
DLN, liver (one lobe), and brain (including olfactory bulbs), were dissected from each 
animal, and total RNA isolated.  The expression level of a panel of host antiviral 
genes (IFNβ, IP-10, p56, and Isgf3γ) was measured from each sample (3 mice per 
group) by real-time PCR. 
The results, shown in Fig. 3.1, demonstrate a robust activation of the innate 
immune response not only in the DLN (Fig. 3.1A), but also distally in both the liver 
(Fig. 3.1B) and the brain (Fig. 3.1C), tissues that are remote from the active site of 
VEE replicon RNA replication.  As early as 1h to 3h following footpad inoculation, a 
high level of antiviral gene induction was detected in the DLN, with IFNβ, IP-10, and 
p56 gene expression at levels of 100-fold over that in mock infected mice.  This 
response reached a peak in the DLN at 6 - 12h following footpad inoculation, with 
expression levels of IP-10, p56, and IFNβ at 400- to greater than 5,000-fold over that 
in mock infected animals.  By 24h, the response within the DLN appeared to be 
waning. 
In uninfected tissues distal to the site of active replication in the DLN, a 
mounting antiviral response was detected in both the liver and brain following 
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footpad VRP inoculation.    Interestingly, the kinetics of this downstream induction 
were similar to that observed in the DLN, with the antiviral gene response initially 
detected at 1 to 3hpi in the liver and brain, peaking at 6 to 12h, and waning by 24h.  
It is important to note that these remote tissues were completely devoid of replicon 
RNA as indicated by real-time PCR for the VEE nsP1 gene (data not shown).  At its 
peak, this antiviral response in the liver and brain reached levels of 10 to nearly 
1,000-fold of that measured in mock animals, suggesting that the entire infected 
animal responded to the invading pathogen, mounting a systemic antiviral response 
reaching far beyond the site of active replication.   Although these remote organs did 
not encounter VRP, they nevertheless were subjected to systemic soluble mediators 
of the innate immune response induced by the active infection in the DLN.  In fact, 
very high levels of biologically active interferon detected in the serum of these same 
mice correlated with the peak antiviral gene response, reaching nearly 400,000 
IU/ml by 6h post infection (Fig. 3.2). 
 
Short duration pretreatment with VRP protects mice from footpad challenge 
with virulent VEE.   
The extent and rapidity of the observed systemic antiviral state induced 
following VRP inoculation led to questions regarding the protective nature of this 
response.  To address whether VRP inoculation rapidly induced a protective state, 
adult female BALB/c mice were inoculated with 2 x 106 IU of null VRP in the RRFP 
for 6, 12, or 24h prior to a virulent challenge with 10 PFU of wildtype VEE 
administered into the opposing LRFP.  Mice were weighed and observed every 24h 
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for signs of clinical disease, with morbidity and mortality compared to mice receiving 
a mock pretreatment followed by virulent VEE challenge.  The results, summarized 
in Table 3.1 and Fig. 3.3, demonstrate that at a dose of 2 x 106 IU, a short duration 
pretreatment with VRP delivered in the footpad can protect animals from death 
following virulent VEE challenge in the opposing footpad.  The 100% mortality 
observed following VEE challenge in mock-pretreated animals was reduced to 0% in 
animals receiving VRP at all pretreatment times tested.  The incidence of morbidity 
observed in VRP treated animals was largely reduced as well, falling from the 100% 
incidence of morbidity in mock-pretreated mice to a range of 0 to 33% morbidity in 
mice receiving VRP.  Allowing even a short 6h window between VRP inoculation and 
VEE challenge was sufficient to effectively protect animals from death, a testament 
to the effectiveness of the early antiviral response induced by VRP. 
To further assess the protective quality of this VRP pretreatment, more 
rigorous routes of VEE challenge were examined.  Following footpad inoculation, 
VEE causes a two-phase disease in mice, much like that which occurs in horses 
following subcutaneous inoculation.  An initial lymphotropic phase is characterized 
by a high serum viremia which seeds infection of the olfactory neuroepithelium, 
followed by invasion of the central nervous system and initiation of a neurotropic 
phase leading to fatal encephalitis (2, 35).  Intranasal delivery of VEE bypasses the 
necessity of a high serum viremia for establishment of the neurotropic phase, by 
granting direct access to the olfactory neuroepithelium.  However, this route still 
requires neuroinvasion of the CNS to establish lethal encephalitis.  When BALB/c 
mice where pretreated by footpad inoculation of 2 x 106 IU of null VRP for 12h or 
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24h prior to virulent intranasal VEE challenge (103 PFU), they were completely 
protected from death.  This is in comparison to the 100% mortality observed in 
mock-pretreated animals (Table 3.2, Fig. 3.4).  Therefore, administering VRP in the 
footpad 12 to 24h prior to a rigorous, intranasal challenge with VEE, effectively 
protected animals from death.  While a 6h VRP pretreatment was sufficient to 
completely protect animals from VEE footpad challenge, the percent mortality 
following intranasal VEE challenge under the same conditions was 50%, indicating 
that the progression of the challenge virus from footpad to brain is likely to be a 
critical parameter of protection within this pretreatment model. 
Intracranial inoculation of VEE bypasses the need for neuroinvasion into the 
CNS by granting direct access to the brain, and therefore serves as a means to 
directly measure viral neurovirulence.  Thus, in our model of protection, intracranial 
VEE inoculation served as the most rigorous challenge route examined.  As 
demonstrated in Fig. 3.5 and summarized in Table 3.3, footpad pretreatment with 
VRP failed to protect animals from a virulent 103 PFU VEE intracranial challenge.  
However, a statistically significant increase in the average survival time of mice that 
received the VRP pretreatment was observed, as compared to the average survival 
time of mice receiving mock-pretreatment.  An intracranial challenge with a lower 
dose of 10 PFU of VEE also resulted in 100% mortality of both mock and VRP 
pretreated animals (data not shown).  Taken together, the VEE challenge 
experiments suggest that while a short duration pretreatment with VRP can 
effectively protect animals from peripheral (footpad) or mucosal (intranasal) 
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challenge with virulent VEE, it cannot protect animals against the extensive 
neurovirulence evident upon direct intracranial administration of VEE. 
 
VRP pretreatment reduces the viral load in the serum and brain of mice 
challenged with VEE. 
To determine whether VRP pretreatment functionally reduced and/or limited 
the replication of VEE following challenge, standard BHK-21 plaque assay was used 
to measure the titer of challenge virus present in the serum and brain.  In parallel to 
the mice monitored for morbidity and mortality following footpad challenge of VEE 
(referring back to Table 3.1 and Fig. 3.3), an additional four mice per group were 
utilized for titer determination.  At 6, 12, or 24h following the standard pretreatment 
of 2 x 106 IU null VRP in the RRFP, mice were challenged in the LRFP with 10 PFU 
of VEE.  At 24h post challenge, serum was collected from the tail vein, followed by 
PBS perfusion and dissection of the brain (including the olfactory bulbs) at 88h post 
challenge.  Titers from VRP pretreated animals were compared to those from mock 
pretreated animals. 
The results, shown in Fig. 3.6, demonstrate that short duration VRP 
pretreatment dramatically reduced the viral load in serum and the brain following 
virulent VEE footpad challenge.  At 24h post challenge, the serum viremia in mock 
pretreated animals had reached 6.5 x 105 PFU/ml, while the viral load in the serum 
of VRP pretreated animals was reduced over two logs to 2.1 x 103 PFU/ml.  
Furthermore, in the brain of mock pretreated animals, viral titers had reached nearly 
7.5 x 106 PFU/gram by 88h post challenge, while in VRP pretreated animals the 
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amount of virus measured in the brain was at or below the limit of detection (≤ 500 
PFU/gram).  Therefore, it is clear that short duration VRP pretreatment effectively 
reduces the viral load in both the serum and brain, thereby controlling viral spread 
following VEE challenge. 
 
Protection from virulent VEE challenge is dependent on the dose of VRP 
pretreatment.    
A VRP pretreatment dose of 2 x 106 IU not only induces a strong antiviral 
response in the DLN and in downstream tissues, but can completely protect animals 
from virulent footpad challenge with VEE when the pretreatment is given a mere 6h 
before challenge.  This same time interval of pretreatment protected 50% of mice 
challenged with VEE intranasally; however, complete protection from intranasal 
challenge ensued if the pretreatment was extended to 12h or 24h.  These results, 
along with the observed extension in the average survival time of intracranially 
challenged mice, suggest that there do exist limitations to the magnitude of 
protection that this VRP pretreatment confers.  To begin elucidating factors 
fundamental to establishing this protection, we first addressed the effect of 
pretreatment dose (Table 3.4, Fig. 3.7). 
Adult BALB/c mice were pretreated with decreasing doses of null VRP in the 
RRFP, and then challenged 6h later in the opposing LRFP with 10 PFU of virulent 
VEE.  Consistent with our previous results, mice that received the standard 
pretreatment dose of 2 x 106 IU of VRP were completely protected from death, while 
those receiving mock pretreatment all succumbed to VEE infection.  However, at 
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VRP pretreatment doses of 105 or 104 IU, protection against mortality was lost, 
suggesting a fairly abrupt dose threshold for the protective effect.  However, it is 
possible that protection may have been observed if pretreatment with a lower dose 
was extended beyond 6h.   
 
Signaling through the IFNαβ receptor is necessary for induction of the 
downstream antiviral gene response, and protection from virulent VEE. 
We have demonstrated that by 6h post inoculation, large amounts of 
biologically active interferon are circulating in the serum of VRP pretreated mice.  
The kinetics of this serum interferon response correlate with the induction of a robust 
host antiviral gene response in pretreated animals, occurring both at the site of 
replication in the DLN as well as in downstream tissues such as the brain and liver.  
We hypothesize that administering a virulent VEE challenge in the context of this 
rapidly induced host innate antiviral response subsequently leads to protection from 
death.  To begin addressing what role the observed innate response plays in the 
protection conferred by VRP pretreatment, mice lacking the IFNαβ receptor were 
employed.  Although levels of serum interferon circulating in IFNαβR-/- mice at early 
times after VRP footpad inoculation are equivalent to those in wildtype 129 mice, 
IFN declines in the knockout mice by 12h (13).  Furthermore, while our group 
recently demonstrated that the lack of the IFNαβ receptor had little effect on the 
antiviral paracrine response within uninfected bystander cells of the DLN, the 
autocrine antiviral gene response in infected cells however was greatly impaired 
(J.L.K., submitted manuscript).  To investigate whether signaling through the IFNαβ 
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receptor was required for the rapid, VRP-induced antiviral response in downstream 
tissues, wildtype 129 or IFNαβR-/- mice were inoculated with 2 x 106 IU of null VRP 
(RRFP).  At 6h post inoculation, the mice were euthanized and PBS perfused.  The 
liver and brain were dissected, and total RNA extracted.  The expression of the 
same panel of four interferon-stimulated genes (IFNβ, IP-10, p56, and Isgf3γ) was 
measured by real-time PCR and compared to levels in mock infected mice. 
The results, shown in Fig. 3.8, demonstrate a virtually complete elimination of 
the downstream antiviral gene response at 6h in mice lacking the IFNαβ receptor.  
This is in stark contrast to the robust responses measured in the same tissues 
isolated from wildtype IFNαβR+/+ 129 mice.  Therefore, although the presence of 
near wildtype levels of serum interferon have been reported in IFNαβR-/- mice at this 
6h post inoculation timepoint, the lack of the IFNαβ receptor greatly impairs the 
early, systemic antiviral response that is induced in downstream tissues of wildtype 
animals.  However, it also is possible that the induction kinetics of the systemic 
antiviral response may only be delayed in IFNαβR-/- mice.   
Protection against VEE challenge was not observed in IFNαβR-/- mice (Table 
3.5 and Fig. 3.9).  However, several studies have described the intrinsic sensitivity of 
VEE to the host interferon response (12, 13, 24, 26, 36-39).  As such, the intrinsic 
interferon sensitivity of VEE makes it difficult to determine whether the lack of 
protection observed in our IFNαβR-/- experiment is truly due to a dampened or 
impaired pretreatment response, or merely a function of the general increased 
susceptibility of these mice to infection with VEE.    
 
 142 
VRP pretreatment does not protect mice from challenge with a heterologous, 
interferon-sensitive virus.   
VRP pretreated animals were challenge with Vesicular stomatitis virus (VSV) 
to determine whether protection extended to a heterologous yet interferon-sensitive 
virus.  VSV is a negative-sense, ssRNA virus that has been utilized extensively to 
study viral pathogenesis, and the interferon response to infection. In the mouse 
model, VSV is highly virulent when delivered intracranially; however, it is difficult to 
induce mortality in animals infected from a subcutaneous route.  The reported 
mortality rate following intranasal inoculation of VSV varies, usually falling between 
30-60% mortality in adult mice (40-42).  However, similar to infection with VEE, 
intranasal inoculation of VSV delivers the virus to the neuroepithelium, where 
replication occurs and spread to the olfactory bulb ensues (43).  Due to the well 
documented interferon sensitivity of VSV, as well as its amenability to the intranasal 
challenge model in which we demonstrated the ability of VRP to protect from lethal 
VEE challenge, VSV was selected as our heterologous challenge virus. 
To address whether a short duration VRP pretreatment could protect from a 
heterologous virus challenge, 6 - 7 week old male BALB/c mice were inoculated in 
the RRFP with 2 x 106 IU of null VRP, and then challenged 24h later with 2 x 106 
PFU of VSV, delivered intranasally.  The mice were monitored daily, and their weight 
and clinical scores recorded.  As summarized in Table 3.6 and Figure 3.10, a 24h 
pretreatment with null VRP was not sufficient to induce protection from a lethal 
intranasal VSV challenge.  These results suggest that the mechanism of protection 
mediated by VRP pretreatment may not be solely attributable to interferon, and/or 
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may be more specifically effective against VEE.  On the other hand, it is possible 
that either the magnitude, duration, or kinetics of the interferon response were not 
sufficient or ideal to bestow protection from VSV challenge.  However, it is clear 
under the conditions tested, that a VRP pretreatment regimen that is capable of 
protecting animals from lethal VEE intranasal challenge cannot protect animals from 
death upon intranasal VSV challenge. 
 
DISCUSSION 
During the course of viral infection in vivo, the manifestation of clinical signs in 
the infected animal serves as a physical indication of the ongoing pathogenesis. 
Countless studies have documented specific changes induced within infected cells 
as the invading pathogen is sensed, and the host response is mounted.  This 
response includes the induction of host defense genes, the activation of immune 
cells, and the presence of soluble immune modulators (e.g., cytokines and 
chemokines).  Alphaviruses are no exception, inducing a strong antiviral response 
both in vitro as well as in vivo.  However, few studies describe on a molecular level 
how the entire infected animal is affected systemically, particularly in tissues that are 
distal to the site(s) of active viral replication. 
Here, utilizing VRP to limit infection to the first infected cells in vivo, we 
demonstrate that not only do host cells at the site of replication sense and respond 
to infection, but systemically there is a rapid activation of the antiviral response, 
including within remote tissues.  Within the liver and brain, distal to the site of VRP 
replication limited to the DLN, antiviral gene expression of greater than 100-fold over 
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mock was detected within hours of VRP footpad inoculation, and peaked at 6 to 12 
h.  This included induction of several interferon-stimulated genes, namely Isgf3γ 
(IRF-9), IP-10 (Cxcl10), p56 (Ifit1), and IFNβ itself, all having well documented roles 
in the host antiviral response.  Isgf3γ, along with STAT1 and STAT2, form the ISGF3 
transcription factor complex which translocates to the nucleus and binds interferon-
stimulated response elements (ISRE) to induce the expression of interferon-
inducible genes (16-18).  The chemokine IP-10, which possesses an ISRE-
containing promoter, is a potent chemoattractant for Th1 lymphocytes and 
monocytes, regulating the in vivo migration of these effector immune cells to sites of 
inflammation.  The p56 gene belongs to a class of stress-inducible antiviral genes 
which are upregulated in response to interferon, dsRNA, and infection by several 
viruses (18, 44).  The specific antiviral action of p56 is mediated through its directed 
disruption of translation initiation, by inhibiting the action of the initiation factor eIF3 
(45, 46). 
Our observation of this rapid, intense induction of genes encoding products 
with a diverse range of antiviral activities, both within the DLN as well as in 
downstream tissues, suggests that the invading pathogen was sensed almost 
immediately following VRP infection, and an innate response initiated on an animal-
wide scale.  Several candidates responsible for this innate detection of VRP infection 
exist, including the pattern recognition receptors (PRR).  PRRs, such as the dsRNA-
dependent protein kinase (PKR), retinoic acid inducible gene-1 (RIG-1), and the Toll-
like receptors (TLRs), serve as sentinels for the innate detection of viral invasion (17, 
47-49).  They do so by recognizing conserved molecular motifs, or “pathogen-
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associated molecular patterns (PAMPs), and upon sensing these pathogenic 
molecules, induce the production of soluble immune mediators.  With mounting 
evidence of the critical role of PRRs in the establishment of both innate and adaptive 
immunity, particularly in dendritic cell populations, future studies within this system 
certainly will include investigating the potential involvement of these innate sensors 
in VRP infection.   
The innate antiviral state that was subsequently induced following VRP 
footpad inoculation appeared, moreover to rapidly promote a protective response, as 
short duration pretreatment with VRP prior to virulent VEE challenge was sufficient 
to effectively protect animals from death.  This included complete protection in mice 
receiving a footpad inoculation with VRP at 6, 12, or 24h prior to challenge in the 
opposing footpad with VEE.  Similar results were observed when VRP pretreated 
mice were challenged intranasally with VEE, with only a slight shift to 50% mortality 
in mice receiving the 6h VRP pretreatment.  The duration of this protective VRP 
pretreatment not only correlated with the timing of peak antiviral gene induction in 
the DLN, liver, and brain, but also with the presence of massive amounts of 
biologically active interferon measured in the serum of pretreated animals. 
Although the same VRP pretreatment was capable of extending the average 
survival time of mice challenged intracranially with VEE, it was insufficient to protect 
these animals from death.  The differences in protection observed from intracranial 
versus footpad or intranasal challenge suggest that the short duration VRP 
pretreatment may be effective in limiting or preventing neuroinvasion, but appears to 
be ineffective in protecting against direct VEE neurovirulence.  Following footpad 
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challenge of VRP pretreated animals, viral titers within the brain were reduced to 
levels at or below the level of assay detection, from the nearly 107 PFU/gram titers in 
mock pretreated animals, suggesting that invasion of the brain may have been 
blocked.  This was coupled with a greater than 2.5 log reduction in serum viremia 
titers to just over 103 PFU/ml measured at 24h.  In previous studies, a correlation 
was established between reaching a critical concentration of at least 104 PFU/ml of 
virus in the serum and the capability of effectively seeding infection of the 
neuroepithelium to achieve neuroinvasion of the CNS (K.A. Bernard and R.E.J., 
unpublished data).  Therefore, it remains unclear whether the reduction in viral brain 
titers following footpad challenge of VRP pretreated animals was the result of an 
antiviral state induced in the neuroepithelium that limited or prevented 
neuroinvasion, or if it was a function of the overall reduction in serum viremia, or 
both.  However, future studies exploiting differences in mortality, antiviral gene 
responses, as well as serum and brain titers in animals receiving less than the 
standard VRP pretreatment dose of 2 x 106 IU of VRP may further elucidate how the 
brain is protected within this system. 
The exact mechanism underlying the protection granted by short duration 
VRP pretreatment remains to be fully defined.  However, direct homologous 
interference between replicon and challenge virus particles is not likely to play a role, 
as the footpad pretreatment and subsequent challenge were administered in 
opposing footpads.  Likewise, the protection from intranasal challenge evident in  
mice pretreated in the footpad with VRP, further argues against homologous 
interference as the mechanism of protection.  Elements of the adaptive immune 
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response also are unlikely contributors to this rapid protection, as the time necessary 
for a protective antibody response strongly argues against involvement of VEE-
specific antibody.  In studies where mice were inoculated with a high dose (105 PFU) 
of a vaccine strain of VEE (TC-83), detectable levels of VEE-specific serum IgG are 
not evident until five days post inoculation (50).  However, a future challenge study 
may be designed in mice deficient in B- and T-cells (RAG-/-) to address the 
contribution, if any, of an early adaptive response. 
The rapidly induced innate response observed systemically in VRP pretreated 
animals may be responsible for the protection from VEE challenge.  The observed 
protection is temporally correlated with the induced innate defense response.  When 
animals were challenged with VEE at times during which the host antiviral gene 
response and the serum interferon levels were suboptimal (e.g., at 1h and 3h post 
VRP pretreatment), they were not protected from death (100% and 50% mortality 
rates, respectively; data not shown).  The most obvious candidate responsible for 
inducing the systemic innate and protective responses may be interferon itself, 
particularly given the well-documented sensitivity of VEE to the interferon response.  
This was supported by the strong local and remote induction of antiviral genes soon 
after VRP administration, and nearly complete loss of the early antiviral gene 
response in the brain of VRP pretreated IFNαβR-/- mice.  However, past studies 
have found that while interferon is necessary for protection against lethal VEE 
infection, it is not sufficient (26, 31).  If there is a another soluble component(s) 
responsible for the protection conferred by VRP pretreatment, then future studies 
designed to transfer serum from pretreated to naïve animals (including IFNαβR-/- 
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mice) prior to VEE challenge may help to elucidate the role of such serum factors in 
protection. 
The failure of VRP pretreatment to protect animals from challenge with VSV, 
a virus that is also sensitive to an interferon-induced antiviral state, suggests that an 
element of the VRP-induced protective response may be specific to VEE.  Although 
VEE and VSV share certain pathogenetic features (e.g., interferon sensitivity, CNS 
access through the olfactory neuroepithelium), the antiviral response induced by 
VRP pretreatment seems to differentially affect each virus.  One possibility is that the 
kinetics of the robust antiviral response following VRP pretreatment are naturally 
well-suited to protect against VEE, a virus that replicates and disseminates very 
quickly in vivo.  Following footpad inoculation of VEE in mice, peak serum viremia is 
established by 12 to 24h.  This is followed by clearance of the virus from the serum 
and peripheral organs by approximately 72h, when the virus has invaded the brain, 
resulting in lethal encephalitis by 6 - 8 days post infection (2).  Therefore, 
administering the VRP pretreatment at 6, 12, or 24h prior to VEE challenge in effect 
confers a head start for the antiviral response to reach peak state at the time of VEE 
inoculation, and/or during early times post challenge when inhibiting VEE replication 
is most critical for protection.   
In contrast, the course and duration of VSV pathogenesis in vivo is generally 
extended in comparison to VEE, evident in the delayed average survival time of 
infected mice.  As such, the rapidly established, peak VRP antiviral response may 
have already resolved at times critical to suppressing VSV replication.  Alternatively, 
or in addition, VRP treated animals may have lapsed into an interferon unresponsive 
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state at a critical point in VSV challenge virus infection (51).  Future studies in which 
the VRP pretreatment is administered at times closer to the VSV challenge may 
elucidate kinetic components among the differences between VEE and VSV 
challenge models. 
On the other hand, the action of interferon-induced genes can be virus-
specific (18, 52, 53).  Thus, it is also possible that VEE and VSV are differentially 
sensitive to the particular antiviral response profile induced by VRP pretreatment.  It 
may be informative to challenge VRP-pretreated animals with another alphavirus, or 
conversely, to pretreat animals with another alphavirus-based replicon particle, 
followed by challenge with VEE.  Such studies may help to define in a larger context 
the specific, antiviral gene profile that is most effective against alphavirus infection.   
The rapid, robust, but transient activation of a systemic antiviral response 
throughout animals receiving VRP pretreatment sheds new light on the dynamics of 
virus replication and host response.  Within just a few hours following infection of the 
first cells in the DLN, the animal begins to respond.  The initial response is in the 
infected cells themselves, where induced mediators of the innate immune response 
act in an autocrine fashion to modulate replication in those cells.  Paracrine 
mediators rapidly induce a response in uninfected bystander cells of the DLN, and 
the same or additional soluble mediators act at a distance to alter the gene 
expression profile in remote uninfected tissues.  By only 6 hrs post-infection, and 
under conditions where the infection is limited only to the first infected cells, the 
innate response is activated throughout the body.  These results suggest a new 
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paradigm of acute virus disease in which the ultimate pathogenesis of the virus may 
be largely determined by events in the first few moments after infection.   
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Figure 3.1. Rapid, systemic activation of the host antiviral response following 
footpad VRP inoculation.  Adult BALB/c mice were inoculated in the right rear 
footpad with 2 x 106 IU of null VRP, or were mock infected with diluent.  At 1, 3, 6, 
12, and 24h following inoculation, the mice were euthanized, perfused with PBS, and 
tissues removed by dissection.  Total cellular RNA was isolated, cDNA synthesized, 
and the expression of a panel of interferon-stimulated genes (IFNβ, IP-10, p56, 
Isgf3g) was assessed by Taqman real-time PCR in the (A) draining lymph node, (B), 
liver, and (C) brain.  The fold induction of each gene is represented by the 
expression in VRP infected animals relative to the expression in mock infected 
animals.  Each bar represents groups of three animals each, plus or minus the 
standard error of the mean (SEM).        
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Figure 3.2.  High levels of biologically active interferon are present in the 
serum of mice inoculated with VRP.  Adult BALB/c mice were inoculated in the 
right rear footpad with 2 x 106 IU of null VRP.  At 1, 3, 6, 12, and 24h following 
inoculation, the mice were euthanized, followed by cardiac puncture and 
exsanguination to collect blood samples.  The levels of type I interferon present in 
the serum of infected mice were measured by a standard biological assay on L929 
cells, and presented as international units (IU) per milliliter.  Each bar represents an 
individual animal, with the limit of detection (LOD) for the assay indicated by the 
dotted line.  The data in this figure and the previous figure correspond to the same 
group of mice. 
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Table 3.1.  Morbidity and mortality of VRP-pretreated (RRFP) adult BALB/c 
mice following challenge with virulent VEE (LRFP) 
 
 
 
   *Average survival time (AST), plus or minus the standard error of the mean (SEM) 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Survival of VRP-pretreated (RRFP) BALB/c mice following virulent 
VEE challenge (LRFP).  Adult BALB/c mice, 6 mice per group, were pretreated by 
inoculation in the right rear footpad (RRFP) with 2 x 106 null VRP for 6, 12, or 24h 
prior to challenge with 10 PFU of virulent VEE in the opposing left rear footpad 
(LRFP).  Mock pretreated mice received diluent alone, in the RRFP, 6h prior to 
challenge.   
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Table 3.2.  Morbidity and mortality of VRP-pretreated (RRFP) adult BALB/c 
mice following intranasal challenge with virulent VEE. 
 
 
 
  *Average survival time (AST), plus or minus the standard error of the mean (SEM) 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  Survival of VRP-pretreated (RRFP) BALB/c mice following 
intranasal challenge with virulent VEE.  Adult BALB/c mice, 5-6 mice per group, 
were pretreated by inoculation in the right rear footpad (RRFP) with 2 x 106 null VRP 
for 6, 12, or 24h prior to intranasal challenge with 103 PFU of virulent VEE.  Mock 
pretreated mice received diluent alone, in the RRFP, 6h prior to challenge.  A higher 
challenge dose of 103 PFU was necessary to achieve a 100% mortality rate in mock 
pretreated animals, due to the inefficiency of intranasal delivery. 
 
  
* 
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Table 3.3.  Morbidity and mortality of VRP-pretreated (RRFP) adult BALB/c 
mice following intracranial challenge with virulent VEE. 
 
 
  
*Average survival time (AST), plus or minus the standard error of the mean (SEM); † p-value of <0.001, by one  
  way ANOVA analysis;  †† p-value of <0.05, by one way ANOVA analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.  VRP-pretreatment of BALB/c mice extends the average survival 
time upon intracranial challenge with virulent VEE.  Adult BALB/c mice, 6 mice 
per group, were pretreated by inoculation in the right rear footpad (RRFP) with 2 x 
106 null VRP for 6, 12, or 24h prior to intracranial challenge with 103 PFU of virulent 
VEE.  Mock pretreated mice received diluent alone, in the RRFP, 6h prior to 
challenge.   
                     
 
* 
 163 
 
 
 
  
 
Figure 3.6.  VRP pretreatment dramatically reduces the viral load in the serum 
and brain of animals challenged with VEE.  Adult BALB/c mice, 3 mice per group, 
were pretreated by inoculation in the right rear footpad (RRFP) with 2 x 106 null VRP 
for 6, 12, or 24h prior to challenge with 10 PFU of virulent VEE in the opposing left 
rear footpad (LRFP).  Mock pretreated mice received diluent alone, in the RRFP, 6h 
prior to challenge.  (A) At 24h post challenge, serum was collected by tail vein bleed.  
(B) At 88h post challenge, the mice were euthanized, perfused with PBS, and the 
brain (including the olfactory bulbs) removed by dissection.  Viral titers were 
determined by standard BHK cell plaque assay.  The limit of detection (LOD) in each 
assay is indicated by the dotted line.   
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Table 3.4.  The effect of VRP pretreatment dose on morbidity and mortality 
following virulent VEE footpad challenge. 
 
 
  
*Average survival time (AST), plus or minus the standard error of the mean (SEM) 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  The dose of the VRP pretreatment is a critical parameter of 
protecting mice from subsequent VEE challenge.  Adult BALB/c mice, 5 mice per 
group, were pretreated with decreasing doses of null VRP (2 x 106 IU, 105 IU, or 104 
IU) inoculated in the RRFP for 6h prior to challenge with 10 PFU of virulent VEE 
(LRFP).  Mock pretreated mice received diluent alone, in the RRFP, 6h prior to 
challenge.   
* 
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Figure 3.8.  Antiviral gene induction in the brain of VRP pretreated animals is 
diminished in IFNαβ receptor knockout mice.  Adult, wildtype 129 or IFNαβ 
receptor knockout (IFNαβR-/-) mice were inoculated in the right rear footpad with 2 x 
106 IU of null VRP, or were mock infected with diluent.  At 6h following inoculation, 
the mice were euthanized, perfused with PBS, and tissues removed by dissection.  
Total cellular RNA was isolated, cDNA synthesized, and the expression of a panel of 
interferon-stimulated genes (IFNβ, IP-10, p56, Isgf3g) was assessed by Taqman 
real-time PCR.  The black bars represent gene expression in wildtype 129 mice, and 
the striped bars represent gene expression in IFNαβR-/- mice.  The fold induction of 
each gene is represented by the expression in VRP infected animals relative to the 
expression in mock infected animals.  Each bar represents groups of three animals 
each, plus or minus the standard error of the mean (SEM).        
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Table 3.5.  Morbidity and mortality of VRP-pretreated (RRFP) adult 129 and 
IFNαβ receptor knockout mice following challenge with virulent VEE (LRFP) 
 
 
 *Average survival time (AST), plus or minus the standard error of the mean (SEM) 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.  VRP-pretreated, IFNαβ receptor knockout mice are not protected 
against virulent VEE challenge.  Adult, wildtype 129 (5 mice per group) or IFNαβ 
receptor knockout mice (8 mice per group) were pretreated by inoculation in the right 
rear footpad (RRFP) with 2 x 106 null VRP for 6, 12, or 24h prior to challenge with 10 
PFU of virulent VEE in the LRFP.  Mock pretreated mice received diluent alone, in 
the RRFP, 6h prior to challenge.   
 
* 
 167 
Table 3.6.  Morbidity and mortality of VRP-pretreated (RRFP) adult BALB/c 
mice following heterologous, intranasal challenge with VSV. 
 
 
 
  *Average survival time (AST), plus or minus the standard error of the mean (SEM) 
 
 
 
 
 
 
 
 
 
 
Figure 3.10.  VRP-pretreated BALB/c mice are not protected against a 
heterologous challenge with VSV.  Adult BALB/c mice, 7-8 mice per group, were 
pretreated by inoculation in the right rear footpad (RRFP) with 2 x 106 null VRP for 
24h prior to challenge with 2 x 106 PFU of vesicular stomatitis virus (VSV) in the 
LRFP.  Mock pretreated mice received diluent alone, in the RRFP, 24h prior to 
challenge.   
 
* 
CHAPTER FOUR 
DISCUSSION AND FUTURE DIRECTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 169 
The interface of viral infection and host response embodies a complex series 
of interactions and regulatory pathways.  As the host senses the virus, and seeks to 
eradicate infection and reestablish homeostasis, the virus seeks to continue its own 
survival and spread.  Thus, the pathogenesis of any given virus and the associated 
injury it causes induces numerous changes in the host.  The consequences are 
dependent on several viral and host factors, which together dictate the outcome of 
infection.  Accordingly, this has been a constant area of active investigation, and our 
understanding of this process advances as innovative tools and sophisticated 
systems fall into place.  However, much remains to be learned.   
In this body of work, we utilized two such systems in an effort to characterize 
the molecular markers of the early virus-host interactions central to Venezuelan 
equine encephalitis virus (VEE) pathogenesis.  First, VEE replicon particles (VRP) 
were utilized to limit infection to the first infected cells.  Second, an mRNP-tagging 
system was developed to overcome an inherent limitation in the application of 
traditional gene profiling methods post viral infection; namely, the inability to 
discriminate the expression profile in infected versus surrounding uninfected 
bystander cells.  Such discrimination is particularly crucial following infection in vivo, 
as the infected cells in a given tissue most often represent a minority population set 
against a background of mostly uninfected cells.  The development and application 
of the VRP mRNP-tagging system bestowed the capability to directly profile the 
infected cell response to VEE, doing so in a sensitive manner.  In fact, had the 
mRNA-tagging system not been utilized, the induction of several genes would have 
gone undetected.  Combined with simultaneous total RNA analysis of the collective 
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response, this system not only revealed the infected cell response, but also granted 
insight into the contribution of the uninfected bystander cell population in the early 
host response to VEE infection.   
We found the response of these two different populations, within the same in 
vitro cell culture or the same tissue in vivo, to be dramatically different, varying in 
quantitative, qualitative, and temporal terms, indicating that the transcriptional 
programs of infected and uninfected cells within the same culture or tissue are 
uniquely affected.  This included, for example, the discovery that infected cells are 
the primary source of the early IL-6 and GM-CSF response to VRP infection in 
BMDC and the DLN.  Furthermore, the induction kinetics of the infected and 
uninfected cell response differed.  Analysis revealed a two-phase innate host 
response to VEE in the DLN.  The first phase consisted of a rapid response within 
the infected cells of the DLN, including the robust activation of several host defense 
genes (IFNβ, IP-10, and GM-CSF) by 6h.  As the infected cell response was waning, 
a second phase of innate response was underway in the surrounding uninfected 
DLN cells, reminiscent of an antiviral autocrine-paracrine signaling loop.  However, 
signaling through the IFNαβ receptor did not appear to be the primary paracrine 
mediator of the defense response in the uninfected DLN cells, while conversely 
autocrine signaling through this receptor was critical to the high levels of antiviral 
gene induction in the infected cell population.  Direct analysis of the infected versus 
uninfected cell responses, including the details of autocrine and paracrine signaling, 
have previously been difficult, if not impossible, to achieve in vivo.   
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The activation of autocrine and paracrine signaling pathways is critical to the 
establishment of the antiviral state.  This is particularly evident from consequences 
inflicted on the host when these pathways are antagonized by the virus (1-4).  
However, much remains unknown concerning the underlying regulatory elements of 
these responses (5-9), In this regard, the mRNP-tagging system offers a novel 
means to tease apart the relative contributions of the infected and bystander cell 
populations, granting unique perspective into the autocrine and paracrine responses 
induced following infection. 
 A common phenomenon during viral infection is the interaction of vastly 
different cell types.  In the brains of mice infected with VEE, this includes the 
interaction of infected neurons with bystander glial cells, such as astrocytes.  
Astrocytes have been implicated in several events that occur in the brains of VEE-
infected animals, including mediating a strong iNOS and TNFα proinflammatory 
response which seems at least partially responsible for the neurodegeneration 
associated with VEE infection (10-13).  Future application of the VRP mRNP-tagging 
system may include direct intracranial inoculation of FLAG-PABP VRP into the brain.  
This analysis would be valuable in deciphering the direct response of infected 
neurons, as well as that of the surrounding uninfected cells which also contribute to 
VEE-induced CNS pathogenesis.  In studies where CNS tissue sections were 
labeled for VEE antigen, and adjacent sections double-labeled for an astrocyte 
marker and apoptosis, it was revealed that apoptosis of neurons not only occurs in 
areas of the brain positive for VEE-antigen, but also in areas of astrogliosis (12).  
These findings suggest that the inflammatory response contributes to VEE-induced 
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pathology in the brain, both within the infected and uninfected cell populations (12-
14).   Application of the VRP mRNP-tagging system in the brain may facilitate the 
identification of the early molecular markers of VEE neurovirulence, including the 
kinetics of the proinflammatory response, as well as the induction of apoptosis within 
these different cell populations. 
 In addition, the mRNP-tagging system will be applicable to other viral 
systems.  For example, a directly applicable pathogenesis model is Ross River virus 
(RRV), a related alphavirus.  RRV is an Old World alphavirus endemic to Australia, 
which causes severe, and often persistent arthritis/arthralgia in humans (15).  A 
mouse model of RRV disease has been developed, with infected mice exhibiting 
severe disease characterized by inflammation of muscle tissue and muscle damage 
(16, 17).  Disease is thought to be initiated by viral replication as well as 
inflammatory cell infiltrates in the affected joints (18, 19), with the primary targets of 
RRV infection recently identified as bone, joint, and skeletal muscle tissues of the 
hind limbs (17).  Characterization of the inflammatory infiltrate within skeletal tissue 
has identified macrophages, NK cells, and T lymphocytes (17).   
At least two recent studies have implicated the innate immune response in 
the induction of RRV-associated disease.  For instance,  depletion of macrophages 
prior to infection completely prevents RRV-induced muscle inflammation (16).  The 
complement system also has been suggested to play a role, perhaps by mediating 
proinflammatory functions of the infiltrates in infected tissues (20).  Certainly the 
development of an RRV mRNP-tagging system would address several aspects of 
RRV pathogenesis in the mouse model.  By discriminating between the infected 
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cells within the joint-associated tissue and the recruited, uninfected inflammatory 
infiltrates, the relative induction of the innate mediators associated with disease 
could be established.  Additionally, comparison of such studies to that in mice 
lacking components of the complement pathway may help identify the specific innate 
effector functions in the proinflammatory infiltrates targeted during RRV infection.  
Such studies would also present an opportunity to compare and contrast the 
modulation of the host response by the New World (encephalitic, e.g., VEE) and Old 
World (arthritic, e.g., RRV) alphaviruses.   
Comparing the host response to wildtype VEE and the nt3A interferon-
sensitivity mutant did not elucidate a novel antiviral effector gene(s) involved in the 
documented attenuation of the mutant.  However, new data suggests that this 
sensitivity may be driven by an alternative pathway, one independent of Mx, PKR, 
and RNaseL.  Infection of mice triply deficient (TD) for these factors were still 
protected upon infection with the nt3A mutant, while wildtype VEE remained virulent 
(L.J. White and R.E. Johnston, unpublished data).  This suggests that an alternative 
innate pathway may exist that is capable of mediating protection from VEE infection.  
It may therefore be pertinent to examine the host response to nt3A mutant in the 
context of this alternative pathway, in other words, within the TD system.  Applying 
the biological pressure induced by the absence of these pathways may be 
necessary to facilitate the activation of key antiviral mediators involved in the nt3A 
attenuation.  In fact, a similar investigation using a strain of Sindbis virus with a 
comparable attenuating phenotype successfully utilized infection in the TD model to 
identify a set of 44 candidate effectors of the alternative pathway (21, 22).  An 
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examination of these 44 candidate genes in the context of VEE infection, as well as 
contrasting host gene induction in TD mice infected with the nt3A mutant, is an 
important next step. 
In the second set of studies presented here, we utilized a VRP-based system 
to ask whether the earliest events following viral infection could establish an antiviral 
response that was sufficient to transform the entire infected animal.  Within just a 
few hours following VRP footpad inoculation, there was a rapid, systemic activation 
of the host antiviral response, both within the DLN and beyond.  Within the liver and 
brain, distal to the site of replication in the DLN, antiviral gene expression of greater 
than 100-fold over mock was detected within hours of VRP footpad inoculation, 
peaking by 6 to 12 h.  The antiviral effects of the VRP pretreatment were evident by 
the dramatic reduction in challenge virus titers in the serum and brain.  In fact, 
pretreatment of mice by footpad VRP inoculation for 6, 12, or 24h prior to virulent 
VEE footpad challenge conferred complete protection from death.  This set of 
experiments successfully documented a rapid modulation of the host innate 
response, occurring within just moments of pathogen invasion, capable of 
transforming the entire infected animal and potentially affecting the outcome of 
infection. 
Although intact interferon signaling was found to be necessary for the 
induction of this systemic antiviral response, interferon itself may not have been the 
sole mediator of protection.  This was demonstrated by the lack of protection in 
VRP-pretreated mice challenged with a heterologous, interferon-sensitive virus 
(VSV).  Future studies involving modified pretreatment regimens and serum transfer 
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will likely facilitate a greater understanding of the underlying mechanism in this 
protection system.  There may, however, be another explanation for the lack of 
protection in the VSV challenge experiments.  A recent study described a 
phenomenon in which the host interferon response experienced a period of 
exhaustion  following infection with Semliki Forest virus (SFV) (23).  A rapid, 
interferon-dependent activation of B and T lymphocytes was described following 
SFV infection, which reverted back to a resting phenotype within 5 days.  However, 
when a secondary infection with an unrelated virus was administered during a period 
of 5 to 9 days after SFV exposure, there was an inability of these lymphocytes to 
reactivate due to an apparent exhaustion of the interferon system.  This refractory 
period, during which the animals could not mount a type I interferon response, was 
likened to a transient immunosuppression, and rendered the mice more susceptible 
to acute viral infections (23).   
In light of the extended replication kinetics of VSV versus VEE infection 
(discussed in Chapter three), it may be pertinent to investigate whether a refractory 
period is induced following VRP pretreatment.  This could be done by administering 
the VRP pretreatment over an extended timecourse, mimicking the 5 to 9 day 
kinetics that were observed in the SFV system, and then challenging with VEE or 
VSV.  Perhaps it makes sense that a period of unresponsiveness should occur for 
some period following acute infection, as the transient nature of the innate immune 
response to infection is an important aspect protecting against the deleterious 
effects of an exaggerated immune response.  In fact, we have documented this 
transient nature in our kinetic examination of host gene responses in the VRP-
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infected animal.  However, the presence of a refractory period and the 
consequences of this phenomenon remain to be defined in our system. 
VEE, being an arthropod-borne virus, is transmitted by mosquitoes in nature 
and targets host dendritic cells at the site of inoculation in the skin (24-26).  In light of 
this natural transmission cycle, another recently published study has interesting 
future implications for the direction of the experimental systems presented here.  
Shabman et al. recently reported that alphaviruses grown in mosquito cells, 
including RRV and VEE,  differed in their ability to induce type I interferon responses 
in comparison to mammalian-cell derived alphaviruses (27).  While mosquito-cell 
derived VEE (mos-VEE) was able to infect dendritic cells as effectively as 
mammalian-cell derived VEE (mam-VEE), mos-VEE was a poor inducer of type I 
interferon.  These results led to a proposed model in which alphaviruses delivered 
by the bite of an infected mosquito can efficiently infect dendritic cells while having 
the ability to avoid the host type I interferon response.  It is likely that this effect 
would only occur during the first round of infection, within the initially infected 
dendritic cells, as virus amplified within the now mammalian host would give rise to 
mam-VEE.  However, this one time advantage is speculated to be critical in 
establishing alphavirus infection in the mammalian host (27).   
An entirely new line of investigation could be developed in which mosquito-
cell derived VRP (mos-VRP) are used throughout the studies presented here.  This 
would include applying a mos-VRP mRNP-tagging system, and contrasting the 
effect on host antiviral gene induction in vivo with that of mam-VRP.  The utilization 
of VRP within this context would allow us to model the initial interaction of mos-VEE 
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with host dendritic cells at the site of inoculation, eliminating the amplification of 
mam-VEE progeny.  In addition, the mRNP-tagging system would provide the 
sensitivity required to specifically profile that minority cell population following 
infection in vivo.  It would be equally interesting to use mos-VRP in our VRP 
pretreatment regimen, and ask if antiviral gene responses are still rapidly induced in 
tissues downstream of the DLN.  If mos-VRP could effectively evade activation of a 
systemic antiviral state, perhaps the observed protection from lethal virus challenge 
would be diminished.  This set of future studies has exciting implications as it returns 
our focus to the natural virus-host interactions occurring during the transition of 
alphavirus infection in the arthropod vector to the vertebrate host.  The body of work 
presented here, as well as the studies proposed for the future, promise to further 
define the impact of early virus-host interactions on the progression of pathogenesis 
and the outcome of alphavirus infection.  
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APPENDIX A 
 
ADDITIONAL DATA CHARACTERIZING THE NT3A MUTANT OF VENEZUELAN 
EQUINE ENCEPHALITIS VIRUS 
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Figure A.1.  Infection with both wildtype and nt3A mutant VRP induces the 
shutoff of host translation, but results in different levels of nonstructural and 
26S protein expression.  (A) Pulse-chase radiolabeling was utilized to assess the 
level of host protein synthesis at various times following VRP infection, in order to 
determine the extent of VRP-induced host translation shutoff. 105 L929 cells were 
either mock treated or infected with wildtype GFP-VRP or nt3A mutant GFP-VRP at 
an MOI of 10.  Two hours before the indicated time post-infection, the media was 
removed and replaced with media lacking methionine and cysteine, and incubated 
for 1 hr at 37°C. This starvation medium was then supplemented with 33 µCi of 
[35S]methionine-[35S]cysteine/ml. Immediately after incubation for 1 h at 37°C, 
monolayers were harvested in NP-40 lysis buffer. Equal volumes of lysate from each 
time point were then separated by sodium dodecylsulfate-polyacrylamide gel 
electrophoresis on an 8% gel. Similar levels of host protein shutoff were observed 
when comparing wildtype and nt3A GFP-VRP infected cells.  However, interestingly 
the nt3A mutation resulted in a decreased production of GFP (≈30 kilodaltons) from 
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the 26S subgenomic promoter throughout infection, as compared to level of GFP 
expression during wildtype GFP-VRP infection (shown by double astericks).  In 
contrast, the same nt3A mutation resulted in the increased production of viral 
nonstructural genes at the earliest times post-infection (nsP2 ≈90 kilodaltons; nsP4 
≈70 kilodaltons), as indicated by the single astericks and expanded in panel (B).  
These differences in expression levels have been verified by immunoprecipitation 
against the nonstructural proteins, as well as through FACS analysis of the mean 
fluorescence intensity of GFP as expressed from wildtype and nt3A mutant GFP-
VRP (data not shown). 
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A.  Caspase 3/7 Activity – BMDC 6hpi 
 
 
 
 
B.  Caspase 3/7 Activity – BMDC 24hpi 
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Figure A.2.  Infection with wildtype and nt3A mutant VRP induces similar 
levels of caspase 3/7 activity in primary BMDC.  The activation of caspase 3 and 
7 is induced by multiple cell death stimuli, ultimately leading to apoptosis.  Therefore, 
caspase 3/7 activity serves as an effective indicator of apoptosis.  Here, the 
Promega Caspase-Glo™ 3/7 One Step Luminescent Assay was utilized to compare 
caspase 3/7 activity during wildtype versus nt3A mutant VRP infection, as a 
measure of the relative level of apoptosis induced during each infection.  Triplicate 
samples of primary BMDC (3 x 104 cells), derived from wildtype 129sv/ev mice, were 
infected at an MOI of 10 with either null-VRP, nt3A mutant null-VRP, GFP-VRP, or 
nt3A mutant GFP-VRP.  Mock treated cells served as the baseline readout for 
apoptosis occurring naturally in the BMDC cultures, while BMDC treated with 
apoptosis inducing agents (1 ug actinomycin D (AMD) or 20 ng TNFα) served as 
positive controls.  (A) At 6 and (B) 24 h, the cultures were analyzed for caspase 
activity by direct lysis in culture, followed by the addition of a proluminescent 
caspase 3/7 substrate for cleavage by caspase 3/7 present in the cell culture, with 
measurement of the relative light units by luminometer analysis (see manufacturer’s 
protocol).  A high level of caspase 3/7 activity was measured from all VRP-infected 
samples, regardless of whether a transgene was expressed from the 26S promoter.  
In addition, a similar level of caspase 3/7 activity was present in BMDC infected with 
wildtype or nt3A mutant VRP, suggesting that a similar level of apoptosis occurs 
during each VRP infection.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
